10575027.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

10575027.trn

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:44:51 ON 12 MAR 2009

=> file reg
FILE 'REGISTRY' ENTERED AT 13:45:38 ON 12 MAR 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2009 HIGHEST RN 1119363-64-2
DICTIONARY FILE UPDATES: 11 MAR 2009 HIGHEST RN 1119363-64-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575027-99.str



10575027.trn

chain nodes :
11 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
14
chain bonds :
4-11 11-12 12-13 12-14 13-15 15-16
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
4-11 11-12 12-13 12-14 13-15 15-16
exact bonds :
2-7 3-10 7-8 8-9 9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:46:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 999 TO ITERATE

100.0% PROCESSED 999 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10575027.trn

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        18084 TO    21876
PROJECTED ANSWERS:             173 TO      747

L2           23 SEA SSS SAM L1

=> d scan
```

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-[[1-[(2-methylphenyl)methyl]-4-piperidinyl]methyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-
MF C25 H33 N3 O

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
MF C27 H30 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea,
N-(3'-chloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
MF C23 H21 Cl N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-[3-methoxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
MF C19 H19 F3 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea,
N-[[4-(dimethylamino)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
MF C20 H25 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-[(2-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
MF C18 H19 F N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-cyclohexyl-N'-[6,7,8,9-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-naphth[1,2-d]imidazol-5-yl]-
MF C35 H40 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-2-quinolinyl]methyl]-
MF C23 H26 F3 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10575027.trn

```
=> s l1 full
FULL SEARCH INITIATED 13:46:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    19833 TO ITERATE

100.0% PROCESSED    19833 ITERATIONS                              477 ANSWERS
SEARCH TIME: 00.00.01

L3          477 SEA SSS FUL L1

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:46:56 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Mar 2009  VOL 150 ISS 11
```

10575027.trn

L4 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2008:833123 Document No. 149:1531010 Preparation of substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives as CB1 cannabinoid receptor antagonists. Martinez, Serge; Rinaldi, Carmona Murielle; Congy, Christian; Barth, Francis; Vernhet, Martine (Sanofi Aventis, Fr.). Fr. Demande FR 2911136 A1 20080711, 71 pp. (French). CODEN: FRXXBL. APPLICATION: FR 2007-95 20070105.
GI



I



II

AB Title compds. I [X = CO, CONR5, CSNH, SO2NR5; R2, R5 = independently H, alkyl; R1 = (un)substituted alkyl, Ph, tetrahydronaphthalenyl, aromatic heterocyclyl, etc.; R3, R4 = independently (un)substituted phenyl; and their acid addition salts, and their hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors (no data) and for treatment of the diseases it implies (no data). Thus, a multi-step synthesis starting from Et 2-chloro-2-[(2,4-dichlorophenyl)hydrazono]acetate was given for pyrazole II. I exhibited an excellent affinity in vitro (IC50 ≤ 1.1•10-7 M) for the CB1 cannabinoid receptors. The antagonist nature of compds. I was demonstrated by adenylate-cyclase inhibition models, and toxicity was compatible with therapeutic use (no data). The interaction of I with the brain CB1 receptors was determined using a test of ex vivo binding of [3H]-CP55940 after i.v. injection to mice (no data). The interaction of I with the peripheral CB1 receptors was determined using a test of reversion of the inhibiting effect of CP55940 on gastrointestinal transit after oral administration to mice (no data). Thus, I are useful for treating psychiatric, metabolic, and gastrointestinal disorders, smoking cessation, etc. (no data).
IT 1038436-01-9P 1038438-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(drug candidate; prepn. of N-(cyanopyrazolyl)methylamines as CB1 antagonists)
RN 1038436-01-9 CAPLUS
CN Urea, N-[[5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1038438-66-2 CAPLUS
CN Urea, N-[[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-cyano-1H-pyrazol-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2008:805597 Document No. 149:1044970 Preparation of N-(2-aminophenyl)benzamide derivative having an urea structure for lowering intraocular pressure. Mogi, Hiroyuki; Tajima, Hisashi; Mishina, Noriko; Yamazaki, Yusuke; Yoneda, Shinji; Watanabe, Katsuhiko; Fujikawa, Junko; Yamamoto, Minoru (Santen Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2008078762 A1 20080703, 190pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2007-JP74912 20071226. PRIORITY: JP 2006-350263 20061226.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Urea-linked N-(2-aminophenyl)benzamide compds. represented by the general formula [I; R1, R2 = H, (un)substituted lower alkyl, Q, Q1; R3 = HO, each (un)substituted lower alkoxy, cycloalkyloxy, aryloxy, or NH2; R4, R5 = halo, (un)substituted lower alkyl, lower alkoxy, hydroxy-lower alkoxy; R6 = halo, HO, CHO, CO2H, cyano, NO2, each (un)substituted lower alkyl, lower cycloalkyl, aryl, heterocyclyl, lower alkoxy, cycloalkyloxy, or aryloxy, etc.; R7 = HO, each (un)substituted lower alkyl, lower cycloalkyl, aryl, lower alkoxy, cycloalkyloxy, or aryloxy; ring A = carbocyclic or heterocyclic ring; ring B = heterocyclic ring containing 1 or a plural number of heteroatom(s) selected from N, O, and S in the ring; X = (un)substituted lower alkylene; Y, Z = a single bond or (un)substituted lower alkylene; l, m,n, o = 2 or 3] or salts thereof are prepared These compds. have an activity of changing the morphol. of a trabecular cell and promote the outflow of aqueous humor by reducing the resistance of the outflow of aqueous humor. They therefore are effective as intraocular pressure lowing drugs for the prevention and/or treatment of a disease associated with an ocular tension, e.g. glaucoma. Thus, N-(2-[(tert-butoxycarbonyl)amino]phenyl)-4-[[[3-(4-methylpiperazin-1-yl)propyl]amino]methyl]benzamide was stirred with 2,3-dihydrobenzo[1,4]dioxin-6-yl isocyanate in CH2Cl2 at room temperature for 40 min to give 94% N-[2-[(tert-Butoxycarbonyl)amino]phenyl]-4-[[N'-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]ureido]methyl]benzamide which was stirred with HCl in MeOH/EtOAc at room temperature for 2.5 h to give 82% N-(2-Aminophenyl)-4-[[N'-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]ureido]methyl]benzamide (II). N-(2-Aminophenyl)-4-[[N'-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(2-dimethylaminoethyl)ureido]methyl]benzamide (III) in vitro showed cell shape index (CSI) of 0.543 in trabecular cell and in vivo lowered intraocular pressure by 18% in male Japanese white rabbit.

L4 ANSWER 2 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 1034494-32-0P, N-[2-[[4-[[[2-(dimethylamino)ethyl][[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]methyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of urea-linked N-(2-aminophenyl)benzamide derivative having urea structure as drugs for lowering intraocular pressure)
RN 1034494-32-0 CAPLUS
CN Carbamic acid, N-[2-[[4-[[[2-(dimethylamino)ethyl][[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]methyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 1034492-02-8P, N-(2-Aminophenyl)-4-[[N-(2-dimethylaminoethyl)-N'-(5,6,7,8-tetrahydronaphthalen-1-yl)ureido]methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of urea-linked N-(2-aminophenyl)benzamide deriv. having urea structure as drugs for lowering intraocular pressure)
RN 1034492-02-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[[2-(dimethylamino)ethyl][[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2008:772813 Document No. 149:1046110 Preparation of N,N'-disubstituted ureas as antagonists of transient receptor potential vanilloid 1. Bayburt, Erol K.; Daanen, Jerome F.; Gomtsyan, Arthur R.; Latshaw, Steven P.; Lee, Chih-Hung; Schmidt, Robert G. (Abbott Laboratories, USA). U.S. Pat. Appl. Publ. US 20080153871 A1 20080626, 45pp. (English). CODEN: USXXCO. APPLICATION: US 2007-954875 20071212. PRIORITY: US 2006-875890P 20061220.
GI



I II

AB The title N,N'-disubstituted ureas I [wherein L = a bond, alkylene, or cycloalkyl; Y1 = (un)substituted NH or CH2; Y2 = O, S, or NCN; Y3 = (un)substituted NH; Ar = (un)substituted (hetero)aryl or fused heterocyclyl; R1 = H, OH, or alkoxy; R2-R5 = independently H, alkenyl, alkoxy, alkoxyalkoxy, etc.], pharmaceutically acceptable salts, or prodrugs thereof were prepared as antagonists of transient receptor potential vanilloid 1 (TRPV1) for treatment of pain. For example, II was prepared in a multi-step synthesis. The compds. showed antagonistic activity with IC50 < 12 μM against human TRPV1.
IT 1034770-09-6P 1034770-10-9P 1034770-11-0P 1034770-12-1P 1034770-13-2P 1034770-14-3P 1034770-15-4P 1034770-16-5P 1034770-17-6P 1034770-18-7P 1034770-19-8P 1034770-20-1P 1034770-21-2P 1034770-22-3P 1034770-23-4P 1034770-24-5P 1034770-25-6P 1034770-26-7P 1034770-27-8P 1034770-28-9P 1034770-29-0P 1034770-30-3P 1034770-32-5P 1034770-33-6P 1034770-34-7P 1034770-35-8P 1034770-36-9P 1034770-37-0P 1034770-38-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of urea derivs. as TRPV1 antagonists)
RN 1034770-09-6 CAPLUS
CN Urea, N-(3,4-dihydro-2H-1-benzopyran-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-10-9 CAPLUS
CN Urea, N-[8-(1,1-dimethylethyl)-3,4-dihydro-2H-1-benzopyran-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-11-0 CAPLUS
CN Urea, N-(3,4-dihydro-7-methoxy-2H-1-benzopyran-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-12-1 CAPLUS
CN Urea, N-(6-chloro-3,4-dihydro-2H-1-benzopyran-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-13-2 CAPLUS
CN Urea, N-[8-(1,1-dimethylethyl)-3,4-dihydro-2H-1-benzopyran-4-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-14-3 CAPLUS
CN Urea, N-(3,4,7,8,9,10-hexahydro-2H-naphtho[1,2-b]pyran-4-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-15-4 CAPLUS
CN Urea,
N-(3,4-dihydro-6-methyl-2H-1-benzopyran-4-yl)-N'-(5,6,7,8-tetrahydro-

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea,
N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-19-8 CAPLUS
CN Urea, N-[(7-ethoxy-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-20-1 CAPLUS
CN Urea, N-[(3,4-dihydro-6-methyl-2H-1-benzopyran-2-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-21-2 CAPLUS
CN Urea, N-[[3,4-dihydro-8-(1-methylethyl)-2H-1-benzopyran-2-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-16-5 CAPLUS
CN Urea, N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-17-6 CAPLUS
CN Urea, N-[(4S)-3,4-dihydro-2H-1-benzopyran-4-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-18-7 CAPLUS

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-22-3 CAPLUS
CN Urea, N-[8-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-methyl-4-quinolinyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 1034770-23-4 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-4-quinolinyl]- (CA INDEX NAME)



RN 1034770-24-5 CAPLUS

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)



RN 1034770-25-6 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-(1,2,3,4-tetrahydro-1-methyl-4-quinolinyl)- (CA INDEX NAME)



RN 1034770-26-7 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-27-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-3-quinolinyl]- (CA INDEX NAME)



RN 1034770-28-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-3-quinolinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-29-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-(1,2,3,4-tetrahydro-1-methyl-3-quinolinyl)- (CA INDEX NAME)



RN 1034770-30-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-3-quinolinyl]- (CA INDEX NAME)



RN 1034770-32-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[1,2,3,4-tetrahydro-1-(phenylmethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-33-6 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



RN 1034770-34-7 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



RN 1034770-35-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[1,2,3,4-tetrahydro-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-36-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[(1,2,3,4-tetrahydro-1-methyl-2-quinolinyl)methyl]- (CA INDEX NAME)



RN 1034770-37-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[(3R)-3-[4-(trifluoromethyl)phenyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1034770-38-1 CAPLUS
CN Urea, N-[(3S)-3-[4-(dimethylamino)phenyl]cyclopentyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-47-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1034770-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1034770-53-0 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-(3,4,7,8,9,10-hexahydro-2H-naphtho[1,2-b]pyran-4-yl)- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 1034770-40-5P 1034770-45-0P 1034770-47-2P
1034770-49-4P 1034770-53-0P 1034770-54-1P
1034770-55-2P 1034770-56-3P 1034770-58-5P
1034770-62-1P 1034770-64-3P 1034770-70-1P
1034770-77-8P 1034770-79-0P 1034770-84-7P
1034770-86-9P 1034770-88-1P 1034770-91-6P
1034770-96-1P 1034770-98-3P 1034771-02-2P
1034771-06-6P 1034771-16-8P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of urea derivs. as TRPV1 antagonists)

RN 1034770-40-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1034770-45-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-54-1 CAPLUS
CN Urea, N-(3,4-dihydro-6-methyl-2H-1-benzopyran-4-yl)-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)



RN 1034770-55-2 CAPLUS
CN Urea, N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)



RN 1034770-56-3 CAPLUS
CN Urea, N-[(4S)-3,4-dihydro-2H-1-benzopyran-4-yl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-58-5 CAPLUS
CN Urea, N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)



RN 1034770-62-1 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[(7-ethoxy-3,4-dihydro-2H-1-benzopyran-2-yl)methyl]- (CA
INDEX NAME)



RN 1034770-64-3 CAPLUS
CN Urea, N-[(3,4-dihydro-6-methyl-2H-1-benzopyran-2-yl)methyl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1034770-79-0 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-4-quinolinyl]- (CA INDEX NAME)



RN 1034770-84-7 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)



RN 1034770-86-9 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-(1,2,3,4-tetrahydro-1-methyl-4-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-70-1 CAPLUS
CN Urea,
N-[[3,4-dihydro-8-(1-methylethyl)-2H-1-benzopyran-2-yl]methyl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)



RN 1034770-77-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034770-88-1 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-4-quinolinyl]- (CA INDEX NAME)



RN 1034770-91-6 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-3-quinolinyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1034770-96-1 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-3-quinolinyl]- (CA INDEX NAME)



RN 1034770-98-3 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-(1,2,3,4-tetrahydro-1-methyl-3-quinolinyl)- (CA INDEX NAME)



RN 1034771-02-2 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-3-quinolinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1034771-06-6 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[[1,2,3,4-tetrahydro-1-(phenylmethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



RN 1034771-16-8 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[[1,2,3,4-tetrahydro-1-methyl-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



IT 1034770-48-3P 1034771-12-4P 1034771-17-9P
1034771-19-1P 1034771-22-6P 1034771-26-0P

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of urea derivs. as TRPV1 antagonists)
RN 1034770-48-3 CAPLUS
CN Urea, N-(6-chloro-3,4-dihydro-2H-1-benzopyran-3-yl)-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)



RN 1034771-12-4 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[[1,2,3,4-tetrahydro-1-(phenylmethyl)-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



RN 1034771-17-9 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[[1,2,3,4-tetrahydro-7-(trifluoromethyl)-2-quinolinyl]methyl]- (CA INDEX NAME)



RN 1034771-19-1 CAPLUS

L4 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[(1,2,3,4-tetrahydro-1-methyl-2-quinolinyl)methyl]- (CA INDEX NAME)



RN 1034771-22-6 CAPLUS
CN Urea, N-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]-N'-[(3R)-3-[4-(trifluoromethyl)phenyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1034771-26-0 CAPLUS
CN Urea, N-[(3S)-3-[4-(dimethylamino)phenyl]cyclopentyl]-N'-[7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6,7,8-tetrahydro-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2008:619673 Document No. 148:5618930 Preparation of spiro-oxindole compounds
as therapeutic agents. Chafeev, Mikhail; Chowdhury, Sultan; Fraser, Robert; Fu, Jianmin; Kamboj, Rajender; Hou, Duanjie; Liu, Shifeng; Seid Bagherzadeh, Mehran; Sviridov, Serguei; Sun, Shaoyi; Sun, Jianyu; Chakka, Nagasree; Hsieh, Tom; Raina, Vandna (Xenon Pharmaceuticals Inc., Can.). PCT Int. Appl. WO 2008060789 A2 20080522, 393pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US81247 20071012. PRIORITY: US 2006-851787P 20061012.
GI



I

AB This invention is directed to methods of using spiro-oxindole compds. I [j, k = 0-3; Q = CR11H, C(O), O, SO0-2, CF2, etc.; R11 = H or OR5; R1 = substituted aralkyl, (un)substituted heterocycloalkylor heteroarylalkyl, etc.; R21-R24 = H, alkyl, alkoxy, etc.; R31-R34 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, haloalkyl, etc.] or their pharmaceutically acceptable salts, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. A few hundred compds. I were prepared Thus, 1'-(2-cyclopropylethyl)spiro{furo[2,3-f][1,3]benzodioxole-7,3'-indol}-2'(1'H)-one (II), was prepared in a multi-step synthesis, starting from isatin and (2-bromoethyl)cyclopropane. Compds. I were tested in various biol. tests. For example, II showed IC50 in the range from 1 nM to 10 nM when tested in guanidine influx assay (in vitro) used for testing and profiling agents against sodium channels.
IT 912667-46-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro-oxindole compds. as sodium channel blockers for treating and preventing hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer)
RN 912667-46-0 CAPLUS
CN Urea, N-[2-(2'-oxospiro[furo[2,3-f]-1,3-benzodioxole-7(6H),3'-[3H]indol]-1'(2'H)-yl)ethyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 4 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 5 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2008:70887 Document No. 148:1447690 Imidazole derivatives as AMPK activators, their preparation, pharmaceutical compositions, and use in therapy. Moinet, Gerard; Marais, Dominique; Hallakou-Bozec, Sophie; Charon, Christine (Merck Patent GmbH, Germany). PCT Int. Appl. WO 2008006432 A1 20080117, 82pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-EP5164 20070612. PRIORITY: FR 2006-6415 20060713.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to imidazole derivs. of formula I, which are activators of AMP-activated protein kinase (AMPK). In compds. I, one of the dotted bonds is a double bond and the other one is a single bond; R1 is (un)substituted C1-8 alkyl, (un)substituted C6-14 aryl, (un)substituted C6-14 aryl-C1-8 alkyl, (un)substituted C6-14 aryloxy-C1-8 alkyl, (un)substituted C6-14 heteroaryl, (un)substituted C6-14 heteroaryl-C1-8 alkyl, or (un)substituted C6-14 heteroaryloxy-C1-8 alkyl; R2 is H, (un)substituted C1-8 alkyl, (un)substituted C3-10 cycloalkyl, (un)substituted C6-14 aryl-C1-8 alkyl, or (un)substituted C2-14 acyl; A is -NH- or -O-; and R3 is H or (un)substituted C1-8 alkyl; including isomers, epimers, tautomers, N-oxides, hydrates, salts, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a pharmaceutically effective amount of at least one compound I in combination with one or more pharmaceutically acceptable vehicles, as well as to the use of the compns. for the treatment of obesity, insulin resistance, and diabetes and related pathologies. O-Silylation of hydroxyimidazole II followed by hydrogenation, addition to 4-(methylthio)phenyl isocyanate, and deprotection gave imidazole III. The compds. of the invention are activators of AMPK, e.g., compound III expressed 311% activation compared with basal activity in the absence of AMP.
IT 1001165-90-7P, 5-Hydroxy-3-[4-[N'-(5,6,7,8-tetrahydronaphthalen-1-yl)ureido]benzyl]-3H-imidazole-4-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazole derivs. as AMPK activators)
RN 1001165-90-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 4-hydroxy-1-[[4-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]phenyl]methyl]- (CA INDEX NAME)

L4 ANSWER 5 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



10575027.trn

L4 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2007:761332 Document No. 147:1663430 Substituted urea derivatives, processes
for preparing them, pharmaceutical compositions containing them, and their
use as modulators of the cardiac sarcomere. Morgan, Bradley P.; Kraynack,
Erica; Lu, Pu-Ping; Muci, Alex; Morgans, David J., Jr. (Cytokinetics, Inc., USA). PCT Int. Appl. WO 2007078815 A2 20070712, 90pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
APPLICATION: WO 2006-US47680 20061213. PRIORITY: US 2005-751118P 20051216.
GI



I



II



III

AB The invention relates to substituted urea derivs. I, processes for preparing
them, pharmaceutical prepns. comprising them, and their pharmaceutical use. I are modulators of the cardiac sarcomere, for example by

L4 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
potentiating cardiac myosin, useful in the treatment of systolic heart failure including congestive heart failure (no data). In compd. I, A is chosen from (hetero)cycloalkyl, and (hetero)aryl groups having from 5 to 7
atoms including the atoms shared with the 6 membered arom. ring contg. W; W is N or C; p is 0 or 1; R1 and R2 independently represent H, CN, halo, etc.; R3 is (un)substituted NH2, alkyl, aryl, etc.; R4 is (un)substituted alkyl and halo; L is a bond, (un)substituted lower alkylene, O, S, SO2, etc.; one of Z1 and Z2 is (un)substituted NHC(O)NHR5 and the other of Z1 and Z2 is R6 [wherein R5 is (un)substituted (hetero)aryl, (hetero)cycloalkyl, etc.; R6 is H, CN, OH, halo, etc.]; including pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixts. thereof. For instance, nitration of indanone (18%) followed by redn. (90%), chlorination (79%), and substitution with methylpiperazine carboxylate hydrochloride (78%) gave the intermediate II as a brown oil. N-redn. (92%) of II followed by reaction with 2-methyl-5-isocyanatopyridine (51%) gave the invention compd. III as a light brown solid.
IT 873701-48-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of urea derivs. as modulators of cardiac sarcomere)
RN 873701-48-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]-1-naphthalenyl]-, methyl ester (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A

L4 ANSWER 7 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2006:1224966 Document No. 146:77040 Preparation of pentafluorosulphanyl-substituted compounds and for use in producing medicaments. Frank, Robert; Sundermann, Bernd; Schick, Hans (Gruenenthal G.m.b.H., Germany). PCT Int. Appl. WO 2006122773 A1 20061123, 77pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2.
APPLICATION: WO 2006-EP4658 20060517. PRIORITY: DE 2005-102005023943 20050520.
GI

I



II

AB The present invention relates to pentafluorosulphanyl-substituted compds. I [R1 = H, F, Cl, Br, I, -CN, -NC, NO2, SO3H, SO2NH2, NH2, OH, SH, Me, Et,
CH2Et, CHMe2, Bu, CHMeEt, CH2CHMe2, CMe3, pnethyl, sec-pentyl, hexyl, OMe,
OEt, OCHMe2, OCMe3, SMe, SEt, SCHMe2, SCMe3, NMe2, NEt2, NHMe, NHEt, NHCOMe, NHCOEt, CONH2, COMe, COEt, CO2H, CO2Me, CO2Et; R2 = ABD, EF, NHG, QBD (at the 2-, 3-, 4-, 5-, 6-position of the Ph ring); Q = oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl or condensed with the Ph ring = benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzimidazolyl; A =
NR3, CONR4, NR3C(:S)NR4, NR5CO, NR5CS, NR6-(aromatic azaheterocyclyl); B =
azaheterocyclyl; D = Ph, 1,3,5-triazinyl, pyridinyl, pyridazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, pyrazinyl; E = CH2CH2NR7CONR8, CH2CH2NR7CSNR8, CH2NR9CONR10, CH2NR9CSNR10, CH:CHCONR11, CH:CHCSNR11, CH2CH2NR12CONR13CH2CH2, CH2CH2NR1CSNR1CH2CH2, CH2NR14CONR15CH2, CH2NR14CSNR15CH2, etc.; F = Ph, naphthyl, quinolinyl,

L4 ANSWER 7 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
isoquinolinyl,quinoxalinyl, quinazolinyl, benzodioxanyl, benzodioxolyl, etc.; G = tetrazaindoles, triazines, pyrimidines, etc.; R3 - R25 = H, Me, Et, Pr-n, Pr-i, Bu-n, Bu-s, Bu-i, Bu-t, pentyl, hexyl; n = 0, 1, 2, 3, 4],
processes for prepg. them, medicaments comprising these compds., and the use of these compds. for producing medicaments. Thus, N-(4-[3-(4-(pentafluorosulfanyl)benzyl)thioureidomethyl]-2-fluorophenyl]methanesulfonamide (II) was prepd. from N-(2-fluoro-4-iodophenyl)methanesulfonamide via cyanolysis with Zn(CN)2 in
DMF contg. catalytic Pd(PPh3)4, hydrogenation over Raney Ni in MeOH, and thiocarbamoylation with 4-(F5S)C6H4CH2NCS in DMF contg. Et3N. The inhibitory activity and binding ability of II towards VR1 receptors was detd. [IC50 = 0.36 μM (rat); IC50 = 0.8 μM (human); Ki = 0.084 μM].
IT 915217-54-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pentafluorosulphanyl-substituted compds. and for use as
medicaments)
RN 915217-54-8 CAPLUS
CN Sulfur, pentafluoro[4-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]phenyl]-, (OC-6-21)- (CA INDEX NAME)



L4 ANSWER 8 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2006:1095378 Document No. 145:4385960 Spiro-oxindole compounds and their preparation, pharmaceutical compositions and use as sodium channel blockers. Chafeev, Mikhail; Chowdhury, Sultan; Fraser, Robert; Fu, Jianmin; Kamboj, Rajender; Hou, Duanjie; Liu, Shifeng; Bagherzadeh, Mehran
Seid; Sviridov, Serguei; Sun, Shaoyi; Sun, Jianyu; Chakka, Nagasree; Hsieh, Tom; Raina, Vandna (Xenon Pharmaceuticals Inc., Can.). PCT Int. Appl. WO 2006110917 A2 20061019, 496pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US14352 20060411. PRIORITY: US 2005-670896P 20050411.
GI



I



II

AB This invention is directed to spiro-oxindole compds. of formula I: as a stereoisomer, enantiomer, tautomer thereof or mixts. thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compns. comprising the compds. and methods of preparing and using the compds. are also disclosed. Compds. of formula I m and n are independently 0, 1 , 2 and 3;

L4 ANSWER 8 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Q is CH2, CHOH and derivs., CO, O, S, SO, SO2, CF3, CONH2 and derivs., and
NHCO and derivs.; R1 is H, (halo)alkyl, alkenyl, alkynyl, (hetero)aryl, cycloalkyl(alkyl), heterocyclyl, etc.; R2a, R2b, R2c, R2c', R3a, R3b, R3c,
and R3c' are independently H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, (halo)alkoxy, halo, cycloalkyl(alkyl), (hetero)aryl(alkyl), aralkenyl, etc.; and their stereoisomers, enantiomers, tautomers, mixts. thereof, and
pharmaceutically acceptable salts, solvates and prodrugs thereof are claimed. Example compd. II was prepd. by spirocyclization of 1-(2-cyclopropylethyl)-3-(6-hydroxy-1,3-benzodioxol-5-yl)-3-(hydroxymethyl)-1,3-dihydro-2H-indol-2-one. All the invention compds. were evaluated for their sodium channel blocking ability.
IT 912667-46-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of spiro-oxindole compds. as sodium channel
blockers useful in treatment of diseases)
RN 912667-46-0 CAPLUS
CN Urea, N-[2-(2'-oxospiro[furo[2,3-f]-1,3-benzodioxole-7(6H),3'-[3H]indol]-1'(2'H)-yl)ethyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2006:945846 Document No. 145:3424250 Use of hydroxy tetrahydro-naphthalene derivatives for prophylaxis and treatment of diseases assocd. with VR1 activity. Alonso-Alija, Cristina; Gupta, Jang; Hinzen, Berthold (Bayer Healthcare AG, Germany). PCT Int. Appl. WO 2006094627 A2 20060914, 16pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-EP1575 20060222. PRIORITY: EP 2005-4878 20050305.
AB This invention relates to new uses of hydroxy-tetrahydro-naphthalenylurea derivs. which are described in WO 03/095420 as an active ingredient of pharmaceutical prepns. for the treatment of diseases associated with vanilloid receptor VR1 activity. The new uses of the present invention are the prophylaxis and treatment of diseases associated with VR1 activity,
in particular for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous
irritants such as tobacco smoke, smog, high levels of atmospheric SO2 and noxious
gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis.
IT 624728-45-6 624728-46-7 624728-47-8
624728-48-9 624728-50-3 624728-51-4
624728-54-7 624728-55-8 624728-56-9
624728-64-9 624728-86-5 624728-87-6
624728-88-7 624728-89-8 624728-90-1
624729-06-2 624729-11-9 624729-19-7
624729-20-0 624729-23-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxytetrahydronaphthalene derivs. for prophylaxis and treatment of diseases associated with VR1 activity)
RN 624728-45-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-46-7 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-47-8 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-48-9 CAPLUS
CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-50-3 CAPLUS
CN Urea,
N-(3-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-51-4 CAPLUS
CN Urea,
N-(4-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-54-7 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-55-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 624728-56-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-64-9 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-86-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-87-6 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-88-7 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-89-8 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-90-1 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-06-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[(2,4,6-trimethoxyphenyl)methyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-11-9 CAPLUS
CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-19-7 CAPLUS
CN Urea, N-[2-(4-chlorophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-20-0 CAPLUS
CN Urea, N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-23-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 9 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 10 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2006:117875 Document No. 144:2126610 Preparation of piperidine derivatives as histamine H3 receptor ligands for treatment of depression. Folmer, James; Hunt, Simon Fraser; Hamley, Peter; Wesolowski, Steven (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2006014136 A1 20060209, 53 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-SE1189 20050727. PRIORITY: SE 2004-1971 20040802.
GI



AB The title piperidine derivs. I [wherein Q = -N(CH2CH2)2N-, -N(CH2CH2)2CH-O-, -N(CH2CH2)2CH-NH-CO-, etc.; Ar = (un)substituted (hetero)aryl], or pharmaceutically acceptable salts, diastereomers, enantiomers, or mixts. thereof were prepared as histamine H3 receptor ligands for treatment of depression. For example, 3,4-dichlorobenzylamine was reacted with 4-nitrophenyl chloroformate in THF in the presence of diisopropylethylamine, followed by the addition of 4-amino-1-methylpiperidine to give II (22%). The biol. activity of the title compds. as histamine H3 receptor ligands binding towards human recombinant H4 receptor was tested (no data). The compds. are useful in therapy, in particular in the treatment of depression (no data).
IT 875586-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperidine and piperazine derivs. as histamine H3 receptor ligands for treatment of depression)
RN 875586-95-1 CAPLUS
CN Urea, N-(1-methyl-4-piperidinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 10 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 11 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2006:117041 Document No. 144:2128000 Preparation of piperidine and piperazine derivatives as histamine H3 receptor ligands for treatment of depression. Folmer, James; Hunt, Simon Fraser; Hamley, Peter; Wesolowski, Steven (Astrazeneca AB, Swed.). PCT Int. Appl. WO 2006014135 A1 20060209, 67 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-SE1188 20050727. PRIORITY: SE 2004-1970 20040802.

GI



I

II

AB The title piperidine and piperazine derivs. with general formula of I and II [wherein R = alkyl; Q = -N(CH2CH2)2CH-, -N(CH2CH2)2N-, -N(CH2CH2)2CH-O-, -N(CH2CH2)2CH-NH-CO-, etc.; Ar = (un)substituted (hetero)aryl], or pharmaceutically acceptable salts, diastereomers, enantiomers, or mixts. thereof were prepared as histamine H3 receptor ligands for treatment of depression. For example, 3,4-dichlorobenzylamine was reacted with 4-nitrophenyl chloroformate in THF in the presence of diisopropylethylamine, followed by the addition of N-methylpiperazine to give N-(3,4-dichlorobenzyl)-4-methylpiperazine-1-carboxamide (73%). The biol. activity of the title compds. as histamine H3 receptor ligands binding towards human recombinant H4 receptor was tested (no data). The compds. are useful in therapy, in particular in the treatment of depression (no data).

IT 875547-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidine and piperazine derivs. as histamine H3 receptor ligands for treatment of depression)

RN 875547-16-3 CAPLUS

CN Urea, N-[3-(1-piperidinyl)propyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 11 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 12 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2006:53665 Document No. 144:1503930 Preparation of heterocyclic phenyl ureas as selective modifiers of cardiac sarcomere for treating heart disease. Morgan, Bradley Paul; Muci, Alex; Lu, Pu-Ping; Kraynack, Erica Anne; Tochimoto, Todd; Morgans, David J. (USA). U.S. Pat. Appl. Publ. US 20060014761 A1 20060119, 70 pp. (English). CODEN: USXXCO. APPLICATION: US 2005-155940 20050616. PRIORITY: US 2004-581197P 20040617.

GI



I

AB Certain substituted urea derivs. of general formula I (wherein W, X, Y, and Z = C or N, provided that no more than 2 = N; n = 1-3; R1 = (un)substituted amino or heterocycloalkyl; R2 = (un)substituted aryl, aralkyl, cycloalkyl, heteroaryl, etc.; R3 = H, halo, CN, (un)substituted alkyl, heterocycloalkyl, or heteroaryl when W = C, but absent when W = N; R4 = H, halo, CN, (un)substituted alkyl, heterocycloalkyl, or heteroaryl when Y = C, but absent when Y = N; and R5 = H, halo, CN, (un)substituted alkyl, heterocycloalkyl, or heteroaryl when X is C, but absent when X = N; R13 is H, halo, CN, OH, (un)substituted alkyl, heterocycloalkyl, or heteroaryl when Z = C, but absent when Z = N; and R6 and R7 = hydrogen, aminocarbonyl, alkoxycarbonyl, (un)substituted alkyl or alkoxy, or together form part of an (un)substituted 3-7-membered ring) selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. Preparation of the compds. is exemplified. For example, Me 4-[4-fluoro-3-[3-(5-methylisoxazol-3-yl)ureido]benzyl]piperazine-1-carboxylate was prepared from 5-methylisoxazol-3-amine and the appropriate piperazinyl aminophenyl compound No biol. data for specific I are given.

IT 873701-48-5P, Methyl 4-[5-[[[[(6-methyl-3-pyridyl)]amino]carbonyl]amino]-1,2,3,4-tetrahydronaphthyl]piperazine-1-carboxylate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic Ph ureas as selective modifiers of cardiac sarcomere for treating heart disease)

RN 873701-48-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,2,3,4-tetrahydro-5-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]-1-naphthalenyl]-, methyl ester (CA INDEX NAME)

L4 ANSWER 12 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

10575027.trn

L4 ANSWER 13 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2005:1103773 Document No. 143:3870290 Preparation of tricyclic pyrazole kinase inhibitors. Makoto, Aoyama; Arnold, Lee D.; Dinges, Juergen; Dixon, Richard W.; Djuric, Stevan W.; Ericsson, Anna M.; Fischer, Kimba; Gasiecki, Alan F.; Gracias, Vijaya J.; Holms, James H.; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Steinman, Douglas H.; Wada, Carol K.; Xia, Zhiren; Akritopoulou-zanze, Irini; Zhang, Henry Q. (Abbott Laboratories, USA; et al.). PCT Int. Appl. WO 2005095387 A1 20051013, 397 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US9900 20050324. PRIORITY: US 2004-556005P 20040324.
GI



I

AB The title compds. I [X1 = C, N; X2 = CH2, CO, O; R1-R3 = H, alkoxyalkoxy, halo, heteroaryl, etc.; R4 is absent or is selected from H, alkoxyalkoxy, halo, heteroaryl, etc.; R5 = heteroaryl, substituted C.tplbond.CH, etc.], useful for inhibiting protein tyrosine kinases, were prepared Thus, reacting 6-[(4-methyl-1-piperazinyl)methyl]-1-indanone with Ph 2-thiophenecarboxylate (prepns. of the reactants given) in the presence of NaH in benzene followed by treating the crude intermediate with hydrazine monohydrate and acetic acid afforded 79% 7-[(4-methyl-1-piperazinyl)methyl]-3-(2-thienyl)-1,4-dihydroindeno[1,2-c]pyrazole. The compds. I inhibited KDR at IC50's between about 50,000 nM to about 1 nM. Also disclosed are methods of making the compds. I, compns. containing the compds. I, and methods of treatment using the compds. I.
IT 866853-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indenopyrazole kinase inhibitors)
RN 866853-18-1 CAPLUS

L4 ANSWER 13 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-[[5-[1,4-dihydro-6-[(4-methyl-1-piperazinyl)methyl]indeno[1,2-c]pyrazol-3-yl]-2-thienyl]methyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 14 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2005:641873 Document No. 143:1532990 Preparation of substituted urea derivatives for use in treating heart failure. Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-Ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J. (USA). U.S. Pat. Appl. Publ. US 20050159416 A1 20050721, 64 pp., Cont.-in-part of Appl. No. PCT/US04/001069. (English). CODEN: USXXCO. APPLICATION: US 2004-890829 20040714. PRIORITY: US 2003-440133P 20030114; US 2003-440183P 20030114; US 2003-476086P 20030604; US 2003-476517P 20030605; US 2003-501376P 20030908; WO 2004-US1069 20040114.
AB The present invention provides substituted urea derivs., pharmaceutical compns. containing the derivs., and methods for the treatment of heart failure including congestive heart failure, particularly systolic heart failure. The compns. are selective modulators of the cardiac sarcomere, for example, potentiating cardiac myosin. The ureas of the invention are represented by the formula R1NHC(O)NHR2 wherein: R1 is optionally substituted aryl or heteroaryl; and R2 is optionally substituted aryl, aralkyl; cycloalkyl, heteroaryl, heteroaralkyl or heterocyclyl, including single stereoisomers, mixts. of stereoisomers, and the pharmaceutically acceptable salts, solvates, and solvates of pharmaceutically acceptable salts thereof.
IT 1055940-96-9
RL: PRPH (Prophetic)
(Preparation of substituted urea derivatives for use in treating heart failure)
RN 1055940-96-9 CAPLUS
CN Urea, N-(3-hydroxyphenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 15 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2005:527397 Document No. 143:780960 Preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases. Collini, Michael D.; Singhaus, Robert R.; Hu, Baihua; Jetter, James W.; Morris, Robert L.; Kaufman, David H.; Miller, Christopher P.; Ullrich, John W.; Unwalla, Rayomand J.; Wrobel, Jay E.; Quinet, Elaine; Nambi, Ponnal; Bernotas, Ronald C.; Elloso, Merle (Wyeth, John, and Brother Ltd., USA). U.S. Pat. Appl. Publ. US 20050131014 A1 20050616, 169 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-10236 20041210. PRIORITY: US 2003-529009P 20031212; US 2004-600296P 20040810.
GI



I

AB This invention provides quinolines of formula I (R1 = H or C1-C3 alkyl; X1 = a bond or an appropriate group to link R2 which is an optionally substituted heterocycle; X2 = a bond or CH2; R3 = optionally substituted Ph, naphthyl, or heterocycle; R4, R5, and R6 = H or F, R7 = H, C1-C4 alkyl, C1-C4 perfluoroalkyl, halogen, NO2, CN, optionally substituted phenyl) that are useful in the treatment or inhibition of LXR mediated diseases (no data). The LXR mediated diseases specifically claimed are, for example, atherosclerosis, Alzheimer's disease, dementia, diabetes, multiple sclerosis, and thyroiditis. Pharmaceutical compns. containing the compds. of the invention and synthetic procedures for preparing them are also claimed.
IT 854767-81-0P, N-[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenyl]-N'-(5,6,7,8-Tetrahydronaphthalen-1-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases)
RN 854767-81-0 CAPLUS
CN Urea, N-[3-[3-benzoyl-8-(trifluoromethyl)-4-quinolinyl]phenyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 15 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2005:395257 Document No. 142:4470180 Preparation of tetrahydronaphthalene and urea derivatives as VR1 antagonists for the prophylaxis and treatment of diseases associated with VR1 activity, such as urological diseases, pain and inflammatory diseases. Bouchon, Axel; Diedrichs, Nicole; Hermann, Achim; Lustig, Klemens; Meier, Heinrich; Pernerstorfer, Josef; Reissmueller, Elke; Mogi, Muneto; Yura, Takeshi; Fujishima, Hiroshi; Seki, Masaomi; Koriyama, Yuji; Yasoshima, Kayo; Misawa, Keiko; Tajimi, Masaomi; Yamamoto, Noriyuki; Urbahns, Klaus; Hayashi, Fumihiko; Tsukimi, Yasuhiro; Gupta, Jang (Bayer Healthcare Ag, Germany). PCT Int. Appl. WO 2005040100 A1 20050506, 149 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-EP11008 20041002. PRIORITY: EP 2003-23288 20031015; EP 2003-23287 20031015; EP 2003-25573 20031108; EP 2003-25572 20031108.

GI



II

AB This invention relates to title compds. of formula A-NH-CO-E (I) [wherein A = 7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl, 5,8-dihydrotetranaphthalen-1-yl; indan-4-yl, inden-4-yl, etc.; E =cycloalkyl optionally fused by aryl, (un)substituted Ph, hetero/aryl, NH-(CH2)n-R4, etc.; n = 0-6; R4 = (un)substituted aryl] and tautomeric or stereoisomers and salts thereof, which are useful as active ingredients of pharmaceutical prepns. I have been synthesized as VR1 antagonists, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urol. disorders or diseases, pain and inflammatory disorders or diseases. Thus, reacting (6-Ethoxy-5,8-dihydronaphthalen-1-yl)amine (preparation given) with 4-Chloro-3-trifluoromethylbenzene isocyanate gave II. The effects of the compds. were examined in the following several assays and pharmacol. tests: measurement of capsaicin-induced Ca2+ influx in a human VR1-transfected

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CHO cell line and in primary cultured rat dorsal root ganglia neurons, resp., measurement of capsaicin-induced bladder contraction, measurement of overactive bladder in anesthetized cystitis rats, measurement of acute pain, persistent pain, neuropathic pain, inflammatory pain and diabetic neuropathic pain (only the 1st assay had data). II showed an IC50 in the range of 0.1 to 0.6 μM in the 1st assay. Specifically disclosed applications of I include the treatment of detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

IT 851266-30-3P, 1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-(6-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of tetrahydronaphthalene and urea derivs. as VR1 antagonists)

RN 851266-30-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-6-oxo-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

851266-55-2P 851266-56-3P 851266-57-4P
851266-58-5P 851266-59-6P 851266-60-9P
851266-61-0P, 1-[(2,2-Difluoro-1,3-benzodioxol-5-yl)methyl]-3-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea
851266-62-1P, 1-[[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]methyl]-3-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of tetrahydronaphthalene and urea derivs. as VR1 antagonists)

RN 851266-32-5 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-6-oxo-1-naphthalenyl)-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 851266-33-6 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-6-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

IT 851266-32-5P 851266-33-6P 851266-34-7P
851266-35-8P 851266-36-9P 851266-37-0P,
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea 851266-42-7P,
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-(7-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)urea 851266-47-2P,
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[7-(hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-1-yl]urea 851266-48-3P,
1-(1,3-Benzodioxol-5-yl)-3-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea 851266-49-4P 851266-50-7P 851266-51-8P
851266-52-9P 851266-53-0P 851266-54-1P

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-34-7 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-6,7-dihydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-35-8 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-6-methoxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-42-7 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-methyl-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-47-2 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[5,6,7,8-tetrahydro-7-(hydroxymethyl)-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-36-9 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-6-hydroxy-7-methoxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-37-0 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-6-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-48-3 CAPLUS
CN Urea, N-1,3-benzodioxol-5-yl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-49-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 851266-50-7 CAPLUS
CN Urea, N-(2,3-dihydro-1H-inden-1-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-51-8 CAPLUS
CN Urea, N-[4-(4-pyridinyloxy)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-52-9 CAPLUS
CN Urea, N-(3-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-53-0 CAPLUS
CN Urea, N-(4-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-54-1 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-55-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (CA INDEX NAME)



RN 851266-56-3 CAPLUS
CN Urea, N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-57-4 CAPLUS
CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-58-5 CAPLUS
CN Urea, N-[3-(4-pyridinyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 851266-59-6 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[6-

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 851266-60-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[6-(trifluoromethyl)-3-pyridinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 851266-61-0 CAPLUS
CN Urea, N-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 16 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851266-62-1 CAPLUS
CN Urea, N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2005:304661 Document No. 142:3737090 Preparation of benzazepines and benzonaphthazepines as selective dopamine D1/D5 receptor antagonists for the treatment of metabolic and CNS disorders. Burnett, Duane A.; Greenlee, William J.; McKirtrick, Brian; Su, Jing; Zhu, Zhaoning; Sasikumar, Thavalakulamgara K.; Mazzola, Robert; Qiang, Li; Ye, Yuanzan (Schering Corporation, USA). U.S. Pat. Appl. Publ. US 20050075325 A1 20050407, 170 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-850530
20040520. PRIORITY: US 2003-472534P 20030522.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Benzazepines I [G = H, halo, alkyl, alkylthio, O2N, NC, HO, alkoxy, alkylsulfinyl, alkylsulfonyl, F3C, F3CO; R1 = H, alkyl, H2C:CHCH2, cycloalkyl, cycloalkylalkyl; R2 = F3CO, O2N, NC, (un)substituted aryl, heteroaryl, amino, aminomethyl, acyl, carboxy, aminocarbonyl, aminosulfonyl, alkoxymethyl,alkoxyiminoformyl; R11 = H, alkyl; R12 = H, R2, halo, HO, alkyl, alkylthio, alkylsulfonyl, alkoxy; V = H2, (un)substituted CH2, CH2CH2] such as II and III are prepared as selective dopamine D1/D5 receptor antagonists for the treatment of metabolic disorders such as diabetes and obesity, eating disorders such as anorexia nervosa and bulimia, and CNS disorders such as obsessive-compulsive disorder and autism. Ecopipam IV is O-acylated with p-nitrobenzoyl chloride, the ester nitrated with nitronium tetrafluoroborate and hydrolyzed with potassium hydroxide to give a mixture of regioisomeric nitrobenzo[d]naphth[2,1-b]azepines which are separated by HPLC; reduction of the
nitro group, attachment of the free phenol to a resin, sulfonylation of the free amine with methanesulfonyl chloride, and cleavage of the product from the resin with trifluoroacetic acid yields II. 9-Data on the binding
of some of the title compds. to the dopamine D1 receptor and their selectivities for the dopamine D1 receptor over the dopamine D2 receptor are given; for example, compound II has a Ki value of 0.45 nM at the dopamine D1 receptor and >6000-fold selectivity for the dopamine D1 receptor over the dopamine D2 receptor.
IT 849511-72-4P 849511-74-6P 849511-76-8P
849511-78-0P 849511-88-2P 849511-90-6P
849511-92-8P 849511-94-0P 849511-96-2P
849511-98-4P 849512-00-1P 849512-02-3P
849512-04-5P 849512-06-7P 849512-08-9P
849512-10-3P 849512-12-5P 849512-14-7P
849512-16-9P 849512-18-1P 849512-20-5P
849512-22-7P 849512-26-1P 849512-28-3P
849512-30-7P 849512-32-9P 849512-35-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzazepines and benzonaphthazepines as
selective dopamine D1/D5 receptor antagonists for treatment of metabolic and CNS disorders such as obesity, diabetes, anorexia, and autism)
RN 849511-72-4 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(3-chlorophenyl)-, rel- (CA INDEX
NAME)

Relative stereochemistry.



RN 849511-74-6 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849511-76-8 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(4-chlorophenyl)-, rel- (CA INDEX
NAME)

Relative stereochemistry.



RN 849511-78-0 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(2-chlorophenyl)-, rel- (CA INDEX
NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849511-88-2 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-cyclohexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 849511-90-6 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(3-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849511-92-8 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(4-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849511-94-0 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(3-cyanophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849511-96-2 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(4-cyanophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849511-98-4 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849512-00-1 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(2-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849512-02-3 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(4-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-04-5 CAPLUS
CN Urea,
N-(4-acetylphenyl)-N'-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-06-7 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(2,5-dichlorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 849512-08-9 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(2,6-dichlorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849512-10-3 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(2,3-dichlorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 849512-12-5 CAPLUS
CN Urea, N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-[(3,4-dichlorophenyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-14-7 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 849512-16-9 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-[3-(trifluoromethyl)phenyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 849512-18-1 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-[4-(trifluoromethyl)phenyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849512-20-5 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-22-7 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-[4-(dimethylamino)phenyl]-, rel-

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 849512-28-3 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(2-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-30-7 CAPLUS
CN Urea, N-[(3aR,9bR)-12-chloro-2,3,3a,4,5,9b-hexahydro-11-hydroxy-3-methyl-1H-benzo[d]naphth[2,1-b]azepin-6-yl]-N'-(diphenylmethyl)-, rel- (CA INDEX

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.



RN 849512-26-1 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-cyclopentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
NAME)

Relative stereochemistry.



RN 849512-32-9 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 849512-35-2 CAPLUS
CN Urea,
N-[(6aR,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-12-hydroxy-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-4-yl]-N'-(2,6-dichloro-4-pyridinyl)-, rel-
(CA INDEX NAME)

L4 ANSWER 17 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Relative stereochemistry.

PAGE 1-A



PAGE 2-A

L4 ANSWER 18 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2005:9235 Document No. 142:86675 Vanilloid receptor 1 inhibitors for treatment of human immunodeficiency virus (HIV)-mediated neuropathies and pain states. Bouchon, Axel; Misawa, Keiko (Bayer Healthcare AG, Germany).
Eur. Pat. Appl. EP 1493438 A1 20050105, 42 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK. (English). CODEN: EPXXDW. APPLICATION: EP 2003-15052 20030703.
AB The invention relates to the application of Vanilloid receptor (VR) 1 inhibitors for drug development and for the treatment of HIV-mediated neuropathies and neuropathic pain states. Further, the inventor identified a novel signaling cascade connecting the HIV receptor CXCR4 to VR1. Thus, the invention provides mol. evidence that HIV-mediated pain states - initiated upon binding of the virus to CXCR4 - can be inhibited by VR1 antagonists blocking the final execution of the CXCR4NR1 pathway. In addition, the invention demonstrates that present standard therapies for HIV-mediated pain (which do not include VR1 inhibitors) can not interfere with the CXCR4/VR1 pathway thus explaining inefficient patient treatment in the clinics. N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-(4-trifluoromethoxy-benzyl)urea (preparation given) completely inhibited gp120-mediated calcitonin gene-related peptide release from dorsal root ganglion neurons.
IT 624728-86-5P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vanilloid receptor 1 inhibitors for treatment of human immunodeficiency virus (HIV)-mediated neuropathies and pain states)
RN 624728-86-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



L4 ANSWER 18 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L4 ANSWER 19 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2004:878168 Document No. 141:3606650 Synergistic methods and compositions using insulin-like growth factor 1 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating cancer. Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis Y. (USA). U.S. Pat. Appl. Publ. US 20040209930 A1 20041021, 66 pp., Cont.-in-part of U.S. Ser. No. 676,214. (English). CODEN: USXXCO. APPLICATION: US 2004-814199 20040331. PRIORITY: US 2002-415416P 20021002; US 2003-676214 20031001; US 2003-677067 20031001.
AB Combination therapies using IGF1R inhibitors in combination with addnl. kinase inhibitors are described for the synergistic treatment of cancer.
IT 302960-34-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGF1 receptor inhibitors with addnl. kinase inhibitors for synergistic treatment of cancer)
RN 302960-34-5 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-2-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 19 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L4 ANSWER 20 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2004:633440 Document No. 141:1677840 Compositions and methods to treat heart failure. Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack, Erica Anne; Lu, Pu-ping; Malik, Fady; Muci, Alex; Qian, Xiangping; Smith, Whitney Walter; Tochimoto, Todd; Tomasi, Adam Lewis; Morgans, David J., Jr. (Cytokinetics, Inc., USA). PCT Int. Appl. WO 2004064730 A2 20040805, 132 pp. DESIGNATED STATES: W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US1069 20040114. PRIORITY: US 2003-440133P 20030114; US 2003-440183P 20030114; US 2003-476086P 20030604; US 2003-476517P 20030605; US 2003-501376P 20030908.

AB Certain substituted urea derivs. selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

IT 1055940-96-9
RL: PRPH (Prophetic)
(Compositions and methods to treat heart failure)

RN 1055940-96-9 CAPLUS

CN Urea, N-(3-hydroxyphenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2004:515474 Document No. 141:713590 Preparation of tetrahydronaphthalene derivatives as vaniloid receptor antagonists. Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Urbahns, Klaus; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya (Bayer Healthcare Ag, Germany). PCT Int. Appl. WO 2004052846 A1 20040624, 81 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP13453 20031128. PRIORITY: EP 2002-27523 20021206.

GI



I

AB The title compds. I [R1 = H, alkyl; X = biphenyl, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of I was demonstrated.

IT 711015-38-2P 711015-39-3P 711015-40-6P
711015-41-7P 711015-43-9P 711015-44-0P
711015-45-1P 711015-46-2P 711015-47-3P
711015-48-4P 711015-49-5P 711015-50-8P
711015-51-9P 711015-52-0P 711015-53-1P
711015-54-2P 711015-55-3P 711015-56-4P
711015-57-5P 711015-58-6P 711015-59-7P
711015-60-0P 711015-61-1P 711015-62-2P
711015-63-3P 711015-64-4P 711015-65-5P
711015-66-6P 711015-67-7P 711015-68-8P
711015-69-9P 711015-70-2P 711015-71-3P
711015-72-4P 711015-73-5P 711015-74-6P
711015-75-7P 711015-76-8P 711015-77-9P
711015-78-0P 711015-79-1P 711015-80-4P
711015-81-5P 711015-82-6P 711015-83-7P
711015-84-8P 711015-85-9P 711015-86-0P
711015-87-1P 711015-88-2P 711015-89-3P
711015-90-6P 711015-91-7P 711015-92-8P
711015-93-9P 711015-94-0P 711015-95-1P
711015-96-2P 711015-97-3P 711015-98-4P
711015-99-5P 711016-00-1P 711016-01-2P
711016-02-3P 711016-03-4P 711016-04-5P
711016-05-6P 711016-06-7P 711016-07-8P

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

711016-08-9P 711016-09-0P 711016-10-3P
711016-11-4P 711016-12-5P 711016-13-6P
711016-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)

RN 711015-38-2 CAPLUS

CN Urea, N-(4'-methyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-39-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 711015-40-6 CAPLUS

CN Urea, N-(4'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-41-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid,

3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-
(CA INDEX NAME)



RN 711015-43-9 CAPLUS
CN Urea, N-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-
hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-44-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid,

3'-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-,
ethyl ester (CA INDEX NAME)



RN 711015-45-1 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-
(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-46-2 CAPLUS
CN Urea,
N-(2'-chloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-
naphthalenyl)- (CA INDEX NAME)



RN 711015-47-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[2'-
(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-48-4 CAPLUS
CN Urea, N-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-
hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-49-5 CAPLUS
CN Urea, N-(3',5'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-
hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-50-8 CAPLUS
CN Urea, N-(3',5'-dimethyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-51-9 CAPLUS
CN Urea,
N-(3'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-52-0 CAPLUS
CN Urea,
N-(4'-methoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-53-1 CAPLUS
CN Urea, N-(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-54-2 CAPLUS
CN Urea,
N-(4'-fluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-55-3 CAPLUS
CN Urea, N-(3',4'-difluoro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-56-4 CAPLUS
CN Urea,
N-(3'-chloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-57-5 CAPLUS
CN Urea, N-(3',5'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-58-6 CAPLUS
CN Urea, N-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-59-7 CAPLUS
CN Urea, N-(2',4'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-60-0 CAPLUS
CN Urea, N-(2',5'-dichloro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-61-1 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-62-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 711015-63-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 711015-64-4 CAPLUS
CN Urea, N-[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-65-5 CAPLUS
CN Urea, N-(4'-acetyl[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-66-6 CAPLUS
CN Urea, N-(3'-nitro[1,1'-biphenyl]-3-yl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-67-7 CAPLUS
CN Urea, N-[4'-[2-(4-morpholinyl)ethoxy][1,1'-biphenyl]-3-yl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-68-8 CAPLUS
CN Urea, N-[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-69-9 CAPLUS
CN Urea, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 711015-70-2 CAPLUS
CN Urea, N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-71-3 CAPLUS
CN Urea, N-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-72-4 CAPLUS
CN Urea, N-[(2',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-73-5 CAPLUS
CN Urea, N-[(2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-74-6 CAPLUS
CN Urea, N-[(2',5'-dimethoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-75-7 CAPLUS
CN Urea, N-[(2',5'-dimethyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-76-8 CAPLUS
CN Urea, N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-79-1 CAPLUS
CN Urea, N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-80-4 CAPLUS
CN Urea, N-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-77-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 711015-78-0 CAPLUS
CN Urea, N-[(2',4'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-81-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 711015-82-6 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-83-7 CAPLUS
CN Urea, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-84-8 CAPLUS
CN Urea, N-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 711015-86-0 CAPLUS
CN Urea, N-[(2'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-87-1 CAPLUS
CN Urea, N-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-88-2 CAPLUS
CN Urea, N-[(2',6'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-85-9 CAPLUS
CN Urea, N-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-89-3 CAPLUS
CN Urea, N-[(3',5'-dimethyl[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-90-6 CAPLUS
CN Urea, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-91-7 CAPLUS
CN Urea, N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-92-8 CAPLUS
CN Urea, N-[(3'-nitro[1,1'-biphenyl]-4-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-93-9 CAPLUS
CN Urea, N-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-94-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-95-1 CAPLUS
CN Urea, N-[[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-96-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]methyl]- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-97-3 CAPLUS
CN Urea, N-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711015-98-4 CAPLUS
CN Urea, N-[(2',5'-dimethoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711015-99-5 CAPLUS
CN Urea,
N-[(2'-methoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-00-1 CAPLUS
CN Urea, N-[(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-03-4 CAPLUS
CN Urea, N-[(3',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-04-5 CAPLUS
CN Urea, N-[(2'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-01-2 CAPLUS
CN Urea, N-[(3'-nitro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-02-3 CAPLUS
CN Urea, N-[(2',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-05-6 CAPLUS
CN Urea, N-[(3',5'-dimethyl[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-06-7 CAPLUS
CN Urea, N-[[4'-(methylthio)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-07-8 CAPLUS
CN Urea, N-[(2',6'-difluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-08-9 CAPLUS
CN Urea, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-09-0 CAPLUS
CN Urea, N-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-10-3 CAPLUS
CN Urea, N-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-11-4 CAPLUS
CN Urea,
N-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-12-5 CAPLUS
CN Urea, N-[[4'-(methylsulfinyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 711016-13-6 CAPLUS
CN Urea, N-[3-(1-naphthalenyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 711016-14-7 CAPLUS
CN Urea,
N-[[4'-(methylthio)-6-(1-piperidinyl)[1,1'-biphenyl]-3-yl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 21 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 624729-51-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydronaphthalene derivs. as vaniloid receptor antagonists)
RN 624729-51-7 CAPLUS
CN Urea, N-(3-iodophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(prepn. of tetrahydronaphthalene derivs. as vanilloid receptor antagonists)
RN 710954-91-9 CAPLUS
CN Urea, N-[[3-(1-piperidinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710954-94-2 CAPLUS
CN Urea, N-[4-(1-piperidinyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710954-97-5 CAPLUS
CN Urea, N-[4-(4-morpholinyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2004:515473 Document No. 141:713580 Preparation of tetrahydronaphthalene derivatives as vanilloid receptor antagonists. Tajimi, Masaomi; Kokubo, Toshio; Shiroo, Masahiro; Tsukimi, Yasuhiro; Yura, Takeshi; Yamamoto, Noriyuki; Mogi, Muneto; Fujishima, Hiroshi; Masuda, Tsutomu; Yoshida, Nagahiro; Moriwaki, Toshiya (Bayer Healthcare Ag, Germany; Urbahns, Klaus). PCT Int. Appl. WO 2004052845 A1 20040624, 63 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP13452 20031128. PRIORITY: EP 2002-27528 20021209.
GI



I

AB The title compds. I [n = 0 - 6; R1 = H, alkyl; R2 = alkenyl, alkynyl, alkyl substituted by amino, etc.; R3 = H, alkenyl, alkynyl, alkyl optionally substituted by amino, etc.; or NR2R3 = heterocyclic ring (further details on said heterocyclic ring are given); R4 = H, halo, alkylthio, alkyl optionally substituted by mono-, di-, tri-halogen, etc.] are prepared The tetrahydronaphthalene derivs. of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, etc. The bioactivity of compds. of this invention was demonstrated.
IT 710954-91-9P 710954-94-2P 710954-97-5P
710955-00-3P 710955-02-5P 710955-04-7P
710955-06-9P 710955-08-1P 710955-10-5P
710955-12-7P 710955-14-9P 710955-16-1P
710955-18-3P 710955-20-7P 710955-22-9P
710955-24-1P 710955-26-3P 710955-28-5P
710955-30-9P 710955-32-1P 710955-35-4P
710955-37-6P 710955-39-8P 710955-41-2P
710955-43-4P 710955-45-6P 710955-47-8P
710955-49-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-00-3 CAPLUS
CN Urea, N-[3-chloro-4-(4-morpholinyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-02-5 CAPLUS
CN Urea, N-[[4-(1-piperidinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-04-7 CAPLUS
CN Urea,
N-[[4-(4-morpholinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-06-9 CAPLUS
CN Urea, N-[[4-(1-pyrrolidinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-12-7 CAPLUS
CN Urea, N-[[4-(hexahydro-1H-azepin-1-yl)-3-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-14-9 CAPLUS
CN Urea, N-[[3-(hexahydro-1H-azepin-1-yl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-08-1 CAPLUS
CN Urea,
N-[[4-(1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-10-5 CAPLUS
CN Urea,
N-[[3-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-16-1 CAPLUS
CN Urea, N-[[3-[[2-(dimethylamino)ethyl]amino]-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-18-3 CAPLUS
CN Urea, N-[[4-(1-methylethoxy)-3-(2-oxo-1-pyrrolidinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-20-7 CAPLUS
CN Urea,
N-[[4-(1-methylethoxy)-3-(1-pyrrolidinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-22-9 CAPLUS
CN Urea,
N-[[3-bromo-4-(1-piperidinyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-28-5 CAPLUS
CN Urea, N-[[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 710955-30-9 CAPLUS
CN Urea,
N-[[4-(1-piperidinyl)-3-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-24-1 CAPLUS
CN Urea, N-[[3-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 710955-26-3 CAPLUS
CN Urea, N-[[3-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-32-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[5-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]-2-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 710955-35-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[5-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]-2-(trifluoromethyl)phenyl]-(CA
INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-37-6 CAPLUS
CN Urea, N-[[3-[4-(hydroxymethyl)-1-piperidinyl]-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-39-8 CAPLUS
CN Urea,
N-[[3-(4-hydroxy-1-piperidinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-45-6 CAPLUS
CN Urea,
N-[[3-(4-morpholinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 710955-47-8 CAPLUS
CN Urea, N-[[3-[(2-hydroxyethyl)methylamino]-4-(trifluoromethyl)phenyl]methyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-41-2 CAPLUS
CN 4-Piperidinecarboxamide, 1-[5-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]-2-(trifluoromethyl)phenyl]- (CA
INDEX NAME)



RN 710955-43-4 CAPLUS
CN Urea,
N-[[3-(1-piperazinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 710955-49-0 CAPLUS
CN Urea, N-[[3-(4-morpholinyl)-4-(trifluoromethyl)phenyl]methyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 23 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2004:220082 Document No. 140:2535560 Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors. Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel
C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F. (Bristol-Myers Squibb Company, USA). U.S. Pat. Appl. Publ. US 20040054186 A1 20040318, 184 pp., Cont.-in-part of U.S. 6,596,746. (English). CODEN: USXXCO. APPLICATION: US 2003-395503 20030324. PRIORITY: US 2000-548929 20000413; US 1999-129510P 19990415.
GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z
= a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together
= O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (
no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.
IT 302960-34-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
RN 302960-34-5 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-2-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2003:913140 Document No. 139:3812590 Preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists. Yura, Takeshi; Mogi, Muneto; Urbahns, Klaus; Fujishima, Hiroshi; Masuda, Tsutomu; Moriwaki, Toshiya; Yoshida, Nagahiro; Kokubo, Toshio; Shiroo, Masahiro; Tajimi, Masaomi; Tsukimi, Yasuhiro; Yamamoto, Noriyuki (Bayer Aktiengesellschaft, Germany; et al.). PCT Int. Appl. WO 2003095420 A1 20031120, 100 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP4395 20030428. PRIORITY: GB 2002-10512 20020508; GB 2002-27262 20021121.
GI



I

AB Title compds. I [R1, R2 = H, alkyl; X = alkyl, YR3; Y = bond, (un)substituted CH2, CH2CH2; R3 = (un)substituted Ph, naphthyl] were prepared for use as VR1 antagonists useful in treating urgent urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD. Thus, 7-ethoxy-5,8-dihydronaphthalen-1-ylamine, prepared from 8-amino-2-naphthol
by N-protection, ethylation, deprotection, and reduction, was treated with
4,3-Cl(F3C)C6H3NCO to give I [R1, R2 = H, X = 4,3Cl(F3C)C6H3] which had IC50 for inhibition of capsaicin-induced Ca influx in the human VR1-transfected CHO cell line ≤ 0.1 μM.
IT 624728-45-6P 624728-48-9P 624728-49-0P
624728-50-3P 624728-51-4P 624728-52-5P
624728-53-6P 624728-54-7P 624728-55-8P
624728-56-9P 624728-57-0P 624728-58-1P
624728-59-2P 624728-60-5P 624728-61-6P
624728-62-7P 624728-63-8P 624728-64-9P
624728-65-0P 624728-66-1P 624728-67-2P
624728-68-3P 624728-69-4P 624728-70-7P
624728-71-8P 624728-72-9P 624728-73-0P
624728-74-1P 624728-75-2P 624728-76-3P
624728-77-4P 624728-78-5P 624728-80-9P

L4 ANSWER 23 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
624728-81-0P 624728-82-1P 624728-83-2P
624728-84-3P 624728-85-4P 624728-86-5P
624728-87-6P 624728-88-7P 624728-89-8P
624728-90-1P 624728-91-2P 624728-92-3P
624728-93-4P 624728-94-5P 624728-95-6P
624728-96-7P 624728-97-8P 624728-98-9P
624728-99-0P 624729-00-6P 624729-01-7P
624729-02-8P 624729-03-9P 624729-04-0P
624729-05-1P 624729-06-2P 624729-07-3P
624729-08-4P 624729-09-5P 624729-10-8P
624729-11-9P 624729-12-0P 624729-13-1P
624729-14-2P 624729-15-3P 624729-16-4P
624729-17-5P 624729-18-6P 624729-19-7P
624729-20-0P 624729-21-1P 624729-22-2P
624729-23-3P 624729-24-4P 624729-25-5P
624729-26-6P 624729-27-7P 624729-28-8P
624729-29-9P 624729-30-2P 624729-31-3P
624729-32-4P 624729-33-5P 624729-34-6P
624729-35-7P 624729-36-8P 624729-37-9P
624729-40-4P 624729-41-5P 624729-42-6P
624729-43-7P 624729-44-8P 624729-45-9P
624729-46-0P 624729-47-1P 624729-48-2P
624729-49-3P 624729-50-6P 624729-51-7P
624729-52-8P 624729-53-9P 624729-54-0P
624729-55-1P 624729-56-2P 624729-57-3P
624729-58-4P 624729-59-5P 624729-60-8P
624729-61-9P 624729-62-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1
antagonists)
RN 624728-45-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-48-9 CAPLUS
CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-49-0 CAPLUS
CN Urea,
N-(2-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624728-50-3 CAPLUS
CN Urea,
N-(3-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-51-4 CAPLUS
CN Urea,
N-(4-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624728-52-5 CAPLUS
CN Urea,
N-(3-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-53-6 CAPLUS
CN Urea,
N-(4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624728-54-7 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[2-
(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-55-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 624728-56-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-
(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-57-0 CAPLUS
CN Benzoic acid, 2-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 624728-58-1 CAPLUS
CN Benzoic acid, 3-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-59-2 CAPLUS
CN Benzoic acid, 4-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 624728-60-5 CAPLUS
CN Urea, N-1-naphthalenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-61-6 CAPLUS
CN Urea, N-2-naphthalenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-62-7 CAPLUS
CN Urea, N-(4-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-63-8 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-64-9 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-65-0 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-66-1 CAPLUS
CN Urea, N-[4-(1-methylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-67-2 CAPLUS
CN Urea, N-(4-phenoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-70-7 CAPLUS
CN Urea, N-[(2-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-71-8 CAPLUS
CN Urea, N-[(3-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-72-9 CAPLUS

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-68-3 CAPLUS
CN Urea, N-[4-(dimethylamino)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-69-4 CAPLUS
CN Urea, N-(phenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-[(4-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-73-0 CAPLUS
CN Urea, N-[(2-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-74-1 CAPLUS
CN Urea, N-[(3-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-75-2 CAPLUS
CN Urea, N-[(4-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-76-3 CAPLUS
CN Urea, N-[(2-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-77-4 CAPLUS
CN Urea, N-[(4-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-78-5 CAPLUS
CN Urea, N-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-80-9 CAPLUS
CN Urea, N-(4-chloro-3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-81-0 CAPLUS
CN Urea, N-(3,5-dimethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-82-1 CAPLUS
CN Urea, N-(4-bromo-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-83-2 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-4-methyl-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-84-3 CAPLUS
CN Urea, N'-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-85-4 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-7-methyl-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-86-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-87-6 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-88-7 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-89-8 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-90-1 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-91-2 CAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-92-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 624728-93-4 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-94-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 624728-95-6 CAPLUS
CN Urea, N-[(2-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-96-7 CAPLUS
CN Urea, N-[(3,4-difluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-97-8 CAPLUS
CN Urea, N-[(3-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-98-9 CAPLUS
CN Urea, N-[(3-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-99-0 CAPLUS
CN Urea, N-[(2,4-dichlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-00-6 CAPLUS
CN Urea, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-01-7 CAPLUS
CN Urea, N-[(3,4-dichlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-02-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 624729-03-9 CAPLUS
CN Urea, N-[(2,4-dimethoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-04-0 CAPLUS
CN Urea, N-[(2-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-05-1 CAPLUS
CN Benzoic acid, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-06-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[(2,4,6-trimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 624729-07-3 CAPLUS
CN Urea, N-[(3-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-08-4 CAPLUS
CN Urea, N-[(4-nitrophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-09-5 CAPLUS
CN Urea, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-10-8 CAPLUS
CN Urea, N-[(3,4-dimethoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-11-9 CAPLUS
CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-12-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 624729-13-1 CAPLUS
CN Benzoic acid, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-14-2 CAPLUS
CN Urea, N-[(4-aminophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-15-3 CAPLUS
CN Urea, N-[(2-aminophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-16-4 CAPLUS
CN Benzeneacetic acid, 4-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 624729-17-5 CAPLUS
CN Urea, N-[[4-(dimethylamino)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-18-6 CAPLUS
CN Urea, N-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-19-7 CAPLUS
CN Urea, N-[2-(4-chlorophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-20-0 CAPLUS
CN Urea, N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-21-1 CAPLUS
CN Urea, N-[4-(4-methylphenoxy)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 624729-22-2 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 624729-23-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-24-4 CAPLUS
CN Urea, N-[1-(4-fluorophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-25-5 CAPLUS
CN Urea, N-[1-(4-bromophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-26-6 CAPLUS
CN Urea, N-(diphenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-27-7 CAPLUS
CN Urea, N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-28-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)



RN 624729-29-9 CAPLUS
CN Urea, N-(1-naphthalenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-30-2 CAPLUS
CN Urea, N-[4-(cyanomethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-31-3 CAPLUS
CN Urea, N-(1-phenylethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-32-4 CAPLUS
CN Urea, N-[1-(1-naphthalenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-33-5 CAPLUS
CN Benzenesulfonamide, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 624729-34-6 CAPLUS
CN Urea, N-[[3-(cyclopentylamino)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-35-7 CAPLUS
CN Urea, N-[[3-(cyclopentylamino)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 624729-36-8 CAPLUS
CN Urea,
N-[2-(4-chlorophenyl)ethyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-37-9 CAPLUS
CN Urea,
N-[2-(4-chlorophenyl)ethyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-40-4 CAPLUS
CN Urea,
N-(2-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-41-5 CAPLUS
CN Urea,
N-(3-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-42-6 CAPLUS
CN Urea,
N-(2-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-43-7 CAPLUS
CN Urea,
N-(3-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624729-44-8 CAPLUS
CN Urea,
N-(2-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-45-9 CAPLUS
CN Urea,
N-(4-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624729-46-0 CAPLUS
CN Urea, N-[3-(1-methylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-47-1 CAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-48-2 CAPLUS
CN Urea,
N-(3-phenoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-49-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 624729-50-6 CAPLUS
CN Urea, N-[3-methoxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 624729-51-7 CAPLUS
CN Urea, N-(3-iodophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-52-8 CAPLUS
CN Urea, N-(4-ethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-53-9 CAPLUS
CN Urea, N-(3-hydroxy-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-54-0 CAPLUS
CN Urea, N-[4-(methylthio)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-55-1 CAPLUS
CN Urea, N-(3-fluoro-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-56-2 CAPLUS
CN Urea, N-(3,4-dimethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-57-3 CAPLUS
CN Urea, N-(3-chloro-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-58-4 CAPLUS
CN Urea, N-(4-hydroxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-59-5 CAPLUS
CN Urea, N-(3,5-dimethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-60-8 CAPLUS
CN Urea, N-(3,4-dimethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-61-9 CAPLUS
CN Urea,
N-(3-ethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-62-0 CAPLUS
CN Urea, N-(4-fluoro-3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



IT 624728-46-7P 624728-47-8P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624728-46-7 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-47-8 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 624729-71-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624729-71-1 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-oxo-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 624729-38-0P 624729-39-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624729-38-0 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[2-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-39-1 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 25 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2003:622568 Document No. 139:1647100 Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A. (Bristol-Myers Squibb Pharma Company, USA). U.S. US 6605623 B1 20030812, 145 pp., Cont.-in-part of U.S. Ser. No. 465,286, abandoned. (English). CODEN: USXXAM. APPLICATION: US 2000-598821 20000621. PRIORITY: US 1998-112717P 19981218; US 1999-161243P 19991022; US 1999-465286 19991217.

GI



AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R6 = alkyl, alkenyl, alkynyl, etc.; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data) for preventing asthma and other allergic diseases. Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. A pharmaceutical composition comprising the compound I was claimed. [This abstract record is one of 15 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275814-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 275814-32-9

L4 ANSWER 25 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

L4 ANSWER 26 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2003:434303 Document No. 139:364450 Preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists.. Devita, Robert J.; Chang, Lehua; Chaung, Danny; Hoang, Myle; Jiang, Jinlong; Lin, Peter; Sailer, Andreas W.; Young, Jonathan R. (Merck & Co., Inc., USA). PCT Int. Appl. WO 2003045313 A2 20030605, 178 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US37556 20021122. PRIORITY: US 2001-333581P 20011127.

GI



AB Title compds. [I; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkylalkyl, aralkyl, etc.; R1R2N = 4-11 membered (bridged) (substituted) heterocyclyl; R3, R4 = H, halo, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, OR7, N(R7)2, cyano, etc.; R3R4 = atoms to form 5-7 membered (substituted) ring; R5 = H, halo, alkyl, perfluoroalkyl, OR7, N(R7)2; R6 = (CH2)nR7, (CH2)nCN, (CH2)nCO2R7, (CH2)nOR7, (CH2)nN(R7)2, etc.; R7 = H, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, aralkenyl, cycloalkylalkenyl, etc.; n = 0-5], were prepared for the treatment or prevention of obesity, eating disorders, osteoarthritis, cancer, AIDS wasting, cachexia, frailty, mental disorders, stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Thus, 2-piperidin-1-ylquinolin-6-amine and (2E)-3-(4-chlorophenyl)prop-2-enoyl chloride were stirred 3 h in HOAc to give (2E)-3-(4-chlorophenyl)-N-(2-piperidin-1-ylquinolin-6-yl)prop-2-enamide hydrochloride. I bound to MCH-1R receptors with IC50 = 0.1-10000 nM.

IT 539854-60-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of 2-aminoquinolines as melanin concentrating hormone receptor (MCH-1R) antagonists)

RN 539854-60-9 CAPLUS

CN Urea, N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-6-quinolinyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 26 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 27 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2003:300646 Document No. 138:3042860 Preparation of 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides as α1A adrenoceptor agonists. Altenbach, Robert J.; Meyer, Michael D.; Kerwin, James F.; Khilevich, Albert; Kolasa, Teodozyj; Rohde, Jeffrey; Carroll, William A.; Searle, Xenia; Yang, Fan (USA). U.S. Pat. Appl. Publ. US 20030073850 A1 20030417, 85 pp., Cont.-in-part of U.S. 6,503,935. (English). CODEN: USXXCO.

APPLICATION: US 2000-506750 20000217. PRIORITY: US 1998-130799 19980807; US 1999-364901 19990729.

GI



I



II

AB The title compds. (I) [wherein R1 = SO2R9 or COR10; R2 = H, (halo)alkyl, aryl(alkyl), or cycloalkyl(alkyl); R3-R6 = independently H, alkoxy, alkenyl, (halo)alkyl, cycloalkyl, halo, or OH; or R6 and R7 together with the C to which they are attached form a 5-7 membered carbocycle or 5-6 membered (un)substituted heterocycle; or R7 and R8 together = :CR12R13; R8 = absent or H; R9 = (aryl)alkenyl, (aryl)alkyl, (aryl)alkynyl, cycloalkyl(alkyl), haloalkyl, heterocycle, or (un)substituted amine; R10 = (aryl)alkyl, alkenyl, (halo)alkoxy, aryl(oxy), cycloalkyl(alkyl), cycloalkyloxy, haloalkyl, or (un)substituted amine, azetidinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, etc.; R12 and R13 = independently H, (aryl)alkyl, alkoxy, aryl, or cycloalkyl(alkyl); or R12 and R13 together with the C to which they are attached form a 3-7 membered carbocycle; R14 = H or alkyl] were prepared as α1A adrenoceptor agonists for the treatment of urinary incontinence or retrograde ejaculation. For example, 4-iodo-1-trityl-1H-imidazole was treated sequentially with EtMgBr, 5-nitrotetralone, and NH4Cl in CH2Cl2 to give 4-(5-nitro-3,4-dihydro-1-naphthalenyl)-1H-imidazole. N-BOC protection, reduction using Pd/C in AcOEt, treatment with EtSO2Cl in the presence of TFA, and conversion to the salt afforded II•maleate. In radioligand

L4 ANSWER 27 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

binding assays, II•maleate showed good selectivity for binding to the α1A adrenoceptor subtype vs. the α1B and α1D subtypes with Ki values of 176 nM, 4620 nM and 1590 nM, resp. In addn., II•maleate was efficacious in constricting the urethra with an IUP ED5 (the mean dose causing a max. increase in intraurethral pressure of 5 mm Hg) of 10.7 nmol/kg in anesthetized dogs.

IT 355133-23-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole derivs. of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides as α1A adrenoceptor agonists)

RN 355133-23-2 CAPLUS

CN Urea, N-cyclohexyl-N-ethyl-N'-[5,6,7,8-tetrahydro-5-(1H-imidazol-5-yl)-1-naphthalenyl]- (CA INDEX NAME)



L4 ANSWER 28 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2003:150534 Document No. 138:2049460 Preparation of N-ureidoalkylpiperidines as modulators of CCR3 chemokine receptor activity for the prevention of asthma and other allergic diseases. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng (Bristol-Myers Squibb Pharma Company, USA). U.S. US 6525069 B1 20030225, 126 pp., Cont.-in-part of U.S. Ser. No. 466,442. (English). CODEN: USXXAM. APPLICATION: US 2000-597400 20000621. PRIORITY: US 1999-466442 19991217; US 1999-161221P 19991022; US 1998-112717P 19981218.

GI



I

AB Title compds. [I; M, Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K, L = CH2, CHR5, CHR6, CR6R6, CR5R6; ≥1 of J, K, L contains R5; Z = O, S, NR1a, CHCN, CHNO2, C(CN)2; R1a = H, alkyl, cycloalkyl, CN, NO2, etc.; E = (substituted) C3-6 carbocyclyl, methylenecarbocyclyl, ethylenecarbocyclyl, etc.; R1, R2 = H, alkyl, alkenyl, alkynyl; R3 = (substituted) alkyl, alkenyl, alkynyl; R4 = null, N-oxide, alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R5 = (substituted) alkylenecarbocyclyl, alkyleneheterocyclyl; R6 = alkyl, alkenyl, alkynyl, alkylcycloalkyl, perfluoroalkyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, CN, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, mercaptoalkyl, acylaminoalkyl, (substituted) phenylalkyl, etc.], were prepared as CCR3 modulators (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) and 3-cyanophenyl isocyanate were stirred 30 min. in THF to give N-3-cyanophenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 8 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275814-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-ureidoalkylpiperidines as modulators of chemokine receptor activity)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 275814-32-9

CMF C30 H40 F N3 O

L4 ANSWER 28 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 29 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2003:150529 Document No. 138:2050520 Preparation of 1-(pyrazol-3-yl)-3-(1-naphthyl)ureas as antiinflammatory agents.
Cirillo, Pier Francesco; Dinallo, Roger; Regan, John Robinson; Riska, Paul S.; Swinamer, Alan David; Tan, Zhulin; Walter, Brian Andrew (Boehringer Ingelheim Pharmaceuticals, Inc., USA). U.S. US 6525046 B1 20030225, 44 pp., Cont.-in-part of U.S. Ser. No. 879,776, abandoned. (English). CODEN: USXXAM. APPLICATION: US 2002-165372 20020607. PRIORITY: US 2000-484638 20000118; US 2001-879776 20010612.

GI



I

AB The title compds. Ar1NHC(:X)NHAr2LQ [Ar1 = pyrazolyl, pyrrolyl, imidazolyl, etc.; Ar2 = Ph, naphthyl, quinolyl, etc.; L = alkylene wherein one or more methylene groups are optionally replaced by O, N or S; Q = Ph, naphthyl, pyridyl, etc.; X = O, S], useful for treating diseases involving inflammation such as chronic inflammatory diseases, were prepared E.g., a multi-step synthesis of I, starting from Me 2,2-dimethyl-3-hydroxypropionate, was given. Representative title ureas showed IC50 of < 10 μM against TNF production in THP cells.

IT 285983-88-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(pyrazol-3-yl)-3-(1-naphthyl)ureas as antiinflammatory agents)

RN 285983-88-2 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[5,6,7,8-tetrahydro-4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2003:57886 Document No. 138:1226410 Method of treating cytokine mediated diseases using pyrazolylureas.. Moss, Neil; Regan, John R. (Boehringer Ingelheim Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2003005999 A2 20030123, 84 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US20649 20020701. PRIORITY: US 2001-304511P 20010711.

GI



I

AB A method of treating lung inflammation, endometriosis, behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, percutaneous transluminal coronary angioplasty, alzheimer's disease, traumatic arthritis, sepsis, chronic obstructive pulmonary disease, and congestive heart failure comprises administration of Ar1NHC(:X)NHAr2LQ [Ar1 = (substituted) pyrrolyl, pyrrolidinyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, furyl, thienyl; Ar2 = (substituted) Ph, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl, tetrahydroisoquinolinyl, benzimidazolyl, benzofuryl, indanyl, indolyl, etc.; L = (O-, S-, or N-interrupted) (unsatd.) (substituted) alkylene; Q = (substituted) Ph, naphthyl, pyridyl, pyrimidinyl, imidazolyl, tetrahydropyranyl, tetrahydrofuryl, dioxanyl, alkoxy, amino, etc.; X = O, S]. Thus, 5-amino-3-tert-butyl-1-(4-methylphenyl)pyrazole was stirred with COCl2 and NaHCO3 in PhMe/CH2Cl2 at 0-5° for 15 min. The organic residue was stirred overnight with 1-amino-4-(4-pyridinylmethoxy)naphthalene dihydrochloride (preparation given) and diisopropylethylamine in THF to give title compound (I). Representative title compds. inhibited TNF production in THP cells with IC50<10 μM.

IT 285983-88-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of treating cytokine mediated diseases using pyrazolylureas)

L4 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 285983-88-2 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[5,6,7,8-tetrahydro-4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2003:22837 Document No. 138:730890 Preparation of N-phenyloxyphenylcarboxamides as anticholesteremic agents. Schmeck, Carsten; Mueller, Ulrich; Schmidt, Gunter; Pernerstorfer, Josef; Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Faeste, Christiane; Haning, Helmut; Woltering, Michael (Bayer Aktiengesellschaft, Germany). PCT Int. Appl. WO 2003002519 A1 20030109, 111 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2002-EP6638 20020617. PRIORITY: DE 2001-10131462 20010629.
GI



I

AB Title compds. [I; X = O, S, SO, SO2, CH2, CHF, CF2, etc.; R1, R2 = H, alkyl; R3, R4 = H, halo, cyano, alkyl, CF3, CHF2, CH2F, vinyl, cycloalkyl; R5 = H, alkyl, halo; R6 = alkyl, Br, Cl, etc.; R7 = H, alkyl, alkanoyl; Z = NHSO2R36, NHCO2R37, NHCONR38R39, NHCOR40; R36-R40 = (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl], were prepared as anticholesteremic agents (no data). Thus, 4-(4-[tert-butyl(dimethyl)silyloxy]-3-isopropylphenoxy)-3,5-dimethylaniline (preparation given) in THF was stirred with hexanoyl chloride and dimethylaminopyridine for 16 h at room temperature followed by further addition of hexanoyl chloride and stirring to give 73% N-[4-(4-hydroxy-3-isopropylphenoxy)-3,5-dimethylphenyl]hexanamide.
IT 482333-34-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenyloxyphenylcarboxamides as anticholesteremic agents)
RN 482333-34-6 CAPLUS
CN Urea, N-(2-ethoxy-5,6,7,8-tetrahydro-1-naphthalenyl)-N'-[4-[4-hydroxy-3-(1-

L4 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methylethyl)phenoxy]-3,5-dimethylphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2002:942809 Document No. 138:247090 Preparation of pyrazole compounds and bis pyrazole-1H-pyrazole intermediates as antiinflammatory agents. Kapadia, Suresh R.; Song, Jinhua J.; Yee, Nathan K. (Boehringer Ingelheim Pharmaceuticals, Inc., USA). U.S. US 6492529 B1 20021210, 37 pp., Cont.-in-part of U.S. 6,372,773. (English). CODEN: USXXAM.
APPLICATION: US 2002-67492 20020205. PRIORITY: US 2000-484638 20000118; US 2001-920899 20010802.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazole compds., e.g. I, as well as bis pyrazole-1H-pyrazole intermediate compds. e.g. II, were prepared The compds. are useful in pharmaceutic compns. for treating diseases or pathol. conditions involving inflammation such as chronic inflammatory diseases. All prepared compds. had IC50 < 10 mM for inhibition of TNFα in lipopolysaccharide stimulated THP cells.
IT 285983-88-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole compds. and bis pyrazole-1H-pyrazole intermediates as antiinflammatory agents)
RN 285983-88-2 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[5,6,7,8-tetrahydro-4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L4 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2001:935575 Document No. 136:697390 Preparation of piperidinoalkylureas as chemokine receptor modulators. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng (Dupont Pharmaceuticals Company, USA). PCT Int. Appl. WO 2001098270 A2 20011227, 333 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US19752 20010620. PRIORITY: US 2000-PV213208 20000621; US 2000-597400 20000621.

AB The title compds. were prepared as chemokine receptor modulators (no data). Thus, PhCH2Z(CH2)3NHR (Z = piperidine-4,1-diyl)(I; R = H)(preparation given) was amidated by 3-(NC)C6H4NCO to give I [R = CONHC6H4(CN)-3].

IT 275814-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinoalkylureas as chemokine receptor modulators)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 275814-32-9

CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

L4 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2001:935574 Document No. 136:697380 Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing (Dupont Pharmaceuticals Company, USA; Bristol-Myers Squibb Pharmaceutical Co.). PCT Int. Appl. WO 2001098269 A2 20011227, 446 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US19745 20010620. PRIORITY: US 2000-213051P 20000621; US 2000-598821 20000621.

GI



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea.

IT 275814-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

L4 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2001:747739 Document No. 135:2886370 Preparation of 7-and 9-carbamate, urea,
thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives for pharmaceutical use as antibiotics. Nelson, Mark L.; Levy,
Stuart B.; Prechette, Roger; Bowser, Todd E.; Ismail, Mohamed Y. (Trustees
of Tufts College, USA). PCT Int. Appl. WO 2001074761 A1 20011011, 88 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, ZW; RW: AT, BE, BF,
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU,
MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
APPLICATION: WO 2001-US10342 20010331. PRIORITY: US 2000-PV193972
20000331; US 2000-PV193879 20000331.
GI



I

AB Tetracycline derivs., such as I [R5 = H, OH, acyloxy, etc.; R6 = H, Me, alkyl, etc.; R7, R9 = arylamino, urea, thiourea, carbamate, thiocarbamate,
etc.; R8 = H, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, etc.], were prepared for pharmaceutical use as antibiotics. Thus, doxycycline
derivative I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = 1-naphthylaminocarbonylamino) was prepared by nitration of doxycycline with
potassium nitrate, Pd/C catalyzed hydrogenation of the nitrate to form 9-aminodoxycycline I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = NH2) followed by
formation of the desired urea by reaction of 9-aminodoxycycline with 1-naphthylisocyanate. The prepared tetracycline derivs. were tested for efficacy against common bacterial strains, such as E. coli, S. aureus, E. hirae, and E. faecalis.

IT 365277-89-0P 365277-91-4P 365277-94-7P
365277-95-8P 365277-96-9P 365278-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical

L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
use as antibiotics)

RN 365277-89-0 CAPLUS
CN 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-7-[[(1-naphthalenylamino)carbonyl]amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 365277-91-4 CAPLUS
CN 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-7-[[(phenylamino)carbonyl]amino]-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-94-7 CAPLUS
CN 2-Naphthacenecarboxamide, 7-[[[[4-chloro-2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 365277-95-8 CAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)amino]carbonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 365277-96-9 CAPLUS
CN 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-7-[[[(4-methoxyphenyl)amino]carbonyl]amino]-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 365278-14-4 CAPLUS
CN 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

3,10,12,12a-tetrahydroxy-6-methyl-7-[[(1-naphthalenylamino)carbonyl]amino]-
1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2001:617982 Document No. 135:1807670 Preparation of 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides as α1A adrenoceptor agonists. Altenbach, Robert J.; Meyer, Michael D.; Kerwin, James F.; Khilevich, Albert; Kolasa, Teodozyj; Rohde, Jeffrey J.; Carroll, William A.; Searle, Xenia B.; Yang, Fan (Abbott Laboratories, USA). PCT Int. Appl. WO 2001060802 A1 20010823, 226 pp. DESIGNATED STATES: W: CA, JP, MX; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US3466 20010201. PRIORITY: US 2000-506750 20000217.

GI



AB The title compds. (I) [wherein R1 = SO2R9 or COR10; R2 = H, (halo)alkyl, aryl(alkyl), or cycloalkyl(alkyl); R3-R6 = independently H, alkoxy, alkenyl, (halo)alkyl, cycloalkyl, halo, or OH; or R6 and R7 together with the C to which they are attached form a 5-7 membered carbocycle or 5-6 membered (un)substituted heterocycle; or R7 and R8 together = :CR12R13; R8 = absent or H; R9 = (aryl)alkenyl, (aryl)alkyl, (aryl)alkynyl, cycloalkyl(alkyl), haloalkyl, heterocycle, or (un)substituted amine; R10 = (aryl)alkyl, alkenyl, (halo)alkoxy, aryl(oxy), cycloalkyl(alkyl), cycloalkyloxy, haloalkyl, or (un)substituted amine, azetidinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, etc.; R12 and R13 = independently H, (aryl)alkyl, alkoxy, aryl, or cycloalkyl(alkyl); or R12 and R13 together with the C to which they are attached form a 3-7 membered carbocycle; R14 = H or alkyl] were prepared as α1A adrenoceptor agonists for the treatment of urinary incontinence or retrograde ejaculation. For example, 4-iodo-1-trityl-1H-imidazole was treated sequentially with EtMgBr, 5-nitrotetralone, and NH4Cl in CH2Cl2 to give 4-(5-nitro-3,4-dihydro-1-naphthalenyl)-1H-imidazole. N-BOC protection, reduction using Pd/C in AcOEt, treatment with EtSO2Cl in the presence of TFA, and conversion to the salt afforded II•maleate. In radioligand binding assays, II•maleate showed good selectivity for binding to the

L4 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
α1A adrenoceptor subtype vs. the α1B and α1D subtypes with Ki values of 176 nM, 4620 nM and 1590 nM, resp. In addn., II•maleate was efficacious in constricting the urethra with an IUP ED5 (the mean dose causing a max. increase in intraurethral pressure of 5 mm Hg) of 10.7 nmol/kg in anesthetized dogs.

IT 355133-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides as α1A adrenoceptor agonists)

RN 355133-23-2 CAPLUS
CN Urea, N-cyclohexyl-N-ethyl-N'-[5,6,7,8-tetrahydro-5-(1H-imidazol-5-yl)-1-naphthalenyl]- (CA INDEX NAME)



L4 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2001:50635 Document No. 134:1158450 Preparation of α,β-annelated butyrolactones as modulators of metabotropic glutamate receptors.. Stolle, Andreas; Antonicek, Horst-Peter; Lensky, Stephan; Voerste, Arnd; Muller, Thomas; Baumgarten, Jorg; Von Dem Bruch, Karsten; Muller, Gerhard; Stropp, Udo; Horvath, Ervin; De Vry, Jean-Marie-Victor; Schreiber, Rudy (Bayer Aktiengesellschaft, Germany). PCT Int. Appl. WO 2001004107 A1 20010118, 215 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (German). CODEN: PIXXD2. APPLICATION: WO 2000-EP6105 20000630. PRIORITY: DE 1999-19932621 19990713.

GI



AB Title compds. [I; A = CH2, CO, C(OH)R4, (CH2)aCHR5; a = 0-4; R4 = H, alkyl; R5 = Ph; R1 = H, alkyl, cycloalkyl, (benzocondensed) (substituted) heterocyclyl; R2, R3 = H, alkyl; DE = CH2COCH2, CH2CH(OH)CH2, CH2C(OH)(CH2OH)CH2, CH2C(:CR31R32)CH2, etc.; R31, R32 = H, Ph, alkyl], were prepared for treatment of cerebral ischemia, skull/brain trauma, pain, and CNS-induced cramps (no data). Thus, N-[(3a''S*,6a''S*)-4-(5-methylenehexahydrocylopenta[c]furan-1-on-6ylmethyl)phenyl]bromoacetamide (preparation given), Et3N, and morpholine were refluxed 20 h in PrOH to give 87% N-[(3a''S*,6a''S*)-4-(5-methylenehexahydrocylopenta[c]furan-1-on-6ylmethyl)-phenyl]-N-morpholineacetamide.

IT 321128-65-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α,β-annelated butyrolactones as modulators of metabotropic glutamate receptors)

RN 321128-65-8 CAPLUS
CN Urea, N-(2-ethoxy-5,6,7,8-tetrahydro-1-naphthalenyl)-N'-[4-[[(3aR,6aR)-tetrahydro-5-methylene-3-oxo-1H-cyclopenta[c]furan-3a(6aH)-yl]methyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2000:756524 Document No. 133:3218780 Preparation of cyclic protein tyrosine kinase inhibitors. Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John (Bristol-Myers Squibb Co., USA). PCT Int. Appl. WO 2000062778 A1 20001026, 300 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US9753 20000412.

PRIORITY: US 1999-129510P 19990415.

GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.

IT 302960-34-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic protein tyrosine kinase inhibitors)

L4 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 302960-34-5 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-2-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L4 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2000:573791 Document No. 133:1640090 Preparation of phenyl ureas and thioureas as orexin receptor antagonists. Coulton, Steven; Johns, Amanda; Porter, Roderick Alan (Smithkline Beecham Plc, UK). PCT Int. Appl. WO 2000047577 A1 20000817, 45 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP1150 20000210. PRIORITY: GB 1999-3266 19990212; GB 1999-26430 19991108.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Z = O, S; R1 = alkyl, alkenyl, alkoxy, etc.; R2-R6 = alkyl, alkenyl, alkoxy, etc.; adjacent pair of R2-R6 together with the carbon atoms to which they are attached form (un)substituted carbocyclyl, heterocyclyl; R7 = alkyl, alkenyl, alkoxy, etc.; n = 0-3] and their pharmaceutically acceptable salts which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, were prepared E.g., treatment of 4-amino-2-methylquinoline with carbonyl diimidazole in CH2Cl2 followed by addition of 6-amino-2-methylbenzoxazole afforded II which showed pKb > 6.0 against orexin-1 receptor. In particular, compds. I are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.

IT 144331-79-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph ureas and thioureas as orexin receptor antagonists)

RN 144331-79-3 CAPLUS

CN Urea, N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 40 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2000:513688 Document No. 133:1203250 Preparation of aromatic heterocyclic ureas as antiinflammatory agents. Cirillo, Pier F.; Gilmore, Thomas A.; Hickey, Eugene R.; Regan, John R.; Zhang, Lin-Hua (Boehringer Ingelheim Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2000043384 A1 20000727, 96 pp. DESIGNATED STATES: W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US29165 19991209. PRIORITY: US 1999-116400P 19990119.

GI



I



II

AB The title compds. [I; Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, etc.; Ar2 = (un)substituted Ph, naphthyl, quinoline, etc.; L = (un)saturated (un)substituted carbon chain wherein one or more methylene groups are optionally replaced by O, N, or S; Q = (un)substituted Ph, naphthyl, pyridinyl, etc.], useful in pharmaceutic compns. for treating diseases or pathol. conditions involving inflammation such as chronic inflammatory diseases, were prepared E.g., a multi-step synthesis of the urea II was given. Representative compds. I were evaluated and showed IC50 of < 10 μM against TNF production in THP cells.

IT 285983-88-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic heterocyclic ureas as antiinflammatory agents)

L4 ANSWER 40 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 285983-88-2 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[5,6,7,8-tetrahydro-4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

2000:420964 Document No. 133:434450 Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo S.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Kim, Ui Tae (Du Pont Pharmaceuticals Company, USA). PCT Int. Appl. WO 2000035454 A1 20000622, 351 pp. DESIGNATED STATES: W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US30336 19991217. PRIORITY: US 1998-PV112717 19981218; US 1999-PV161184 19991022.

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given.

Compds. I are effective at 1.0-20 mg/kg/da (oral dosage).

IT 275814-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

L4 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CM 1

CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2000:420963 Document No. 133:434440 Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo; Clark, Cheryl Mcardle; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A. (Du Pont Pharmaceuticals Co., USA). PCT Int. Appl. WO 2000035453 A1 20000622, 316 pp. DESIGNATED STATES: W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US30335 19991217. PRIORITY: US 1998-PV112717 19981218; US 1999-PV161137 19991022.

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

IT 275814-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275814-33-0 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2000:420962 Document No. 133:434430 Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. (Du Pont Pharmaceuticals Company, USA). PCT Int. Appl. WO 2000035452 A1 20000622, 388 pp. DESIGNATED STATES: W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US30334 19991217. PRIORITY: US 1998-PV112717 19981218; US 1999-PV161221 19991022.

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

IT 275814-32-9P 275814-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275814-32-9 CAPLUS

CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 275814-33-0 CAPLUS
CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2000:420961 Document No. 133:434420 Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G. (Du Pont Pharmaceuticals Company, USA). PCT Int. Appl. WO 2000035451 A1 20000622, 394 pp. DESIGNATED STATES: W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US30332 19991217. PRIORITY: US 1998-PV112717 19981218; US 1999-PV161243 19991022.

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

IT 275814-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275814-33-0 CAPLUS
CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-,

L4 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2000:420959 Document No. 133:434410 Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Gardner, Daniel S. (Du Pont Pharmaceuticals Company, USA). PCT Int. Appl. WO 2000035449 A1 20000622, 327 pp. DESIGNATED STATES: W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US30292 19991217. PRIORITY: US 1998-PV112717 19981218; US 1999-PV161122 19991022.

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given.
Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

IT 275814-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275814-33-0 CAPLUS
CN Urea, N-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

L4 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CRN 275814-32-9
CMF C30 H40 F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
2000:314688 Document No. 132:3344550 2-Ureidothiazole derivatives, process for their preparation, and their use as antitumor agents. Pevarello, Paolo; Amici, Raffaella; Traquandi, Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi, Antonella (Pharmacia & Upjohn S.p.A., Italy). PCT Int. Appl. WO 2000026203 A1 20000511, 95 pp. DESIGNATED STATES: W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP8307 19991027. PRIORITY: GB 1998-23873 19981030.
GI



I

AB The title 2-ureido-1,3-thiazole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein R = halo, nitro, (un)substituted amino, C1-6 alkyl, C3-6 cycloalkyl, aryl, or arylalkyl; R1 = (un)substituted C1-6 alkyl, 3- to 6-membered carbocycle or 5- to 7-membered heterocycle, aryl, arylcarbonyl, or arylalkyl; R2 = H, straight or branched C1-4 alkyl, C2-4 alkenyl, or alkynyl; or NR1R2 = (un)substituted, optionally benzo-condensed or bridged 5- to 7-membered heterocycle, or 9- to 11-membered spiro-heterocycle]. The compds. are active as cdk/cyclin inhibitors, and are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity. The proliferative disorders include cancer and a wide variety of other conditions, such as Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. Over 230 invention compds. are claimed and/or prepared in examples. For instance, reaction of Ph isocyanate with 2-amino-5-bromo-1,3-thiazole hydrobromide in the presence of Et3N gave title compound I [R = Br, R1 = Ph, R2 = H]. The similarly prepared title compound I [R = iso-Pr, R1 = 3,5-dimethylphenyl, R2 = H] inhibited cdk2/cyclin A complex in vitro with an IC50 of 0.56 μM.
IT 267430-46-6P, N-(5-Isopropyl-1,3-thiazol-2-yl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of ureidothiazole derivs. as antitumor agents)
RN 267430-46-6 CAPLUS

L4 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-[5-(1-methylethyl)-2-thiazolyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1999:325902 Document No. 130:3525460 Preparation of amides containing leucine or methionine for inhibition of the interaction of vascular cell-adhesion molecule-1 (VCAM-1)and fibronectin with integrin very late antigen 4 (α4β1). Brittain, David Robert; Johnstone, Craig (Zeneca Limited, UK). PCT Int. Appl. WO 9924398 A2 19990520, 74 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-GB3334 19981109. PRIORITY: GB 1997-23789 19971112.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = II (in the para or meta position); R2, R3 = H, NO2, alkyl, etc.; R2 and R3 together with the Ph to which they are attached form a 9-10 membered bicyclic ring system; R4 = alkyl; R5 = H, alkyl; R6 = alkyl, alkylcycloalkyl, alkylalkoxyl, etc.; R7 = alkyl, alkoxylcarbonyl, alkenyl, etc.; R8 = (un)substituted aryl, heteroaryl, bicyclic heteroaryl ring system linked to the nitrogen via a ring carbon, etc.; R9, R10 = H, alkyl; NR8R9 = dihydroindolyl, dihydroquinolinyl; R11 = CO2H, tetrazolyl, alkyl sulfonylcarbamyl, sulfo, sulfino; Y = O, S, SO2; m = 0-1; n = 0-4; with the proviso that when m and n cannot both be 0 and when m = 1, n = 0] and their pharmaceutically acceptable salts, useful in the treatment of multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease and psoriasis, were prepared E.g., a multi-step synthesis of amide III was given. Compds. I are effective at 0.1-15 mg/kg/day.
IT 225100-86-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amides containing leucine or methionine for inhibition of the interaction of vascular cell-adhesion mol.-1 (VCAM-1)and fibronectin with integrin very late antigen 4 (α4β1))
RN 225100-86-7 CAPLUS
CN 1,3-Benzodioxole-5-propanoic acid, β-[[(2S)-4-methyl-1-oxo-2-[[2-[4-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]phenoxy]acetyl]amino]pentyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L4 ANSWER 48 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

1999:325793 Document No. 131:52520 Preparation of benzothiazolecarboxamides as protein tyrosine kinase inhibitors. Das, Jagabandhu; Barrish, Joel C.;
Wityak, John (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 9924035 A1 19990520, 220 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US23204 19981102. PRIORITY: US 1997-65042 19971110.

AB R2R3NZZ1NR4R5 [R2,R3 = H, NH2, (ar)alkyl, aryl, etc.; R4,R5 = H, (ar)alkyl, aryl, etc.; NR4R5 = heterocyclyl; Z = (un)substituted benzothiazole-2,4-, -2,5-, -2,6-, or -2,7-diyl; Z1 = CH2CO, CS] were prepared as protein tyrosine kinase inhibitors (no data). Thus, 4-(H2N)C6H4CO2Et was cyclocondensed with NaSCN and the protected and saponified product amidated by 2,4,6-trimethylaniline to give, after deprotection, H2NZCONHR4 (R4 = 2,4,6-trimethylphenyl, Z = benzothiazole-2,6-diyl).

IT 225520-70-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 225520-70-7 CAPLUS

CN 6-Benzothiazolecarboxamide, 2-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



L4 ANSWER 49 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

1998:709065 Document No. 129:3307400 Original Reference No. 129:67459a,67462a Preparation of bicyclic aryl or bicyclic heterocyclic ring containing (4-methylpiperazin-1-yl)phenyl compounds having a combined
5HT1A, 5HT1B and 5HT1D receptor antagonistic activity. Gaster, Laramie Mary; Wyman, Paul Adrian (Smithkline Beecham PLC, UK). PCT Int. Appl. WO 9847885 A1 19981029, 42 pp. DESIGNATED STATES: W: CA, JP, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1998-EP2265 19980414. PRIORITY: GB 1997-7876 19970418; GB 1998-1635 19980126.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = II, III (P1 = bicyclic aryl, bicyclic heterocyclic ring containing 1-3 heteroatoms selected from O, N and S; P2, P3
= Ph, bicyclic aryl, 5-7 membered heterocyclic ring containing 1-3 heteroatoms
selected from O, N and S, or bicyclic heterocyclic group containing 1-3 heteroatoms selected from O, N or S, providing that at least one of P2 and
P3 = bicyclic aryl or bicyclic heterocyclic group; R11 = H, halo, C1-6 alkyl, etc.; R12, R13 = H, halo, C1-6 alkyl, etc.; a, b = 1-3; A = a bond,
O, CH2, etc.); L = C(V)DG, DGC(V), YC(V)DG1; V = O, S; D = N, C, CH; G and
G1 = H, C1-6 alkyl; Y = NH, NR5 (wherein R5 = C1-6 alkyl), CH2, O; X = N, C; R2, R3 = H, halo, OH, etc.; R4 = H, C1-6 alkyl], useful as CNS agents, were prepared Thus, treatment of 4-(pyridin-4-yl)naphth-1-ylamine with triphosgene in the presence of Et3N in CH2Cl2 followed by the addition of a
solution of 4-chloro-3-(4-methylpiperazin-1-yl)aniline in CH2Cl2 afforded 27%
IV which showed pKi of > 8.0 at 5-HT1A, 5-HT1B and 5HT1D receptors.

IT 215162-59-7P 215162-89-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic aryl or bicyclic heterocyclic ring containing (4-methylpiperazin-1-yl)phenyl compds. having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity)

RN 215162-59-7 CAPLUS

CN Urea, N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 49 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 215162-89-3 CAPLUS

CN Urea, N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1997:803803 Document No. 128:664680 Original Reference No. 128:12915a,12918a
Phenyl derivatives useful as blockers of chloride channels.
Christophersen, Palle; Pedersen, Ove (Neurosearch A/S, Den.; Christophersen, Palle; Pedersen, Ove). PCT Int. Appl. WO 9745111 A1 19971204, 29 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-EP2724 19970526. PRIORITY: DK 1996-602 19960524.

AB The present invention relates to a method for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to a living animal body in need thereof a therapeutically effective amount of a Ph derivative, such as N-[3-(trifluoromethyl)phenyl]-N'-(2-hydroxy-5-nitrophenyl)urea.

IT 160383-97-1P 200267-58-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(benzene derivs. useful as blockers of chloride channels)

RN 160383-97-1 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 200267-58-9 CAPLUS
CN Urea, N-[2-hydroxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1997:537574 Document No. 127:1616970 Original Reference No. 127:31347a,31350a 2-Amino heterocycles and their therapeutic uses as leukotriene biosynthesis inhibitors. Es-Sayed, Mazen; Yamamoto, Masaru; Frobel, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen (Bayer Aktiengesellschaft, Germany). PCT Int. Appl. WO 9724328 A1 19970710, 275 pp. DESIGNATED STATES: W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, IS, JP, KE, KP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1996-EP5643 19961216. PRIORITY: GB 1995-26560 19951227.

GI



II

AB 2-Amino heterocycles R1R2NCOR3 [I; R1 = H, Me, (un)substituted 6-membered aromatic heterocycle containing ≤2 N atoms and optionally benzo-fused; R2 = (un)substituted adamantyl, cycloalkyl, pyridyl, Ph, CH2Ph, tetralin-5-yl, 2-norbornyl, 1-azabicyclo[2.2.2]oct-3-yl; or NR1R2 forms α-carboline residue; R3 = (un)substituted or cyclic amino groups linked via a bond, carbonyl, or alkylene group] are disclosed. I can be used for the production of medicaments which inhibit leukotriene synthesis (in particular LTB4), and are especially useful for the treatment and control of respiratory diseases and inflammatory processes (no data). For instance, condensation of 2-chloropyridine with 4-MeOC6H4NH2 at 150° gave 2-(4-methoxyanilino)pyridine, which reacted with ClCO2CCl3 and then HN(CH2Ph)2 in dioxane at 60° to give title compound II plus a byproduct.

IT 193557-16-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-amino heterocycles as leukotriene biosynthesis inhibitors)

RN 193557-16-3 CAPLUS
CN Urea, N,N-bis(phenylmethyl)-N'-2-pyridinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1997:429497 Document No. 127:506620 Original Reference No. 127:9669a,9672a
N-(Piperazinylalkoxyphenyl)-N'-phenylalkylurea derivatives as ACAT inhibitors for the treatment of atherosclerosis. Inoue, Shinya; Taniguchi, Masao; Tarao, Yoshihiro; Suzuki, Kazuo; Takahashi, Chizuko; Kawai, Mizue; Mitsuka, Masayuki (Mitsubishi Chemical Corporation, Japan).
Eur. Pat. Appl. EP 773218 A1 19970514, 77 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1996-118113 19961112.
PRIORITY: JP 1995-294048 19951113.

GI



I



II

AB Compds. represented by formula I and their salts, hydrates, and solvates are claimed [wherein R1, R2, R3 = H, OH, C1-3 alkoxy, etc.; R4 = C1-7 alkyl, C3-7 cycloalkyl, etc.; R5, R6 = H, C1-3 alkyl, etc.; Y = C1-3 alkyl, heterocyclic group containing 1-4 N and 5 or 6 ring-member atoms, or C6-10 aryl; m = 1-3; and n = 2-4]. I have excellent inhibitory activity against acyl coenzyme cholesterol acyl transferase (ACAT), and are useful as active ingredients of medicines for preventive and/or therapeutic treatment of hyperlipemia and atherosclerosis. For instance, bis(trichloromethyl) carbonate was amidated sequentially with 2-[3-(4-phenyl-1-piperazinyl)propoxy]-6-methylaniline and then with N-pentyl(5-imidazolyl-2-methoxyphenyl)methylamine to give title compound II.
At 12.1 mg/kg in rats on a high-cholesterol diet, II.2HCl gave a 50% reduction in total serum cholesterol.

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 191025-58-8P 191025-59-9P 191025-60-2P
191025-63-5P 191025-77-1P 191025-78-2P
191026-14-9P 191026-15-0P 191026-16-1P
191026-17-2P 191026-18-3P 191026-19-4P
191026-20-7P 191026-25-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (piperazinylalkoxyphenyl)phenylalkylurea derivs. as ACAT inhibitors)
RN 191025-58-8 CAPLUS
CN Urea, N-heptyl-N-[[3-methoxy-2-(phenylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191025-59-9 CAPLUS
CN Urea, N-[[3-methoxy-2-(phenylmethoxy)phenyl]methyl]-N-(4-phenylbutyl)-N'-

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 191026-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (piperazinylalkoxyphenyl)phenylalkylurea derivs. as ACAT inhibitors)
RN 191026-39-8 CAPLUS
CN Urea, N-heptyl-N-[2-[3-methoxy-2-(phenylmethoxy)phenyl]ethyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



IT 191026-13-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (piperazinylalkoxyphenyl)phenylalkylurea derivs. as ACAT inhibitors)
RN 191026-13-8 CAPLUS
CN Urea, N-heptyl-N-[2-(2-hydroxy-3-methoxyphenyl)ethyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191025-60-2 CAPLUS
CN Urea, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-pentyl-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191025-63-5 CAPLUS
CN Urea,
N-[[5-(1H-imidazol-1-yl)-2-methoxyphenyl]methyl]-N-(phenylmethyl)-N'-

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 191025-77-1 CAPLUS
CN Urea, N-[[3-methoxy-2-(2-pyridinylmethoxy)phenyl]methyl]-N-pentyl-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191025-78-2 CAPLUS
CN Urea, N-[[3-methoxy-2-(2-pyridinylmethoxy)phenyl]methyl]-N-pentyl-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]-, hydrochloride (1:3) (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



●3 HCl

RN 191026-14-9 CAPLUS
CN Urea, N-heptyl-N-[2-[3-methoxy-2-(2-pyridinylmethoxy)phenyl]ethyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A

●3 HCl

RN 191026-15-0 CAPLUS
CN Urea, N-heptyl-N-[[2-(2-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191026-16-1 CAPLUS
CN Urea, N-(3-phenylpropyl)-N-[[2-(2-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191026-17-2 CAPLUS
CN Urea, N-propyl-N-[[2-(2-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 191026-18-3 CAPLUS
CN Urea, N-propyl-N-[[2-(3-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191026-19-4 CAPLUS
CN Urea, N-propyl-N-[[2-(4-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 191026-20-7 CAPLUS
CN Urea, N-methyl-N-[[2-(2-pyridinylmethoxy)phenyl]methyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 191026-25-2 CAPLUS
CN Urea, N-heptyl-N-[2-[3-methoxy-2-(2-pyridinylmethoxy)phenyl]ethyl]-N'-[5,6,7,8-tetrahydro-2-[3-(4-phenyl-1-piperazinyl)propoxy]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1995:605367 Document No. 123:94650 Original Reference No. 123:1991a,1994a
Carboxamide and urea derivatives having ACAT-inhibiting activity.
Jikihara, Tetsuo; Shirasaka, Tadashi; Suzuki, Kazuo; Suzuki, Hiroko; Taniguchi, Masao; Inoue, Shinya (Mitsubishi Kasei Corp., Japan). Eur. Pat. Appl. EP 591830 A1 19940413, 53 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-115714 19930929. PRIORITY: JP 1992-260325 19920929; JP 1992-262476 19920930; JP 1992-299686 19921110.
GI



I



II

AB Carboxamide derivs. I (R1, R2 = alkyl, etc.; R1R2 = alkylene; group, R3 = H, dialklamino, etc.; R4 = H, alkyl, etc.; R5 = alkyl, etc.; q = 0-3; p = 0-1; A = heterocyclic ring) were disclosed. I are useful as pharmaceuticals for treating hyperlipemia or atherosclerosis. An example compound, (±)-N-(2,6-diisopropylphenyl)-3-(2,3-methylenedioxyphenyl)octanamide (II) was prepared For II the IC50 for inhibition of expression of ACAT was 0.01 μM.
IT 163704-80-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amides and urea derivs. as anticholesteremics and antiatherosclerotics)
RN 163704-80-1 CAPLUS
CN Urea, N-[2-(1,3-benzodioxol-4-yl)heptyl]-N'-[5,6,7,8-tetrahydro-2-(1-methylethoxy)-1-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 163704-81-2P 163704-82-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amides and urea derivs. as anticholesteremics and antiatherosclerotics)
RN 163704-81-2 CAPLUS
CN Urea, N-[2-(1,3-benzodioxol-4-yl)heptyl]-N'-(5,6,7,8-tetrahydro-2-methoxy-1-naphthalenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163704-82-3 CAPLUS
CN Urea, N-[2-(1,3-benzodioxol-4-yl)heptyl]-N'-(2-ethoxy-5,6,7,8-tetrahydro-1-naphthalenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L4 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1995:305146 Document No. 122:808910 Original Reference No. 122:15363a,15366a
Preparation of arylurea and amide derivatives and their use in the control
of cell membrane potassium channels. Olesen, Soeren-Peter; Moldt, Peter; Pedersen, Ove (Neurosearch A/S, Den.). PCT Int. Appl. WO 9422807 A1 19941013, 56 pp. DESIGNATED STATES: W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1994-EP1008 19940330. PRIORITY: DK 1993-411 19930407.
GI



I

AB Title compds. I (X, Z = HN, H2C, at least one of X and Z being HN; Y = O, S, NCN, HN; B, D, E, F = C, N, at least 3 of B, D, E, and F being C; R1, R4 = H, halo, F3C, HO2C, alkyl-O2C, aryl-O2C, H2NCO, NC, alky, alkoxy, HO,
etc.; R2 = H, F3C, HO2C NC, HOCH2, aryloxy, etc.; R3 = H, halo, HO2C, NC, alkylcarbonyl, etc.; R2R3, R3R4 with the Cs to which they are attached form an (unsatd.) addnl. fused carbocyclyl; one of R11, R12 = halo, F3C, HO2C, NC, alkyl, alkoxy HO, O2N, HOCH2, etc. and the other is H; A = H, AR12 and the Cs to which they are attached form (unsatd.) fused carbocyclyl) or a salt thereof, are prepared I are claimed for treatment of
arterial hypertension, coronary artery spasms, asthma, irritable bowel syndrome, spastic bladder, ischemia, psychosis, convulsions. 2-Hydroxy-5-nitroaniline and 3-(trifluoromethyl)phenyl isocyanate were added to MePh and stirred overnight at room temperature to give I (X, Z = HN, Y
= O, B, D, E, F, = C, R1 = R3 = R4 = R12 = H, R2 = O2N, R11 = F3C) (II). The activity (1-10 μM) was demonstrated by I (R2 = H, R3 = Cl, everything else as in II). Pharmaceutical formulations comprising I are given.
IT 160383-97-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylurea and amide derivs. and their use in control of cell
membrane potassium channels)
RN 160383-97-1 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-1-

L4 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1995:47808 Document No. 122:81671 Original Reference No. 122:15527a,15530a
Aryne chemistry of podocarpic acid derivatives. Cambie, Richard C.; Higgs, Paul I.; Rutledge, Peter S.; Woodgate, Paul D. (Department Chemistry, University Auckland, Auckland, N. Z.). Australian Journal of Chemistry, 47(8), 1483-508 (English) 1994. CODEN: AJCHAS. ISSN: 0004-9425.
GI



I

AB The anthranilic acid I (R1 = CO2H, R2 = NH2), a key intermediate for the generation of an aryne at C13 of podocarpic acid derivs., was synthesized from the 14-amino compound I (R1 = H, R2 = NH2) which in turn was generated
regiospecifically in high yield by treatment of the 13-bromo compound I [R1
= Br, R2 = N(CO2)2] with NaNH2-NH3(l). The amine was converted into the anthranilic acid by two sep. routes: firstly by directed lithiation and trapping of the lithium species with a CO2 moiety, and secondly by oxidative cleavage of an isatin fused across positions 13 and 14.
IT 160455-41-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(aryne chemical of podocarpic acid derivs. from anthranilate-related precursor)
RN 160455-41-4 CAPLUS
CN Urea, N,N'-bis[4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-8-(methoxymethyl)-4b,8-dimethyl-1-phenanthrenyl]-, [4bS-[1(4bR*,8R*,8aS*),4bα,8α,8aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN

1994:631366 Document No. 121:2313660 Original Reference No. 121:42211a,42214a Cholecystokinin and gastrin antagonists. Bock, Mark G.; Bergman, Jeffrey M.; Freidinger, Roger F. (Merck and Co., Inc., USA).

PCT Int. Appl. WO 9415924 A1 19940721, 77 pp. DESIGNATED STATES: W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1994-US334 19940111. PRIORITY: US 1993-3927 19930113.

GI



I

II

AB Benzodiazepine derivs. I [R1 = alkyl, cyclopropyl; R2 = (un)substituted phenyl; R = amino acid group] were disclosed. I are antagonists of gastrin and cholecystokinin (CCK). A specifically claimed example compound, 3-[[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]phenylalanine (II), was prepared

IT 158325-77-0P 158325-84-9P 158325-85-0P 158325-86-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin/gastrin antagonist)

RN 158325-77-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 8-[[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,4-tetrahydro-, methyl ester (CA INDEX NAME)

L4 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 158325-84-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 5-[[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,4-tetrahydro-, methyl ester (CA INDEX NAME)



RN 158325-85-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 2-amino-5-[[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-1,2,3,4-tetrahydro-, methyl ester (CA INDEX NAME)

L4 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 158325-86-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 2-amino-5-[[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-1,2,3,4-tetrahydro- (CA INDEX NAME)



L4 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1994:77280 Document No. 120:772800 Original Reference No. 120:13905a,13908a
Preparation of N-biphenylylymethylbenzimidazoles as angiotensin II antagonists.. Hauel, Norbert; Narr, Berthold; Ries, Uwe; Van Meel, Jacques; Wienen, Wolfgang; Entzeroth, Michael (Thomae, Dr. Karl, G.m.b.H., Germany). Ger. Offen. DE 4212748 A1 19931021, 40 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1992-4212748 19920416.
GI



I

AB Title compds. [I; R1, R2 = alkyl; R1R2 = 1,3-propylene, 1,4-butylene; R3 = R8NR7CONR6; R6 = H, alkyl, cyclopentyl, cyclohexyl, phenylalkyl; R7 = H, alkyl, alkenyl, Ph, phenylalkyl, cycloalkyl; R8 = H, alkyl; R7R8 = atoms to form an alkyleneimino or morpholino system; R6R7 = alkylene, glutarimino, maleimido, phthalimino, etc; R4 = cycloalkyl, (O-, S-, or NH-interrupted) alkyl; R5 = carboxy, cyano, SO3H, (triphenylmethyl)tetrazolyl, group metabolizeable in vivo to a carboxy group, alkylcarbonylaminosulfonyl, etc.], were prepared Thus, 4,5-dimethyl-6-phthalimino-2-propyl-1H-benzimidazole and 4'-bromomethyl-2-(2-triphenylmethyltetrazol-5-yl)biphenyl were stirred 15 h with KOCMe3 in Me2SO to give 54.8% 4'-[(4,5-dimethyl-6-phthalimino-2-propylbenzimidazol-1-yl)methyl]-2-(triphenylmethyltetrazol-5-yl)biphenyl. I bound to rat lung angiotensin II receptor prepns. with IC50 = 5.0-190.0 nM, and in other testing showed no toxic side effects at up to 30 mg/kg i.v. Various generic I drug formulations are given.
IT 152171-98-7P 152172-01-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)
RN 152171-98-7 CAPLUS
CN Urea, N-cyclohexyl-N'-[6,7,8,9-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-naphth[1,2-d]imidazol-5-yl]- (CA INDEX NAME)

L4 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 152172-07-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of angiotensin II antagonist)
RN 152172-07-1 CAPLUS
CN Urea, N-cyclohexyl-N'-[6,7,8,9-tetrahydro-2-propyl-3-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-3H-naphth[1,2-d]imidazol-5-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L4 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 152172-01-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[5-[[(cyclohexylamino)carbonyl]amino]-6,7,8,9-tetrahydro-2-propyl-3H-naphth[1,2-d]imidazol-3-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 152172-00-4
CMF C35 H40 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1992:628431 Document No. 117:2284310 Original Reference No. 117:39357a,39360a Preparation of urea derivatives as preventive agrochemical pesticides.. Aman, Shunji; Watanabe, Hiroyuki; Tsuzuki, Kenji; Takematsu, Tetsuo (Tosoh Corp., Japan). Jpn. Kokai Tokkyo Koho JP 04178363 A 19920625 Heisei, 7 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1990-303902 19901113.
GI



I

AB Urea derivs. I [R1 = H, lower alkyl, lower alkoxy; R2 = lower alkyl, lower alkenyl, 4-morpholinyl, (lower alkoxycarbonyl-, carbamoyl-, or arylcarbonyl-substituted) Ph, five-membered heterocyclyl, etc.] are prepared as preventive agrochem. pesticides. I are especially useful as microbicides, insecticides, and acaricides. Thus, 0.3 g Et2NH in C6H6 was treated with 0.7 g 5,6,7,8-tetrahydro-1-naphthyl isocyanate and refluxed for 4 h to give 0.94 g 3-(5,6,7,8-tetrahydro-1-naphthyl)-1,1-diethylurea (II). II, at 600 ppm, showed good preventive activity against tomato late blight. Formulation examples are given.
IT 144331-51-1P 144331-52-2P 144331-53-3P
144331-54-4P 144331-55-5P 144331-56-6P
144331-57-7P 144331-58-8P 144331-59-9P
144331-60-2P 144331-61-3P 144331-62-4P
144331-63-5P 144331-64-6P 144331-65-7P
144331-66-8P 144331-67-9P 144331-68-0P
144331-69-1P 144331-70-4P 144331-71-5P
144331-72-6P 144356-56-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as preventive agrochem. pesticide)
RN 144331-51-1 CAPLUS
CN Urea, N-4-morpholinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-52-2 CAPLUS
CN Urea, N-(1-methyl-1-phenylethyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-53-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-57-7 CAPLUS
CN Urea, N-(5-nitro-2-thiazolyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-58-8 CAPLUS
CN Urea, N-2-pyridinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 144331-54-4 CAPLUS
CN Urea, N-2-pyrimidinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-55-5 CAPLUS
CN Urea, N-(5-methyl-2-pyrimidinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-56-6 CAPLUS
CN Urea, N-(4,5-dimethyl-2-pyrimidinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-59-9 CAPLUS
CN Urea, N-(5-chloro-2-benzoxazolyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-60-2 CAPLUS
CN Urea, N-4-pyrimidinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-61-3 CAPLUS
CN Urea, N-(4-methyl-2-benzothiazolyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)



RN 144331-62-4 CAPLUS
CN Urea, N-[6-chloro-2-(methylthio)-4-pyrimidinyl]-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-63-5 CAPLUS
CN Urea,
N-(2,6-dichloro-3-pyridinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-
(CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-64-6 CAPLUS
CN Urea, N-(2-benzoylphenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-65-7 CAPLUS
CN Benzamide,
3-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-
(CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-66-8 CAPLUS
CN Urea,
N-(2,3-dihydro-1H-inden-5-yl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-
(CA INDEX NAME)



RN 144331-67-9 CAPLUS
CN Benzoic acid, 4-[[[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-68-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-2-thiazolyl- (CA INDEX NAME)



RN 144331-69-1 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-1,3,4-thiadiazol-2-yl- (CA
INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-70-4 CAPLUS
CN Urea, N-1H-pyrazol-3-yl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-71-5 CAPLUS
CN Urea, N-1H-imidazol-2-yl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-72-6 CAPLUS
CN Urea, N-1H-imidazol-5-yl-N-methyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144356-56-9 CAPLUS
CN Urea, N-(5-nitro-2-pyridinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1992:607160 Document No. 117:2071600 Original Reference No. 117:35633a,35636a Preparation of urea derivatives as preventive agrochemical pesticides.. Aman, Shunji; Watanabe, Hiroyuki; Tsuzuki, Kenji; Takematsu, Tetsuo (Tosoh Corp., Japan). Jpn. Kokai Tokkyo Koho JP 04178362 A 19920625 Heisei, 7 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1990-303903 19901113.

GI



I

AB Urea derivs. I [R1 = H, lower alkyl, lower alkoxy; R2 = lower alkyl, lower alkenyl, 4-morpholinyl, (lower alkyl-, lower alkoxy-, halo-substituted) Ph, five-membered heterocyclyl, etc.] are prepared as preventive agrochem. insecticides, acaricides and microbicides. Thus, 0.47 g 4-amino-2-methylquinoline in C6H6-DMF was mixed with 0.52 g 1,2,3,4-tetrahydro- 1-naphthylisocyanate, and refluxed overnight to give 0.46 g 3-(1,2,3,4-tetrahydro-1-naphthyl)-1-(2-methyl-4-quinolyl)urea (II). II, at 600 ppm, showed good preventive activity against tomato late blight. Formulation examples are given.

IT 101574-48-5P 144331-51-1P 144331-52-2P
144331-53-3P 144331-58-8P 144331-68-0P
144331-69-1P 144331-70-4P 144331-71-5P
144331-73-7P 144331-74-8P 144331-75-9P
144331-76-0P 144331-77-1P 144331-78-2P
144331-79-3P 144331-80-6P 144331-81-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as preventive agrochem. pesticide)

RN 101574-48-5 CAPLUS
CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-51-1 CAPLUS
CN Urea, N-4-morpholinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-52-2 CAPLUS
CN Urea, N-(1-methyl-1-phenylethyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-53-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-1H-1,2,4-triazol-5-yl- (CA
INDEX NAME)



L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-70-4 CAPLUS
CN Urea, N-1H-pyrazol-3-yl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX
NAME)



RN 144331-71-5 CAPLUS
CN Urea, N-1H-imidazol-2-yl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 144331-58-8 CAPLUS
CN Urea, N-2-pyridinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-68-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-2-thiazolyl- (CA INDEX NAME)



RN 144331-69-1 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-N'-1,3,4-thiadiazol-2-yl- (CA
INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 144331-73-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-74-8 CAPLUS
CN Urea, N-(4-methylphenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-75-9 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-76-0 CAPLUS
CN Urea, N-4-pyridinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-77-1 CAPLUS
CN Urea, N-(5,6-dimethyl-1,2,4-triazin-3-yl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-80-6 CAPLUS
CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-81-7 CAPLUS
CN Urea, N-(4,5-dihydro-2-thiazolyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 144331-78-2 CAPLUS
CN Urea, N-3-quinolinyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



RN 144331-79-3 CAPLUS
CN Urea, N-(2-methyl-4-quinolinyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1992:20957 Document No. 116:209570 Original Reference No. 116:3699a,3702a
Preparation of quinolylmethylurea derivatives as anticholesteremics.
Ito,
Noriki; Matsuda, Koyo; Iwaoka, Kiyoshi; Iizumi, Yuichi (Yamanouchi Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9113871 A1 19910919, 37 pp. DESIGNATED STATES: W: AU, CA, FI, HU, JP, KR, US; RW: AT, BE, CH,
DE, DK, ES, FR, GB, GR, IT, LU, NL, SE. (Japanese). CODEN: PIXXD2.
APPLICATION: WO 1991-JP320 19910308. PRIORITY: JP 1990-60755 19900312.
GI



AB R1(CH2)nNR2CONHR3 [I; R1 = quinolyl, benzofuranyl, carbazolyl, etc.; R2 = cycloalkyl, R3 = (halo- or alkyl)phenyl, tetrahydronaphthyl; n = 0-6], useful as anticholesteremics and antiarteriosclerotics, are prepared
Refluxing a mixture of amine II and carbamate III in MePh gave urea derivative
IV, which showed ED50 of 514 mg/kg in lowering serum cholesterol in rats. Also prepared and tested were 27 addnl. I.
IT 138141-70-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticholesterolemic agent)
RN 138141-70-5 CAPLUS
CN Urea, N-cycloheptyl-N-(2-dibenzofuranylmethyl)-N'-(5,6,7,8-tetrahydro-1-naphthaleny1)- (CA INDEX NAME)



L4 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1992:20789 Document No. 116:207890 Original Reference No. 116:3663a,3666a
Preparation of N-aryl-N-carbocyclyl-N'-phenylurea derivatives as ACAT inhibitors. Ito, Noriki; Matsuda, Koyo; Iwaoka, Kiyoshi; Iizumi, Yuichi (Yamanouchi Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 447116 A1 19910918, 22 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1991-301868 19910306. PRIORITY: JP 1990-60754 19900312.
GI



I

AB R1ANR2CONHR3 (R1 = condensed carbocyclyl; R2 = cycloalkyl which may have a
bridgehead; R3 = (substituted) tetrahydronaphthyl, -Ph; A = bond, C1-6 alkylene), are prepared as ACAT (acyl-CoA cholesterol acyltransferase) inhibitors. N-Cycloheptyl-2-fluorenylmethylamine (preparation given) and Ph
(2,4,6-trimethylphenyl)carbamate in MePh were refluxed 15 h to give urea derivative I. I inhibited ACAT activity with IC50 at 7.3 + 10-8M.
IT 138046-65-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cholesterol acyltransferase inhibitor)
RN 138046-65-8 CAPLUS
CN Urea, N-bicyclo[2.2.1]hept-2-yl-N-(9-phenanthrenylmethyl)-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1987:1846 Document No. 106:18460 Original Reference No. 106:371a,374a Use of acylurea compounds for controlling endoparasites and ectoparasites of warm-blooded animals. Potter, Michael Fred; Rotramel, George Lorton; Caruso, Andrew James; Chou, David Teh Wei; Cain, Paul Alfred (Union Carbide Corp., USA). PCT Int. Appl. WO 8603941 A1 19860717, 173 pp. DESIGNATED STATES: W: AU, BR, DK, FI, HU, JP, KR, LK, MW, NO, SD, SU; RW:
AT, BE, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1985-US2545 19851227. PRIORITY: US 1984-687249 19841228; US 1985-723588 19850415; US 1985-804638
19851209.
AB The urea derivs. R1CONR2C(Y)NR3R4 [R1 = (un)substituted carbocyclic or heterocyclic ring, etc.; R2, R3 = H, (un)substituted alkyl -benzyl, PhSO2,
PhS, etc., R4 = H, R1; Y = O, S] are prepared as endo- and ectoparasiticides. Thus, 3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylaniline (preparation given) was reacted with 2,6-difluorobenzoyl isocyanate in MePh at 50°, to give
1-[3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylphenyl]-3-(2,6-difluorobenzoyl)urea (I). Addition of 25 ppm I to the feed of chicken, totally controlled lice (Menacanthus stramineus).
IT 105621-96-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as endo- and ectoparasiticide)
RN 105621-96-3 CAPLUS
CN Benzamide,
N-[[(4-chloro-5,6,7,8-tetrahydro-1-naphthalenyl)amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



L4 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1978:540207 Document No. 89:140207 Original Reference No. 89:21589a,21592a Sulfonamides with schistosomal activity. Horstmann, H.; Goennert, R.; Andrews, P.; Pellegrino, J. (Bayer A.-G., Wuppertal, Fed. Rep. Ger.). Proc. Int. Conf. Schistosomiasis, Meeting Date 1975, Volume 1, 215-20. Editor(s): Abdallah, Ahmed. Inst. Res. Trop. Med.: Cairo, Egypt. (English) 1978. CODEN: 38UAAT.
GI



I, R=alkyl or aryl, R1=acyl

AB Substituted glycyl sulfonamides I administered to infected mice showed activity against Schistosoma mansoni at high doses. Among the N-acyl-N-alkyl derivs., anti-schistosomal activity was found only when the
acyl group was Ac or trifluoroacetyl; varying the alkyl group, activity was maximum at 3 C atoms. Among the N-acetyl-N-aryl derivs., p-substituted
Ph derivs. were the the most active, with maximum actvity at 4 C atoms; compds. with highly branched substituents were more active than their straight chained counterparts. The most active compound BAY d9778 (I, R =
Ac, R1 = C6H4CMe3) [67707-19-1] was tested in Cebus monkeys and found to be inactive, possibly due to metabolism
IT 67707-43-1
RL: BIOL (Biological study)
(schistosoma infestation response to, species differences in)
RN 67707-43-1 CAPLUS
CN Acetamide, N-[[[4-(aminosulfonyl)phenyl]amino]carbonyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



L4 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1976:592653 Document No. 85:192653 Original Reference No. 85:30811a,30814a
New heterocyclic derivatives of 1'- and
3'-amino-5',6',7',8'-tetrahydro-2'-acetonaphthones. Prieto, Jose; Vega,
Armando; Moragues, Jacinto (Inst. Invest., Lab. Almirall S. A.,
Barcelona,
Spain). Journal of Heterocyclic Chemistry, 13(4), 813-19 (English) 1976.
CODEN: JHTCAD. ISSN: 0022-152X.
GI



AB The acetonaphthones I (R = 1- and 3-NH2) were prepared by reduction of
the low
temperature nitration products of I (R = H). New heterocyclic compds.,
e.g., II
and III were prepared from I (R = 1- and 3-NH2).
IT 60947-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclization of)
RN 60947-14-0 CAPLUS
CN Benzamide, N-[[[5,6,7,8-tetrahydro-2-(1-thioxoethyl)-1-
naphthalenyl]amino]carbonyl]- (CA INDEX NAME)



L4 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1959:2065 Document No. 53:2065 Original Reference No. 53:358d-i,359a-i,360a
New N,N'-disubstituted thioureas and ureas of biological interest.
Buu-Hoi, Ng. Ph.; Xuong, Ng. D.; Suu, V. T. (Univ. Paris). Journal of
the
Chemical Society 2815-21 (Unavailable) 1958. CODEN: JCSOA9. ISSN:
0368-1769.
AB The reactivity of several classes of aromatic and heterocyclic amines
towards aryl isocyanates and isothiocyanates was investigated. Aryl
isocyanates were more reactive than the corresponding isothiocyanates. A
large number of new N,N'-diarylthioureas and ureas and their heterocyclic
analogs, most of them bearing halogen groups, were prepared for testing
as
potential antiviral and antibacterial agents. 3-ClC6H4NHAc (34 g.) and
36
g. N-bromosuccinimide in 300 cc. dry CCl4 refluxed 4 hrs., cooled, the
precipitate filtered off, treated with hot H2O, the residue heated 1 hr.
with 50
cc. HCl in 100 cc. 70% aqueous EtOH, cooled, and basified with NH4OH
gave 38
g. 4,3-BrClC6H3NH2, m. 68° (EtOH), free from isomers and
by-products. Similarly were prepared 4,2-BrMeC6H3NH2, m. 55°, and
4,3-BrFC6H3NHAc, m. 152° (MeOH), deacetylated with HCl to
4,3-BrFC6H3NH2, m. 72-3° (H2O), which, with chloranil in boiling
EtOH yielded 3,6-bis(4-bromo-3-fluoroanilino)-2,5-dichloro-1,4-
benzoquinone, m. above 320°. 2-MeC6H4NHAc (45 g.) and 35 g.
N-chlorosuccinimide in 300 cc. CCl4 refluxed 4 hrs. and the resulting
product deacetylated gave 28 g. 4,2-ClMeC6H3NH2, b40 189-92°, m.
30°. 1,3-Disubstituted ureas were obtained practically
quantitatively by adding a C6H6 solution of 1 mole aryl isocyanate to 1
mole
amine in an appropriate solvent at room temperature The following
substituted
carbanilides were prepared (substituents and m.p. given): 2,4-Fgr;2,
222°; 3,4-F2, 216°; 2',4',4-F2Cl, 262°; 3',4',4-F2Cl,
246°; 3,4-FBr, 230°; 3,3',5',4 -FCl2Br, 257°;
3,4,4'-FBrCl, 289°; 3,3',5-Cl3, 233°; 3,3',4',5-Cl4,
265°; 2',3,3',5-Cl4, 272°; 3,3',5',4-Cl3Br, 273°;
2',4',3,5-F2Cl2, 229°; 3,5,3',4'-Cl2F2, 232°; 2-F3C,
182°; 4-Ac, 186°; 4,4'-Ac(F), 218°; 4,4'-Ac(Cl),
233°; 3',5',4-Cl2(Ac), 236°; 3',4',4-Cl2(Ac), 259°;
4-Bz, 203°; 4,4'-Bz(Cl), 250°; 4-Et2N, 189°;
4,4'-F(Et2N), 213°; 4,4'-Cl(Et2N), 227°; 3,4,4'-Cl2(Et2N),
177°; 3,5,4'-Cl2(Et2N), 180°; 4-Pr2N, 155°;
4,4'-F(Pr2N), 144°; 4,4'-Cl(Pr2N), 169°. The following
RNHCONHR' (I) were prepared (R = 5-chloro-2-pyridyl in all cases) (R' and
m.p. given): Ph, 214°; p-ClC6H4, 236°; p-FC6H4, 216°;
3,4-Cl2C6H3, 277°; 3,5-Cl2C6H3, 284°. I (R =
5-nitro-2-pyridyl) (R' and m.p. given): Ph, 238°; p-ClC6H4,
285°; p-FC6H4, 283°; 3,4-Cl2C6H3, 291°; 3,5-Cl2C6H3,
268°. I (R = 5-nitro-2-thiazolyl) (R' and m.p. given): Ph,
259°; p-ClC6H4, 284°; p-FC6H4, 254°; 3,4-Cl2C6H3,
296°. I (R = 2-pyrimidyl) (R' and m.p. given): p-ClC6H4,
238°; p-FC6H4, 234°; 3,4-Cl2C6H3, 253°; 3,5-Cl2C6H3,
275°. I (R = 4,6-dimethyl-2-pyrimidyl) (R' and m.p. given):
p-FC6H4, 212°; p-ClC6H4, 216°; 3,4-Cl2C6H3, 232°;

L4 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
3,5-Cl2C6H3, 236°. I (R = 2,4-dimethyl-6-pyrimidyl) (R' and m.p.
given): p-ClC6H4, 249°; 3,4-Cl2-C6H3, 251°; 3,5-Cl2C6H3,
267°. Other compds. reported were (compd. and m.p. given):
(4-ClC6H4NH)2CO, 318°; 1-phenyl-3-(5,6,7,8-tetrahydro-1-
naphthyl)urea, 205°; the 4-chloro-5,6,7,8-tetrahydro-1-naphthyl
analog, 258°; 1-(1-acetyl-7-naphthyl)-3-(p-chlorophenyl)urea,
242°; 1-(p-chlorophenyl)-3-(2-phenanthridinyl)urea, 280°;
1-(3,4-dichlorophenyl)-3-(6-quinolyl)urea, 288°. RNHCSNHR' (II)
were prepd. by treating 1 mole of the appropriate amine in warm EtOH with
1 mole aryl isothiocyanate; slight heating at 60° was required when
the amine and(or) the isothiocyanate was ogr;-substituted. The following
II were prepd. (R, R', m.p. given): p-FC6H4, Z (= 3-pyridyl), 190°;
p-ClC6H4, Z, 198°; p-BrC6H4, Z, 220°; p-MeC6H4, Z,
175°; 2,4-Me2C6H3, Z, 172°; p-MeOC6H4, Z, 201°;
p-EtOC6H4, Z, 178°; p-Me2CHCH2CH2OC6H4, Z, 136°; p-FC6H4, Y
(= 4-methyl-2-pyridyl), 182°; p-ClC6H4, Y, 216°; p-BrC6H4,
Y, 222°; p-FC6H4, W (= 5-methyl-2-pyridyl), 202°; p-ClC6H4,
W, 212°; p-BrC6H4, W, 219°; p-MeC6H4, W, 182°;
2,4-Me2C6H3, W, 200°; p-MeOC6H4, W, 214°; p-EtOC6H4, W,
190°; p-Me2CHCH2CH2OC6H4, W, 132°; p-FC6H4, X (=
5-chloro-2-pyridyl), 198°; p-ClC6H4, X, 230°; p-BrC6H4, X,
238°; Ph, X, 195°; p-MeC6H4, X, 194°; p-EtC6H4, X,
173°; p-MeOC6H4, X, 226°; p-EtOC6H4, X, 181°;
p-Me2CHCH2CH2OC6H4, X, 151°. The following substituted PhNHCSNHPh
were prepd. (substituents and m.p. given): 3,4',4-F2Br, 185°;
3,4,4'-FBr2, 213°; 3,4,4'-Cl2F, 135°; 3,5,4'-Cl2F,
176°; 3,4,4'-Cl3, 160°; 3,4,4'-Cl2Br, 172°;
2,3,4'-Cl2F, 161°; 2,3,4'-Cl3, 199°; 2,3,4'-Cl2Br,
201°; 2,4'-BrF, 188°; 2,4'-BrCl, 198°; 2,4'-Br2,
202°; 2,4'-Br(MeO), 181°; 2,4'-Br(EtO), 190°;
2,4'-BrEt, 185°; 2,4'-BrMe, 193°; 2,4,2'-Me2Br,
170°; 3,4'-BrF, 128°; 3,4'-BrCl, 133°;
3,4'-Br(EtO), 129°; 3,4'-Br(Me2CHCH2CH2O), 119°; 4,4'-FI,
167°; 4,4'-ClI, 213°; 4,4'-BrI, 224°;
4,4'-Br(EtO), 197°; 4,4'-Br(Me2CHCH2CH2O), 192°; 3,4-F2,
148°; 3,4,4'-F3, 162°; 3,4,4'-F2Cl, 164°;
3,4,4'-F2Br, 178°; 3,4,4'-F2Et, 136°; 2',4',3,4-Me2F2,
151°; 3,4,4'-F2(EtO), 163°; 3,4,4'-F2(Me2CHCH2CH2O),
146°; 2,4-F2, 136°; 2,4,4'-F3, 176°; 2,4,4'-F2Br,
190°; 2,4,4'-F2Et, 155°; 2,4,2',4'-F2Me2, 149°;
2,4,4'-F2(EtO), 148°; 2,4,4'-F2(Me2CHCH2CH2O), 132°;
3,4,4'-ClBrF, 178°; 3,4,4'-Cl2Br, 187°; 3,4,4'-ClBr2,
191°; 3,3',4,4'-Cl2Br2, 216°; 2,4,4'-MeClF, 117°;
2,4,4'-MeCl2, 150°; 2',4,4'-MeBrCl, 167°; 2,4,4'-MeBr2,
185°; 2,4,4'-MeBrCl, 172°; 4,4'-F(Et2N), 148°;
4,4'-Cl(Et2N), 173°; 4,4'-Br(Et2N), 199°; 4,4'-F(Pr2N),
141°; 4,4'-Cl(Pr2N), 167°; 4,4'-Br(Pr2N), 172°;
2,4',4-MeCl(Et2N), 190°; 4',2-FEt, 120°; 4',2-ClEt,
139°; 2,4'-Et2, 125°; 2,4'-Et(EtO), 160°;
4,4'-Cl(R) (R = cyclohexyl), 229°; 4-R, 185°; 2,4'-MeO(R),
176°; 4,4'-R(Me), 176°; 4,4'-R(Et), 151°;
4,4'-R(EtO), 170°; 4,4'-R(Me2CHCH2CH2O), 155°; 4,4'-F(R),
163°; 3,4,4'-Me2(F), 164°; 3,4,4'-Me2Cl, 168°;
3,4,4'-Me2Br, 172°; 3,4,4'-Me3, 108°; 2,3',4,4'-Me4,
128°; 3,4,4'-Me2(MeO), 120°; 3,4,4'-Me2(Me2CHCH2CH2O),
105°; 2,5,4'-Me2F, 147°; 2,5,4'-Me2Cl, 160°;
2,5,4'-Me2Br, 178°; 2,2',4,5'-Me4, 133°; 2,5,4'-Me2(MeO),
126°; 2,5,4'-Me2(EtO), 119°; 2,4,5,4'-Me3F, 156°;
2,4,5,4'-Me3Cl, 175°; 2,4',5-MeEtPr, 116°; 2,5,4'-MePr(EtO),

L4 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
93°; 2,5,4'-MePr(MeO), 113°; 2,4,5-EtFBu, 95°;
2,5,4'-EtBu(EtO), 122°; 2,5,4'-EtBu(MeO), 110°; 4-AcNH,
198°; 4',4-Me(AcNH), 224°; 2,4,4'-Me2(AcNH), 184°;
4,4'-Et(AcNH), 199°; 4,4'-F(AcNH), 220°; 4,4'-Br(AcNH)
229°; 4,4'-MeO(AcNH), 216°; 4,4'-EtO(AcNH), 215°;
4,4'-AcNH(Me2CHCH2CH2O), 188°; 4,4'-(Et2N)2, 173°;
4,4'-Et(Et2N), 147°; 2,4,4'-Me2(Et2N), 146°; 4,4'-Et2N(EtO),
153°; 4,4'-Et2N(Me2CHCH2CH2O), 132°; 4,4'-Et(Pr2N),
148°; 2,4,4'-Me2(Et2N), 171°; 2,3',4-Me2(Et2N), 136°;
2,4,4'-Me(Et2N)(MeO), 165°; 2,2',4-Me(MeO)(Et2N), 151°;
2,2',4',4-Me3(Et2N), 168°. Other thioureas reported were:
1-(p-fluoro-), m. 139°, 1-(p-chloro-), m. 192°, and
1-(p-bromophenyl)-3-(5,6,7,8-tetrahydro-1-naphthyl)thiourea, m.
196°. Refluxing 2 hrs. an EtOH soln. of equimolar amts. of
2,3-dichloro-1,4-naphthoquinone and the appropriate aryl amine gave the
following 3-substituted 2-chloro-1,4-naphthoquinones (3-substituent and
m.p. given): 4,3-BrClC6H3NH, 255°; 4,2-ClMeC6H3NH, 213°;
4,2-BrMeC6H3NH, 218°; 3,5-Cl2C6H3NH, 269°; 2,4-F2C6H3NH
198°; 3,4-F2C6H3NH, 199°; 4-Et2NC6H4NH, 159°;
4-Pr2NC6H4NH, 118°. The following 1-substituted
2,5-dimethylpyrroles were prepd. by refluxing a few hrs. the appropriate
amine and (AcCH2)2 (1-substituent, b.p./mm., and m.p. given): 4-Et2NC6H4,
181°/17, 85°; 4-Pr2NC6H4, 208°/18, 57°;
3,4-F2C6H3, 155°/30, 57°; 4,3-BrClC6H3, 181°/18,
58°. ω-Bromo-4-chloroacetophenone (2.3 g.) and 1.3 g.
2-amino-5-chloropyridine in 20 cc. EtOH refluxed 6 hrs., cooled, and the
ppt. recrystd. from EtOH gave 1.5 g.
6-chloro-2-(p-chlorophenyl)imidazo[1,2-a]pyridine, m. 209°.
Similarly were prepd. the 2-(p-bromophenyl)-6-chloro-, m. 221°, the
6-chloro-2-(p-fluorophenyl)-, m. 199°, and the
2-(3-bromo-4-methoxyphenyl)-6-chloro compds., m. 194°.
IT 101574-48-5P, Urea, 1-phenyl-3-(5,6,7,8-tetrahydro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)
RN 101574-48-5 CAPLUS
CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



10575027.trn

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN
1950:679 Document No. 44:6790 Original Reference No. 44:109h-i,110b-i,111a-i,112a-i,113a-i,114a-i,115a-b Polyurethans. IV. Mono- and polyisocyanates. Siefken, Werner Annalen der Chemie, Justus Liebigs, 562, 75-136 (Unavailable) 1949. CODEN: 9X224Y. OTHER SOURCES: CASREACT 44:679.
GI For diagram(s), see printed CA Issue.
AB cf. Bayer, C.A. 42, 6160c; Hebermehl, C.A. 43, 1604i. A comprehensive review of the researches in this field made by the staff of the former I. G. Farbenind., W. Altner, D. Delfs, A. Dierichs, E. Hartmann, E. Liese, A. Modersohn, S. Petersen, E. Prell, R. Putter, H. Rinke, W. Schulte, G. Schwaebel, H. Schwarz, G. Spielberger, K. Taube, A. Pielmann, K. Sigwart, H. Brock, J. Mierbach, E. Scholz, H. Glaser, F. Moller, and R. Schroter, including a brief literature survey with 62 refs. In general the HCl salts of amines were treated with COCl2 in excess, and the resultant HCl was rapidly removed by choosing a solvent in which the RNCO, but not HCl was soluble Temps. were regulated to insure conversion of the intermediate RNHCOCl into RNCO. In the aliphatic series, the yields of RNCO were uniformly satisfactory and arylaliph. amines, or alicyclic or heterocyclic amines, underwent very similar conversions. The reaction also applied to compds. of the type RCH(NH2)R'. Solvents used included PhMe, xylene, PhCl, Cl2C6H4, and C6H3Cl3, so chosen that the b.ps. of the solvent and the resulting RNCO showed a sufficient difference. The amine-HCl may be dissolved in the solvent, or the free amine may be dissolved and then treated with dry HCl. Normally COCl2 was added until any insol. HCl salt was fully dissolved, the volatile gases then swept out by means of an inert gas, and the resulting products fractionated. Polymerization products were retained as still residues; their amts. could be materially increased by the use of metallic catalysts (such as FeCl3, SnCl4, ZnCl2, Fe carbonyl derivs., etc.). In individual cases, HCl is removed from RNHCOCl by means of Ca(OH)2 or derivs. of CH2.O.CH2 (sometimes resulting in decreased yields of RNCO). In special cases were used substituted ureas of the type RR'NCONHR'' (formed from RR'NCOCl + H2NR''), where R'' is a relatively small alkyl group and may be converted into R''NCO by heating above 200°. Another possibility was to treat compds. of the type 2-HOC6H4OCONHR with the formation of RNCO and o-C6H4(OH)2. The conversions of amines containing such substituents as Cl, CN, OR', CO2R', COCl, etc., into analogous isocyanates is discussed. Diamine, triamine, or tetramine HCl salts on COCl2 treatment may be converted into analogous di-, tri-, and tetraisocyanates. Difficulties in the choice of suitable (large-scale) reactors are discussed. Whereas for an aliphatic RNCO, phosgenation may be carried out in stainless steel, aromatic di- and triamines require Pb-lined reactors. Batch or continuous phosgenation may be used. In determining the percentage NCO in an isocyanate, 2 methods were used: a cumbersome gravimetric method depending on the formation of a difficultly soluble Ph urea by condensation of RNCO with PhNH2, and the more practical procedure in which RNCO is treated with a known excess of Bu2NH

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
in PhCl, thus giving rise very rapidly to Bu2NCONHR, and the unchanged Bu2NH is then titrated with HCl in the presence of MeOH (within 5 min. after inception of the quant. reaction). In the formation of 1,6-hexamethylene diisocyanate (I), b15 132° [bis(methylurethane), m. 113-14°], on repeated fractionation a small forerun was 6-chlorohexyl isocyanate (II), b12 108° [methylurethane (III), b10 150-2°; Cl(CH2)6NHCONH2, m. 128-9°]. [HCl.H2N(CH2)3]2 loses NH4Cl, forming CH2.(CH2)4.CH2.NH.HCl, which reacts with COCl2 to give CH2.(CH2)4.CH2.NCOCl (isomeric with II), b11 116-18° (methylurethane, C6H12NCO2Me, b13 96-7°; and urea, C6H12NCONH2, m. 123-4°). III heated with PhONa formed PhOCH2(CH2)5NHCO2Me, which when heated with aq. HCl-AcOH gave 6-phenoxyhexylamine-HCl, m. 142-3°. I in pseudocumene, heated 2 h. with pure COCl2 at 160-65°, was not converted into II. On the other hand mixts. of HCl (gas) and COCl2 acting on I gave small amts. of II after 48 h. phosgenation. The course of the reaction is discussed. Possibly Cl2CN(CH2)6NCO is first formed from I and then split into ClCN and II. MeO(CH2)3NH2.HCl treated 7 h. in 1-C10H7Cl at 140-50° with COCl2 with stirring gave 81% Cl(CH2)3NCO, b16 54.6-4.8°, together with smaller amts. of (ClCH2)2CH2, b1630°, which with PhONa yielded (PhOCH2)2CH2, m. 61° (from EtOH). NC(CH2)5NH2, b16 118-19°, treated in PhCl with HCl, followed by COCl2 at 120-30°, gave 94% NC(CH2)5NCO, b12 134-5° [NC(CH2)5NHCONH2, m. 142° (from EtOH)]. CH2(NH2.HCl)CO2Et in PhMe with COCl2 gave 84.5% OCNCH2CO2Et, b11 67-8°, which with PhNH2 in Et2O yielded PhNHCONHCH2CO2Et, m. 111° (from EtOH). From BuO(CH2)3NH2.HCl in PhMe was formed BuO(CH2)3NCO, b11 76-8°, and PhNHCONH(CH2)3OBu, m. 59-60° (from Et2O). By heating Ph2NCONHMe at 240-90°, 1 mol. MeNCO, b. 38-40°, and 1 mol. Ph2NH were formed. 2-HOC6H4O2CNHEt, m. 142-4°, at 210-50° yielded EtNCO, b. 58-60°, and o-(HO)2C6H4. In 1-C10H7Cl at 150° (PhNH)2CO with COCl2 gave PhNCO, b16 55-7°. In C6H4Cl2, 3-HOCH2-C6H4NH2.HCl and COCl2 gave 3-ClCH2C6H4NCO (V), b11 118-19°; 3-ClCH2C6H4NHCO2Me, m. 87-8°, with pyridine yields 1-[3-(carbomethoxyamino)benzyl]pyridinium chloride, C14H15O2N2Cl, m. 223-4°. Similarly, 3-MeOCH2C6H4NH2.HCl (VI) on phosgenation gave 96% 3-MeOCH2C6H4NCO, b11 108°, and 4% V; 3-MeOCH2-C6H4NHCONH2, m. 122-4°. VI treated in C6H4Cl2 at 140° with HCl prior to phosgenation gives 3-ClCH2C6H4-NH2.HCl, converted readily into V. 3,3'-Bianisidine HCl salt in PhCl and COCl2 at 150-60° gave after vacuum distn. at 150° a high yield of 3,3'-dimethoxy-4, 4'-biphenylene diisocyanate (VII), m. 121-2°, forming a complex, 2VII.PhCl, m. 125-6°. The bis(methylurethane) of VII m. 215-16°. The following are examples of phosgenation of free bases. When 800 g. COCl2 in 2 l. o-Cl2C6H4 in an ice-salt bath was treated with 200 g. molten (4-H2NC6H4)2CH2 so that a temp. of about 0° was maintained, and the suspension was then heated to 130°, 215 g. (4-OCNC6H4)2CH2, b0.1 156-8°, was formed [bis(methylurethane), C17H18O4N2, m. 183-3.5°]. Similarly in PhCl, 4-H2NC6H4CO2Me with COCl2 gave 4-OCNC6H4CO2Me, b11 122-4°, m. 49° (methylurethane, m. 177-8°), and tetrahydro-1,5-naphthylenediamine in C6H4Cl2 gave a mixt. of tetrahydro-1,5-naphthylene diisocyanate, b0.09 129-32°, and a smaller amt. of 7,8-dihydro-1-naphthyl isocyanate, b15 137-8° [methylurethane, m. 86-7°; phenylurea (VIII), m. 210-12°], which was shown not to be identical with 1-naphthyl

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
isocyanate, b12 140-2° (methylurethane, m. 122-3°; phenylurea, m. 220-2°), or with tetrahydro-ar-1-naphthyl isocyanate, b14 134-5° [methylurethane, m. 62-3°; phenylurea, m. 193-4°, also formed by hydrogenating VIII]. The following are examples of phosgenation of carbamic acids. 1,4-Diaminocyclohexane (345 g.) in 3 l. o-Cl2C6H4 was satd. at 90-95° with CO2, stirred 8 h., 700 g. COCl2 introduced at 0°, the CO2 removed, the mixt. heated to 160°, and more COCl2 added until after 14-16 h. the soln. was clear; fractional distn. yielded a mixt. of 1,4-cyclohexane diisocyanates, 1,4-(ONC)2C6H10, transform, m. 63-4° (from petr. ether) [bis(methylurethane), m. 264° (from MeOH)], and liq. cis form [characterized by its bis-(methylurethane), C10H18O4N2, m. 139-40° (from Me2CO)]. Similarly, 4,4'-diaminodicyclohexylmethane gave 4,4'-(dicyclohexyl)methane diisocyanate, (4-OCNC6H10)2CH2, salvelike mass, b0.5-0.6 165-80°. The following are examples of phosgenation in the vapor phase. A mixt. of 450 g. COCl2 and 245 g. PhNH2 passed in 1 h. through a tube at 230-40° while 130 g. 1-C10H7Cl was dropped in, gave 86% PhNCO. By entraining 80 g. p-(H2N)2C6H4 with 35 l. CO2 at 270-80° per h., heating the mixt. to 470°, introducing 470 g. COCl2/h., and condensing in PhCl, S. obtained p-C6H4(NCO)2, m. 93-4° (after sublimation) [bis(methylurethane), m. 207°]. To 86.7 g. 3-HO2CC6H4NH2.HCl in 2 l. H2O contg. 30 cc. HCl was added 42 cc. CSCl2, thus forming 67 g. 3-HO2CC6H4NCS, m. 165° (from MeOH); acid chloride, b14 152-4°, m. 22-3°, 40 g. of which in 200 cc. PhCl refluxed with 16 g. powd. NaN3 gave 32 g. 3-OCNC6H4CNS, b14 140-2°, f.p. 4-6°. The following other isocyanates, RNCO, and their derivs. were prepd. by methods analogous to those outlined. Most of these are new, but no differentiation has been made between new compds. and products previously prepd. In all cases (uncor.) b.p. or m.ps. were checked and some of the compds. were obviously impure. R = CH2:CHCH2, b. 87-9°; Pr, b. 88°; Bu, b. 114-16° (corresponding phenylurea, m. 129-30°); Me2CHCH2, b. 104-5° (phenylurea, m. 151-2°); Me3C, b. 85° (phenylurea, m. 167-8°). Am, b. 136-7° (AmNHCONHPh, m. 92-3°); isohexyl, b14 46°; BuCHEtCH2, b15 75-9°; dodecyl, b11 140-6°; tetradecyl, b14 165-70°; hexadecyl, b14 186-8°; oleyl, b0.05-0.06 135-40°; octadecyl, b11 190-210°; CH2.CH2.SO2.CH2.CH (not characterized) (phenylurea, m. 190°); cyclohexyl, b11 54°; 2-decahydronaphthyl, b12 116-17°; C6H11CH2C6H10, b0.25 120-3°; MeEtCH, b. 101-2° (phenylurea, m. 154°); iso-PrCHMe, b. 118-20° (phenylurea, m. 143-4°); Et2CH, b. 125-6° (phenylurea, m. 177-8°); Pr2CH, b13 58-9°; PhCHMe, b13 90-4°; PhCH2CH2CHMe, b12 117°; (C6H13)2CH, b12 139-41°; PrCH(C11H23), b12 150-70°; C17H35CHMe, b0.1 140-60°; ClCH2CH2, b16 42° [(ClCH2CH2NH)2CO, m. 128-9°]; Cl(CH2)4, b11 70-1° (phenylurea, m. 107°); Cl(CH2)5, b13 100° (methylurethane, m. 44°); Cl(CH2)7, b13 111°; Cl(CH2)4O(CH2)2CH2, b0.1 76°; NC(CH2)2, b12 104°; [NC(CH2)2NH2CO, m. 148°]; NC(CH2)3, b10 103° [NC(CH2)3NHCONH2, m. 142°]; MeO2C(CH2)5, b14 118°; MeO(CH2)3 (impure) (phenylurea, m. 79-80°); EtO(CH2)3 (impure) (phenylurea, m. 66°); PrO(CH2)3, b11 60-1° (phenylurea, m. 62°); iso-Pr(CH2)3 (impure); BuO(CH2)3, b11 76-8° (phenylurea, m. 59-60°); iso-BuO(CH2)3, b14 78° (phenylurea, m. 80°); sec-BuO(CH2)3 (impure) (phenylurea, m. 53-4°);

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
cyclohexyloxypropyl, b11 113-14° (phenylurea, m. 100°); BuOCH2CH2O(CH2)3, b11 123-4° (phenylurea, liq.); C8H17O(CH2)3, b11 135° (phenylurea, m. 55-6°); iso-C8H17, isomer, b11 125-8°; C10H21O(CH2) 3, b11 160-2° (phenylurea, m. 58-9°); 3-(iso-octylcyclohexyloxy)propyl, b0.1-0.2 140-52°; o-tolyl, b9.5 63.2-3.4°; m-tolyl, b9.5 65.7-66.3°; p-tolyl, b10 67.6-67.8°; benzyl, b10 82-4° (phenylurea, m. 167-8°); xylyl (tech.), b12 78-80°; phenethyl, b10 98-100° (urea, m. 112°); 2,4,5-Me3C6H2, b12 100-1°; 2,4,6-isomer, b11 96-7°; Ph(CH2)3, b12 115°; 4-cyclohexylphenyl, b4 128-30°; 4-PhCH2C6H4, b0.07 120° (methylurethane, m. 78-9°; urea, m. 158-9°); 2-methyl-4-cyclohexylphenyl, b4.5 138-42°; 3,4,6-Cl3C6H2, b11 124-6°, m. 60-1°; 3, 4-Cl2C6H3, b12 111-12°, m. 45° (methylurethane, m. 111-12°; urea, m. 153-4°); 2-O2NC6H4, b17 135°, m. 40-1°; 3-isomer, b11 130-1°, m. 50-1°; 4-isomer, b11 137-8°, m. 57°; 2-ClC6H4, b10 83.5°; 3-isomer, b10.5 83-6°; 4-isomer, b9.5 80.6-0.9°, m. 31-2° (methylurethane, m. 115°); 3-FO2SC6H4, b31-2 154-6°, m. 25° (methylurethane, m. 93°); 3-NCC6H4, b12 123°, m. 50-1° (methylurethane, m. 97-8°); 4,3-Cl(F3C)C6H3, b14 86-9°; 3,4-HO2C(HO)C6H3, decomp. (methylurethane, m. 221°); 2, 4-Me(O2N)C6H3, b23 168°, m. 75-8°; 4, 3-Me-(O2N)C6H3, b0.2 100-2°; 2-MeOC6H4, b10 94.8-5.5°; 3-isomer, b10 94.6-4.8°; 4-isomer, b9.5 47.6-7.8°; 2, 5-Me(SCN)C6H3, b16.5 164° (methylurethane, m. 136-7°); 4,3-Cl(MeO2CNH) C6H3, b11 116 °, m. 80°; 4-MeO2CC6H4, b. 122-4°, m. 49° (methylurethane, m. 177-8°); 2,4,5-Me2(O2N)C6H2, b2 110-25°; 3-MeCHClC6H4, b11 116°; EtOCC6H4, b12 104-6°; 2, 5-(MeO)2C6H3, b26-7 152-4°; 4-EtO2CC6H4, b17 144-8°, m. 30-2°; 3, 4-Cl2C6H3(CH2)3, b14-15 176-8°; 4,3-Me(MeO2CNH) C6H3, m. 87°; 4,3-Me(EtO2CNH)C6H3, m. 72°; 4, 2-Cl(4-ClC6H4O) C6H3, m. 44-6°; 3-PhMeNSO2C6H4, m. 74-5°; 4-PhN:NC6H4, m. 97-8° (ethylurethane, m. 151°); 3, 4-Me(4-MeOC6H4N:N) C6H3, m. 80°; 5-methyl-2-methoxy-4-(2-chlorophenylazo)phenyl, m. 153°; 2-naphthyl, b14 144°, m. 56° (methylurethane, m. 113°); 5-nitro-1-naphthyl, m. 121-2° (methylurethane, m. 170°); 8-chloro-1-naphthyl, b0.1 125-7° (methylurethane, m. 119-20°); 1-chloro-2-naphthyl, b0.3 120°, m. 52-3° (methylurethane, m. 115-16°); tetrahydro-ac-2-naphthyl, b10 134-6° (phenylurea, m. 169-70°); decahydro-2-naphthyl, b12 116-17°; 3-phenanthryl, b4 198-204°, m. 48° (methylurethane, m. 140-2°); 4-(6-methyl-2-benzothiazolyl)phenyl, m. 143-4° (methylurethane, m. 203-5°); 9-ethyl-3-carbazolyl, b0.1 172-8°, m. 48° (methylurethane, m. 118-20°); 3-(9-carbazolyl)propyl, b7 240-2° (methylurethane, m. 107-9°); 3-pyrenyl, m. 92° (methylurethane, m. 203°); 12-chrysenyl, m. 155-6° (methylurethane, m. 204°); 9,10-ethanoanthr-11-ylmethyl, m. 92-4° (methylurethane, m.p. not given). The following diisocyanates (and derivs.) were prepd., a no. of them by an azide degrdn. method not discussed (R = -NCO): (CH2CH2R)2, b14 75-6°; R(CH2)3R, b14 86-7°; RCH2CH:CHCH2R (impure) [bis-(methylurethane), m. 137°]; R(CH2)4R, b14 102-4° [bis-(methylurethane), m. 129-30°]; (RCH2CH2)2S, b0.5-1 100-20° {bis-urea[H2NCONH(CH2)2]2S, m. 210°}; R(CH2)5R, b15 123-5° [bis(methylurethane), m. 114-15°]; RCH2CHMeCH2CH2R, b9 98-9° (bis-urea, m. 181-2°); R(CH2)6R, b14 130-2°

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[bis(methylurethane), m. 113-14°]; [RCH2(CH2)2]2O, b14 137°
(bis-urea, m. 141°); S-analog, b0.3-0.4 118°; R(CH2)7R, b14
140-2° [bis(methylurethane), m. 97.5-8°]; RCH2CMe2(CH2)2H2R,
b12 120-2°, b16 132-4°; RCH2(CH2)2CH(OMe)(CH2)2) CH2R, b12
142-5°, (p-chlorophenylurea, m. 217-18°); R(CH2)8R, b11
146-8° [bis(methylurethane), m. 111-12°];
RCH2CMe2CH2CHMeCH2R, b5 106° (bis-urea, m. 159-62°);
R(CH2)9R, b0.5 121° [bis(methylurethane), m. 102-5°];
R(CH2)10R, b0.8 128° [bis(methylurethane), m. 115°];
R(CH2)2CH(OBu)(CH2)3R, b2 142-55° (decompn.);
R(CH2)3O(CH2)4O(CH2)3R, b0.1 130-5°; R(CH2)11R, 0.06 124°
[bis(methylurethane), m. 97-8°]; R(CH2)12R, b0.08 135°
[bis(methylurethane), m. 117-18°]; [R(CH2)6]2S, b0.7-0.8
180-5° [bis(methylurethane), m. 87°]; m-C6H4(CH2R)2, b12
159-62°, [bis(methylurethane), m. 110-11°]; p-isomer, b16
172°, m. 45-6° [bis(methylurethane), m. 184°]; 1,
2-C6H10(CH2R)2 (cyclohexane), b23-24 165-8°; 1,4-isomer, b11
154-6° [bis(methylurethane), m. 163°]; p-C6H4(CH2CH2R)2,
b0.1-0.2 142-5°; 1, 4-C10H6(CH2R)2, b1 183-4°
[bis(methylurethane), m. 167°]; 1, 5-isomer, m. 88-9°
[bis(methylurethane), m. 215-16°];
RCH2CH.CH2.CHMe.CH2.CHMe.CH(CH2)3R, b4 165-72°; [C6H4(CH2)3R]2, m.
29° [bis(methylurethane), m. 156-7°]; (IX), m. 235-7°
(analogous dicyanate not characterized). RCH.CH2.CHR.CH2.CH2.CH2, b14
120-30°; impure CHMe.CHR.CH2.CHR.CH2.CH2, b12 127-9° Et
homolog, b19 140-4°; CH2(CH2.CH2.CHR.CH2.CH2.CH)2, b0.5-0.6
165-80°; MeCH(C6H10R)2 homolog, b4.5 198-208°
[bis-(methylurethane), m. 182-3°]; Me2C(C6H10R)2 homolog, b8-10
208-30°; (CH2.CH2.CHR.CH2.CHMe.CH)2 CH2, b5 200-12°;
3,3'-dimethyl isomer, b9 198-210°; 3,3',5,5'-tetra-Me homolog, b7
205-12° [bis(methylurethane), m. 204-7°]; p-RCH2C6H4R, b19
152°; p-RCH2CH2C6H4R, b15 156°; m- RCH(Me) C6H4R , b11
134° [bis (methlurethane) , m. 112-13°]; m-RCH2CH2CH2C6H4R,
b0.5 118-20°; p-isomer, b0.5 100-115°; m-RCHMeCH2CH2C6H4R,
b2 146-9°; p-isomer, b3.5 142-5°;
tetrahydro-1,5-naphthylene diisocyanate, b0.04 117-18°,
4-(4-RC6H10)C6H4R (termed "4,4'-hexahydrobenzidine deriv."), b0.7
155-60°, m. 38-44° [bis(methylurethane), m. 216°
(poorly)]; 4-(4-RC6H10-CH2)C6H4R, b0.2-0.3, m. 152-6°; m-C6H4R2
b12, 104-6°, m. 51° [bis(methylurethane), m.
157-7.5°]; p-isomer, b12 110-12°, m. 94-6°
[bis(methylurethane), m. 209-10°]; 1,2,4-MeC6H3R2, b18
124-6°, m. 21° (33° also given) [bis(methylurethane),
m. 170-1°]; 1 2, 6-isomer, b18 129-33°; 1,2,5-isomer, b15
138-9°, m. 39°; 1,3,5-isomer, b17 133.5-4.5°;
1,3,2,4-Me2C6H2R2, b17 140-4°; 1,3,4,6-isomer, b15 139°, m.
70-1°; 1,4,2,5-isomer, b14 138-43°, m. 82° (also
given as 76°); 1,2,4-EtC6H3R2, b12 124-6°;
1,2,4-iso-PrC6H3R2, b12 136-40° [bis(methylurethane), m.
160-7°]; ??-Et2C6H2R2 b11 138-40°; ??-iso-Pr2C6H2R2, b12
148-60°; 1,2,4-C1C6H3R2 , b11 122-4°; 1,2,4-O2NC6 H3R2,
b14 160-80° [bis(methylurethane), m. 197-8°]; 1,2,5-isomer,
b4 165-73°, m. 59-61° [bis(methylurethane), m.
157-8°]; 1,3,4,6-Cl2C6H2R2, b12 140-6°; 1,3,2,4-isomer,
b1.5 120-6°, m. 64-5° [bis(methylurethane), m.

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
184-5°]; 1,4,2,5-isomer, m. 134-7°;
1,4,2,5-Cl(MeO) C6H2R2, m. 134°; 1,2,4-MeOC6H3R2, m. 75°;
1,2,5-isomer, m. 89°; 1,4,2,5-Me(MeO) C6H2 R2, m. 106-7°;
1,2,4-EtOC6H3R2, b16 162-4°, m. 56°; 1,3,4,6-(MeO)2 C6H2 R2
, m. 125° [bis-(methylurethane), m. 154°]; 1, 4, 2,
5-isomer, m. 180-1°; 1,2,4-PrOC6H3R2, b15 164-5°; 1-iso-BuO
homolog, b14 180-1°; 1,4,2,5-(EtO)2C6H2R2, m. 128°;
(p-RC6H4N:)2, m. 158-61° [bis(methylurethane), m. 241-3°];
p-[4, 2-RMeC6H3 N:N) C6H4R, m. 123-5° [bis(methylurethane), m.
244-8°]; 1, 4-(p-RC6H4N:N)C6H10 R, m. 177-8°,
[bis(methylurethane), m. 210-12°]; p-(o-RC6H4O)C6H4R, m.
60-2°; (p-RC6H4)2 O, b5 196°, m. 66-8°;
(o-RC6H4OCH2)2 and (o-RC6H4CH2CH2)2O (prepd. but not characterized). The
following diisocyanato derivs. of naphthalene were prepd.: 1, 4, m.
67-70° [bis(methylurethane), m. 220-2°]; 1, 5, m.
130-2° (subliming in high vacuum) [bis(methylurethane), m.
245-6°]; 2, 6, m. 152-4° [bis(methylurethane), m.
244-6°]; 2, 7, m. 152-3°; (2, 1-RC10H6)2 , m. 132-3°
[bis(methylurethane), m. 185-7°]. The following diisocyanato
derivs. of Ph2 were formed: 2, 4', b0.5 140-50°
[bis(methylurethane), m. 171-2°]; 4, 4' (X), b0.5 150-60°
[bis(methylurethane), m. 244°]; 3, 3'-di-Me deriv. of X, m.
68-9° [bis(methylurethane), m. 208°]; 3, 3'-di-MeO deriv. of
X, m. 121-2° [bis(methylurethane), m. 215-16°]; 2-NO2 deriv.
of X, m. 119-21° [bis(methylurethane), m. 211-12°]. The
following diisocyanates were formed: (p-RC6H4)2CH2, b0.2 170°, m.
46° (also given as 37.6°) [bis(dimethylurethane), m.
183-3.5°]; (2, 4-MeRC6H3)2CH2, b5 208-11°, m. 65-7°;
p-R(C6H42CMe2, b5.6 212°, m. 91.5°; (2,5,4-Me2RC6H2)2CH2, m.
127.6°; (p-RC6H4)2CH611(?), b0.1 195-200°
[bis(methylurethane), m. 173°]; [4, 3-R(MeO) C6H3]2 CH2, m.
97-8°; [3, 4-R(MeO) C6H3]2 CH2 , m. 90-3°; [3,
4-R(EtO)C6H3]2 CH2 , m. 74°; [4, 2, 5-RMe (MeO) C6H2]2CH2, m.
128-9°; [4, 3-RC1C6H3]2 CMe2 , m. 100-1°; (m-RC6H4)2 CO, m.
118-20°; 1,2,4-PhCH2CH2C6H3R2 , b20 223-7°
[bis(methylurethane), m. 154-5°]; m-(p-RC6H4)2 CHC6H4NO2 (not
characterized) [mono- or bis(phenylurea), sinters about 145°];
p-isomer (not characterized) [mono- or bis(phenylurea) (?), m.
224-6°]; (4, 2, 5-RMe2C6H2)2 CHPh, m. 116-18°. The
following diisocyanato derivs. of fused rings and of arom. S compds. were
formed: 2, 7-R2-fluorene, m. 133°; 2, 6-R2-anthraquinone, m.
250-2°; 9-ethyl-2, 7-R2-carbazole (S. gives 3, 6), m.
122-3°; 3, 8-R2-pyrene, m. 234° [bis-(methylurethane), m.
264°]; 5, 11-R2-chrysene, m. 274° (S. gives 2, 8). The
following diisocyanates were prepd. from arom. S-contg. compds.
1,2,4-PhSC6H3R2 , m. 73-4°; (p-RC6H4 S)2 , m. 58-60°;
(p-RC6H4)2 SO2 , m. 154° [bis-(methylurethane), m. 262-4°];
XI, m. 166-8° [bis(methylurethane), m. 235-7°];
1,2,4-(p-MeC6H4SO2) C6 H3R2 (impure); p-(3, 4-RMeC6H3SO3) C6H4R, m.
67.5°; 4-MeO analog, m. 104-6°; (5, 2-RMeC6H3S)2 , m.
77-8°; 2, 5-isomer, m. 74-6°; 3, 4-isomer, m. 88°;
[3, 4-R(MeO)-C6H3S]2 , m. 66-7°; 4, 3-isomer, m. 101° [3,
4-R(MeO)C6H3]2 SO2 , m. 165°; 1, 3, 4-(3, 4-RMeC6 H3SO2 NH)C6H3MeR,
m. 191-6°; (p-RC6H4SO2NHCH2)2 (m. poorly 178°); [4,
3-R(MeO)C6H3CH2]2S (not characterized); [3, 4-R(MeO)C6H3SCH2]2, m.

L4 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
118°; [4, 3-R(MeO)C6H3CH2]2 SO2 (not characterized); [3, 4-(MeO)
C6H3SO2CH2]2, m. 265-7°; [3, 4-(MeO)C6H3SO2NHCH2]2, m. 192°.
The following triisocyanates were formed: 1, 2-4, 6-MeC6H2R3, b1-3
133-9°, m. 75° [tris(methylurethane), m. 195°]; 1, 3,
5, 2, 4, 6-Me3C6R3, m. 93° [tris(methylurethane), m. 284°];
1, 3, 7-C10H5R3, m. 162-3° [tris(methylurethane), m. 217°];
p-(2, 4-R2C6H3) C6H4R, b1.5-2 194-8°, m. 71°; p-(2,
4-R2C6H3CH2)C6H4R, undistillable; p-(2, 4, 3-R2MeC6H2CH2)C6 H4R, b4
224°, m. 75-7° [tris(methylurethane), m. 167°];
(p-RC6H4)3CH, m. 89-90°. The following were also formed: (4, 2,
5-MeR2C6H2)2 CH2, m. 154-6°; (p-RC6H4)2NCOCl, b2-3 230-4°,
m. 74-77° [bis(methylurethane), m. 182-4°]. The following
dimers of the type formula [1,2,4-RC6H3(NCO)2]2 were prepd.: R = Cl, m.
177°; Me, m. 156°; Et, m. 148°; EtO, m.
185-6°; Me2CH, m. 125°; Me2 CHO, m. 158°; iso-BuO, m.
176°. Also formed was [1,2,5-MeC6H3(NCO)2]2 , m. 186°.

IT 101574-48-5P, Urea, 1-phenyl-3-(5,6,7,8-tetrahydro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)

RN 101574-48-5 CAPLUS

CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)



10575027.trn

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 13:51:23 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar  6, 2009 (20090306/UP).

=>
Connection closed by remote host

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
```

10575027.trn

```
 NEWS 19  FEB 23  MEDLINE now offers more precise author group fields
                  and 2009 MeSH terms
 NEWS 20  FEB 23  TOXCENTER updates mirror those of MEDLINE - more
                  precise author group fields and 2009 MeSH terms
 NEWS 21  FEB 23  Three million new patent records blast AEROSPACE into
                  STN patent clusters
 NEWS 22  FEB 25  USGENE enhanced with patent family and legal status
                  display data from INPADOCDB
 NEWS 23  MAR 06  INPADOCDB and INPAFAMDB enhanced with new display
                  formats
 NEWS 24  MAR 11  EPFULL backfile enhanced with additional full-text
                  applications and grants
 NEWS 25  MAR 11  ESBIOBASE reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
```

10575027.trn

experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575027-888.str



chain nodes :
11 12
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
13 14 16
chain bonds :
11-12 12-13 12-14
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :

10575027.trn



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:30:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 827 TO ITERATE

100.0% PROCESSED 827 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 14815 TO 18265
PROJECTED ANSWERS: 0 TO 0

FILE COVERS 1907 - 12 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 11 Mar 2009 (20090311/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

10575027.trn

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
2005:429388 Document No. 142:4634650 Preparation of bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators. Mogi, Muneto; Fujishima, Hiroshi; Tajimi, Masaomi; Yamamoto, Noriyuki; Urbahns, Klaus; Hayashi, Fumihiko; Tsukimi, Yasuhiro; Gupta, Jang; Yuasa, Hiroaki (Bayer Healthcare A.-G., Germany). PCT Int. Appl. WO 2005044786 A1 20050519, 63 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-EP12050 20041026. PRIORITY: EP 2003-25571 20031108; EP 2003-27003 20031122.
GI

Q7= 

Q8= 

AB This invention relates to bicyclic amide, carbamate or urea derivs. of formula A-NHCO-Y-(CH2)m -X-(CH2)p-R1 and salts thereof [A = Q7, Q8; wherein Q1, Q4 = direct bond, methylene; Q2 = CHR2, or CO; Q3 = CHR3 or CO
(wherein R2, R3 = H, HO, C1-6 alkoxy, C1-6 alkanoyloxy or (un)substituted 1-6 alkyl); with the proviso that Q1 and Q4 can be direct bond t the same time; R2 = R3 ≠ H; when Q = direct nd, then R3 = HO, C1-6 alkoxy, or C1-6 alkanoyloxy; Q5 = CH or R5 (wherein R5 = HO, C1-6 alkoxy, C1-6 alkanoyloxy, or (un)substituted C1-6 alkyl); Q6 = CH or CR6 (wherein R6 = HO, C1-6 alkoxy, C1-6 alkanoyloxy, or (un)substituted C1-6 alkyl); with the proviso that Q5 ≠ Q6 = CH; m = 0-3; p = 0, 1; X = a bond, O, NR4 (wherein R4 = H, C1-6 alkyl), with the proviso that when m = 0, then X = a
bond; Y = CH2, O or NH; R1 = each (un)substituted aryl or heteroaryl] which are useful as active ingredients of pharmaceutical prepns. The bicyclic amide, carbamate or urea derivs. of the resent invention has vanilloid receptor (VR1) antagonistic activity (no data). These compds. can be used for the prophylaxis and treatment of diseases associated with VR1
activity, in particular for the treatment of urol. diseases or disorders such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; pain such as chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia,

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
neurodegeneration, and stroke; and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). Thus, a mixt. of 70.0 mg 7-amino-1,2,3,4-tetrahydronaphthalen-2-ol and 95.0 mg 4-chloro-3-trifluoromethylphenyl isocyanate in 10 mL DMF was stirred at 50° for 2 h, concd. under reduced pressure, and purified by silica gel chromatog. to give 49.9 mg N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea.
IT 1044170-15-1 1044170-27-5
RL: PRPH (Prophetic)
(Preparation of bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators)
RN 1044170-15-1 CAPLUS
CN Urea,
N-(4-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



RN 1044170-27-5 CAPLUS
CN Hydrazinecarboxamide, 2-(2-cyclohexylethyl)-N-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



IT 851773-81-4P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea 851773-82-5P, N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[4-(trifluoromethyl)benzyl]urea 851773-85-8P, N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[2-[[4-(trifluoromethyl)phenyl]amino]ethyl]urea 851773-86-9P, N-(7-Hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[2-[4-(trifluoromethyl)phenoxy]ethyl]urea 851773-89-2P, N-[2-[[4-Chloro-3-(trifluoromethyl)phenyl]amino]ethyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea 851773-90-5P, N-[2-[4-Chloro-3-(trifluoromethyl)phenoxy]ethyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea 851773-91-6P, N-[2-[[4-Chloro-3-(trifluoromethyl)phenyl]amino]ethyl]-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea 851773-92-7P, N-[2-[4-Chloro-3-(trifluoromethyl)phenoxy]ethyl]-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Uses)
(prepn. of bicyclic amides, carbamates or urea derivs. as vanilloid receptor antagonists)
RN 851773-81-4 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



RN 851773-82-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 851773-85-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)-N'-[2-[[4-(trifluoromethyl)phenyl]amino]ethyl]- (CA INDEX NAME)



RN 851773-86-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)-N'-[2-[4-(trifluoromethyl)phenoxy]ethyl]- (CA INDEX NAME)



RN 851773-89-2 CAPLUS
CN Urea, N-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 851773-90-5 CAPLUS
CN Urea, N-[2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



RN 851773-91-6 CAPLUS
CN Urea, N-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]ethyl]-N'-(5,6,7,8-tetrahydro-6-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



RN 851773-92-7 CAPLUS
CN Urea, N-[2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl]-N'-(5,6,7,8-tetrahydro-6-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



10575027.trn

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
1999:487265 Document No. 131:1160840 Preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers. Gross, Michael F.; Castle, Neil A. (Icagen, Inc., USA).
PCT Int. Appl. WO 9937607 A1 19990729, 101 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US1663 19990127. PRIORITY: US 1998-72719P 19980127.

GI



AB Title compds. [I; R = X2Y2R1; R1 = H, alkyl, (hetero)aryl, etc.; R3,R4 = H, alkyl, (hetero)aryl(alkyl), etc.; R5 = X1Y1R2; R2 = H, alkyl, alkoxy, (di)alkylamino, (hetero)aryl(alkyl), etc.; R6 = H, (un)substituted alkyl, (di)(alkyl)amino, etc.; X1 = bond, CH2, CO, SO2, etc.; X2 = CO, CS, So2; Y1 =bond, alkylene, CH:CH, etc.; Y2 = bond, CH2, O, NH, CH:CH, etc.; Z = CH2 or CH2CH2; dashed line = optional addnl. bond] were prepared Thus, 7-nitro-1-tetralone was converted in 4 steps to trans-1-amino-7-nitro-2-naphthol which was amidated by 4-EtC6H4SO2Cl and the reduced product N-alkylated by 4-(F3CO)C6H4CH2Br to give title compound trans-II. Data for biol. activity of I were given.

IT 1099526-10-9
RL: PRPH (Prophetic)
(Preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1099526-10-9 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[(phenylamino)carbonyl]amino]-1-naphthalenyl]- (CA INDEX NAME)



10575027.trn

```
=> file reg
FILE 'REGISTRY' ENTERED AT 14:35:19 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAR 2009  HIGHEST RN 1119363-64-2
DICTIONARY FILE UPDATES:  11 MAR 2009  HIGHEST RN 1119363-64-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575027-9999.str
```





```
ring nodes :
1  2  3  4  5  6  7  8  9  10
ring/chain nodes :
11  12
chain bonds :
9-11  11-12
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-10  4-5  5-6  7-8  8-9  9-10
exact/norm bonds :
9-11
exact bonds :
2-7  3-10  7-8  8-9  9-10  11-12
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS
```

10575027.trn

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 14:35:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 36490 TO ITERATE

5.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 718379 TO 741221
PROJECTED ANSWERS: 30059 TO 34893

L6 50 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 14:35:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 733201 TO ITERATE

100.0% PROCESSED 733201 ITERATIONS 32022 ANSWERS
SEARCH TIME: 00.00.03

L7 32022 SEA SSS FUL L5

=> file caplus
FILE 'CAPLUS' ENTERED AT 14:35:51 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 11 Mar 2009 (20090311/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l7
L8       58115 L7

=> s l7 and vanilloid
         58115 L7
          2397 VANILLOID
           257 VANILLOIDS
          2443 VANILLOID
                 (VANILLOID OR VANILLOIDS)
L9          41 L7 AND VANILLOID

=> s l7 and potassium channel
         58115 L7
        714845 POTASSIUM
            19 POTASSIUMS
        714848 POTASSIUM
                 (POTASSIUM OR POTASSIUMS)
        332865 CHANNEL
        194216 CHANNELS
        422949 CHANNEL
                 (CHANNEL OR CHANNELS)
         32608 POTASSIUM CHANNEL
                 (POTASSIUM(W)CHANNEL)
L10        146 L7 AND POTASSIUM CHANNEL

=> dscan ti l10
DSCAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d scan ti
```

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Treating pain, diabetes, and disorders of lipid metabolism using spiro(azetidine-piperidine)derivatives and their preparation

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Myocardial ischemia tolerance in the newborn rat involving opioid receptors and mitochondrial K+ channels

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI 2,2-Dialkylnaphthalen-1-ones as new potassium channel activators

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI μ-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI High-Speed Screening and QSAR Analysis of Human ATP-Binding Cassette Transporter ABCB11 (Bile Salt Export Pump) To Predict Drug-Induced Intrahepatic Cholestasis

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Dual regulation by δ opioid receptor agonists on delayed rectified potassium channels in NG108-15 cells

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Method using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Characterization of the currents induced by sigma ligands in NCB20 neuroblastoma cells

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Agonist-specific regulation of μ-opioid receptor desensitization and recovery from desensitization

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Pyridoxal-5'-phosphate and related compounds in combination with therapeutic cardiovascular compounds for treating angina.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of azole compounds as PTP1B inhibitors

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Combination therapeutic compositions containing benzene compounds

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Propranolol antagonizes coronary artery relaxation by a potassium channel opener

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Pyrano-[2,3b]-pyridines as potassium channel antagonists

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Correlation of HERG K+ channel protein expression to chemosensitivity of tumor cells to doxorubicin and its modulation by erythromycin

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of anticancer chemotherapeutic drugs on the acetylcholine receptor-operated potassium current in guinea pig atrial myocytes

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Peptide for protection against ischemia and reperfusion injury

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Asymmetric bioreduction of a β-tetralone to its corresponding (S)-alcohol by the yeast Trichosporon capitatum MY 1890

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Treating pain, diabetes, and disorders of lipid metabolism using spiro(azetidine-piperidine)derivatives and their preparation

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Method for treatment and prevention of epilepsy

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Role of Opioid Receptors in Cardioprotection of Cold-Restraint Stress and Morphine

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Desensitization of μ-opioid receptor-evoked potassium currents: initiation at the receptor, expression at the effector

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Effects of adriamycin and ethydium bromide on Ca2+-dependent K+ channels of human erythrocytes

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Genetic markers associated with cardiac arrhythmias and their use in risk management

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Peristalsis in the Guinea Pig Small Intestine in Vitro is Impaired by Acetaminophen but not Aspirin and Dipyrone

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions comprising chelidonine or derivatives

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI The effects of adriamycin and adriamycin complexes with transitional metals on Ca2+-dependent K+ channels of human erythrocytes

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI δ-opioid receptor mediates the cardioprotective effect of ischemic postconditioning

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Gene expression profiles for diagnosis, prognosis and selection of treatment of acute myeloid leukemia

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Analgesic methods using endothelin receptor ligands

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions containing membrane-potential agents for reversal of multidrug resistance

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in
    a rat brain tumor model

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Use of sildenafil, vardenafil and other phosphodiesterase V inhibitors to enhance permeability of the abnormal blood-brain barrier

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Remifentanil Preconditioning Confers Cardioprotection via Cardiac κ- and δ-Opioid Receptors

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 146 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN
TI Insights into the cardioprotective function of adenosine A1 and A3 receptors

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10575027.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 14:28:38 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 14:29:50 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2               0 S L1
L3              13 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:30:40 ON 12 MAR 2009
L4               2 S L3

     FILE 'REGISTRY' ENTERED AT 14:35:19 ON 12 MAR 2009
L5             STRUCTURE UPLOADED
L6              50 S L5
L7           32022 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 14:35:51 ON 12 MAR 2009
L8           58115 S L7
L9              41 S L7 AND VANILLOID
L10            146 S L7 AND POTASSIUM CHANNEL

=> file reg
FILE 'REGISTRY' ENTERED AT 14:38:14 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
```

10575027.trn

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS 3 NOV 26 MARPAT enhanced with FSORT command
 NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
 NEWS 5 NOV 26 Two new SET commands increase convenience of STN
                  searching
 NEWS 6 DEC 01 ChemPort single article sales feature unavailable
 NEWS 7 DEC 12 GBFULL now offers single source for full-text

10575027.trn

```
                  formats
 NEWS 24  MAR 11  EPFULL backfile enhanced with additional full-text
                  applications and grants
 NEWS 25  MAR 11  ESBIOBASE reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009

=> his
HIS IS NOT A RECOGNIZED COMMAND
```

10575027.trn

STRUCTURE FILE UPDATES: 11 MAR 2009 HIGHEST RN 1119363-64-2
DICTIONARY FILE UPDATES: 11 MAR 2009 HIGHEST RN 1119363-64-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575027-9999.str





10575027.trn

SAMPLE SCREEN SEARCH COMPLETED - 36490 TO ITERATE

5.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 718379 TO 741221
PROJECTED ANSWERS: 30059 TO 34893

L2 50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:09:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 733201 TO ITERATE

100.0% PROCESSED 733201 ITERATIONS 32022 ANSWERS
SEARCH TIME: 00.00.02

L3 32022 SEA SSS FUL L1

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009

10575027.trn

```
=> s l4 and pd<=10152003
           342 PD<=10152003
                 (PD<=10152003)
L5           1 L4 AND PD<=10152003

=> s l4 and pd<=2003
      23971135 PD<=2003
                 (PD<=20039999)
L6       42824 L4 AND PD<=2003

=> s l6 and "potassium channel"
        714845 "POTASSIUM"
            19 "POTASSIUMS"
        714848 "POTASSIUM"
                 ("POTASSIUM" OR "POTASSIUMS")
        332865 "CHANNEL"
        194216 "CHANNELS"
        422949 "CHANNEL"
                 ("CHANNEL" OR "CHANNELS")
         32608 "POTASSIUM CHANNEL"
                 ("POTASSIUM"(W)"CHANNEL")
L7          55 L6 AND "POTASSIUM CHANNEL"

=> file reg
FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

10575027.trn

```
     (FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 15:09:33 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2          50 S L1
L3       32022 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009
L4       58115 S L3
L5           1 S L4 AND PD<=10152003
L6       42824 S L4 AND PD<=2003
L7          55 S L6 AND "POTASSIUM CHANNEL"

     FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009

     FILE 'CAPLUS' ENTERED AT 15:11:14 ON 12 MAR 2009
L8             TRA L7 1- RN :     2659 TERMS

     FILE 'REGISTRY' ENTERED AT 15:11:17 ON 12 MAR 2009
L9          2659 SEA L8

=> s l9 and l3
L10         237 L9 AND L3

=> d scan
```

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propynamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl-
MF C27 H21 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-nitro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H27 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Morphinanium, 4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-17-(2-propen-1-yl)-, iodide (1:1), (5α,17R)-
MF C20 H24 N O4 . I
CI COM

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]methylamino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy-N-(3-pyridinylmethyl)-
MF C33 H35 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(phenylmethyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3(2H)-Pyridazinone, 6-[(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)oxy]-, trans- (9CI)
MF C16 H15 Br N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanamide, N-[8-[[(4-cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C26 H25 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(phenylmethyl)-
MF C33 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-7-fluoro-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C17 H16 F N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C28 H25 Cl N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(2-thienylsulfonyl)amino]-2-naphthalenyl]-
MF C22 H22 N2 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 2,4-dichloro-N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C20 H16 Cl2 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5α)-
MF C17 H19 N O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propynamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(4-methylphenyl)-
MF C28 H23 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 237 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(phenylmethyl)sulfonyl]amino]-2-naphthalenyl]-
MF C25 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10575027.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 15:09:33 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2          50 S L1
L3       32022 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009
L4       58115 S L3
L5           1 S L4 AND PD<=10152003
L6       42824 S L4 AND PD<=2003
L7          55 S L6 AND "POTASSIUM CHANNEL"

     FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009

     FILE 'CAPLUS' ENTERED AT 15:11:14 ON 12 MAR 2009
L8             TRA L7 1- RN :     2659 TERMS

     FILE 'REGISTRY' ENTERED AT 15:11:17 ON 12 MAR 2009
L9          2659 SEA L8
L10          237 S L9 AND L3

=> s l10 and c10/rf
       1627131 C10/RF
L11         210 L10 AND C10/RF
```

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]-
MF C25 H26 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-6,7-dichloro-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C17 H15 Cl2 N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]methylamino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy-
MF C29 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C25 H26 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-, (2E)-
MF C28 H30 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-2-naphthalenyl]-
MF C24 H21 F3 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarbonitrile, 8-[(1,6-dihydro-6-oxo-3-pyridazinyl)oxy]-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, trans- (9CI)
MF C17 H15 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H27 F N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarbonitrile, 8-amino-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, (7R,8R)-rel-
MF C13 H14 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-(pentyloxy)-
MF C30 H36 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-ethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-nitro-1-naphthalenyl]-, rel-
MF C18 H20 N2 O5 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C31 H30 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C34 H36 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI)
MF C15 H16 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propynamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(4-methylphenyl)-
MF C28 H23 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 2,4-dichloro-N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C20 H16 Cl2 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C26 H25 Cl N2 O5 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-[(4-methoxyphenyl)methylamino]-
MF C28 H33 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[(4-pyridinylmethyl)amino]-1-naphthalenyl]-
MF C24 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-acetyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C27 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-7-chloro-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C17 H16 Cl N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-, (2E)-
MF C28 H30 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-7-nitro-, (1R,2R)-rel-
MF C10 H12 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[(phenylamino)carbonyl]amino]-1-naphthalenyl]-
MF C25 H27 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-(dimethylamino)-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C27 H31 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C29 H35 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(2-thienylsulfonyl)amino]-2-naphthalenyl]-
MF C22 H22 N2 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-7-fluoro-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C17 H16 F N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1(2H)-Quinolineacetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3,4-dihydro-
MF C29 H33 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propynamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl-
MF C27 H26 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[(1E)-2-phenylethenyl]sulfonyl]amino]-2-naphthalenyl]-
MF C26 H26 N2 O5 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-, trans- (9CI)
MF C20 H20 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methyl-
MF C26 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1(2H)-Naphthalenone, 4-amino-3,4-dihydro-3-hydroxy-6-methoxy-2,2-dimethyl-, (3R,4R)-rel-
MF C13 H17 N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-ethyl-N-methyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[(3-methoxyphenyl)methyl]methylamino]-1-naphthalenyl]-
MF C28 H34 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopropanecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-N-(3-pyridinylmethyl)-
MF C28 H31 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]-, (2E)-
MF C25 H24 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(phenylmethyl)-
MF C33 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3(2H)-Pyridazinone, 6-[(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)oxy]-, trans- (9CI)
MF C16 H15 Br N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-3-(trifluoromethoxy)-
MF C25 H23 F3 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1(2H)-Naphthalenone, 4-amino-7-bromo-3,4-dihydro-3-hydroxy-2,2-dimethyl-, (3E,4R)-rel-
MF C12 H14 Br N O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-ethoxy-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-
MF C28 H32 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(5-chloro-2-naphthalenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy-
MF C28 H25 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methyl-N-(3-pyridinylmethyl)-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-2-naphthalenyl]-
MF C31 H28 F3 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-4-methoxy-, trans- (9CI)
MF C21 H20 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl-, (2E)-
MF C27 H23 Cl N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyanamide, [1-(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-4,5-dihydro-1H-imidazol-2-yl]-, trans- (9CI)
MF C16 H17 Br N4 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C27 H30 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(phenylmethyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Propanamide, N-[8-[[(4-ethylphenyl)sulfonyl](3-pyridinylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2,2-dimethyl-
MF C29 H35 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Isoindol-1-one, 2-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-2,3-dihydro-, rel-
MF C20 H18 Br N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-pentylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C29 H34 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-
MF C26 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 2-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C24 H23 F N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-
MF C17 H27 N O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-pentylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C29 H34 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-6-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C17 H16 Br N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Piperidinecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-1-(phenylmethyl)-
MF C31 H37 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-nitro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H27 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(2-naphthalenylsulfonyl)amino]-2-naphthalenyl]-
MF C28 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-
MF C28 H32 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-, (1S-trans)- (9CI)
MF C15 H18 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-
MF C26 H27 F N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Butanamide, N-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-4-chloro-, rel-
MF C16 H19 Br Cl N O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-chloro-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C25 H25 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenol, 1,2,3,4-tetrahydro-7-nitro-1-[(phenylmethyl)amino]-, (1R,2R)-rel-
MF C17 H18 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C32 H32 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, 4-methoxy-2,3,6-trimethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[(3-pyridinylmethyl)amino]-1-naphthalenyl]-
MF C26 H31 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarbonitrile, 5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-8-[(3-oxo-1-cyclopenten-1-yl)oxy]-, trans- (9CI)
MF C18 H17 N O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-nitrophenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C24 H23 N3 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Pyridinecarboxamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C19 H17 N3 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C28 H33 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(2-pyridinylmethyl)-
MF C32 H33 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Pyridinone, 1-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-methoxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel-
MF C18 H19 N O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-(4-chlorophenyl)-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-, (2E)-
MF C28 H29 Cl N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenol, 6-bromo-1,2,3,4-tetrahydro-, (2S)-
MF C10 H11 Br O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-chloro-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-
MF C25 H25 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, 2-phenoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C25 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-[(phenylmethyl)amino]-
MF C27 H31 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxyphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C25 H26 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarbonitrile, 8-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, (7R,8R)-rel-
MF C21 H18 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(3-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-
MF C26 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Isoquinolinecarboxamide, 2-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-1,2,3,4-tetrahydro-
MF C30 H35 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C31 H30 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(2-phenylethyl)sulfonyl]amino]-2-naphthalenyl]-
MF C26 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Urea, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-N'-methyl-, trans- (9CI)
MF C15 H19 N3 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3,4-dimethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]-
MF C25 H26 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1(2H)-Naphthalenone, 4-amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-, (3E,4R)-rel-
MF C12 H15 N O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C26 H31 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-, (2E)-
MF C26 H26 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[8-[[(3-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-
MF C24 H23 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarbonitrile, 8-[[1,6-dihydro-6-oxo-1-(2-propenyl)-3-pyridazinyl]oxy]-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, trans-(9CI)
MF C20 H19 N3 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3,5-dimethoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-nitrophenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C25 H25 N3 O8 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide,
N-[(7R,8R)-8-amino-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-2-naphthalenyl]-N-methyl-, rel-
MF C15 H20 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-
MF C27 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, N-[(1R,2R)-7-amino-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]-4-propyl-, rel-
MF C19 H24 N2 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-(phenylamino)-
MF C26 H29 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10575027.trn

L11 210 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C32 H32 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10575027.trn

```
=> file caplus
FILE 'CAPLUS' ENTERED AT 15:17:07 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Mar 2009  VOL 150 ISS 11
FILE LAST UPDATED: 11 Mar 2009  (20090311/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 15:09:33 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2          50 S L1
L3       32022 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009
L4       58115 S L3
L5           1 S L4 AND PD<=10152003
L6       42824 S L4 AND PD<=2003
L7          55 S L6 AND "POTASSIUM CHANNEL"

     FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009

     FILE 'CAPLUS' ENTERED AT 15:11:14 ON 12 MAR 2009
L8             TRA L7 1- RN :     2659 TERMS

     FILE 'REGISTRY' ENTERED AT 15:11:17 ON 12 MAR 2009
L9          2659 SEA L8
L10          237 S L9 AND L3
L11          210 S L10 AND C10/RF
```

10575027.trn

FILE 'CAPLUS' ENTERED AT 15:17:07 ON 12 MAR 2009

=> s l11
L12 1253 L11

=> s l12 and l7
L13 10 L12 AND L7

=> d cbib abs hit str 1-
'STR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and

10575027.trn

```
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y
```

10575027.trn

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
2003:202410 Document No. 138:226705 Novel pharmaceuticals comprising drug conjugates with polypeptide carriers. Picariello, Thomas (New River Pharmaceuticals Inc., USA). PCT Int. Appl. WO 2003020200 A2 20030313, 2059 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US43117 20011116. PRIORITY: US 2000-248705P 20001116; US 2000-248611P 20001116; US 2000-248609P 20001116; US 2000-248607P 20001116;
US 2000-248608P 20001116; US 2000-248606P 20001116; US 2000-248604P 20001116; US 2000-248603P 20001116; US 2000-248601P 20001116; US 2000-248600P 20001116; US 2000-248712P 20001116; US 2000-248711P 20001116;
US 2000-248709P 20001116; US 2000-248708P 20001116; US 2000-248707P 20001116; US 2000-248706P 20001116; US 2000-248704P 20001116; US 2000-248703P 20001116; US 2000-248702P 20001116; US 2000-248701P 20001116.
AB A pharmaceutical composition comprising a polypeptide and an active agent attached to said polypeptide is disclosed.
IT 76-42-6D, Oxycodone, polypeptide conjugates 42200-33-9D, Nadolol, polypeptide conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel pharmaceuticals comprising drug conjugates with polypeptide carriers)
RN 76-42-6 CAPLUS
CN Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 42200-33-9 CAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (CA INDEX NAME)

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1999:487265 Document No. 131:1160840 Preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers. Gross, Michael F.; Castle, Neil A. (Icagen, Inc., USA). PCT Int. Appl. WO 9937607 A1 19990729, 101 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US1663 19990127. PRIORITY: US 1998-72719P 19980127.
GI



AB Title compds. [I; R = X2Y2R1; R1 = H, alkyl, (hetero)aryl, etc.; R3,R4 = H, alkyl, (hetero)aryl(alkyl), etc.; R5 = X1Y1R2; R2 = H, alkyl, alkoxy, (di)alkylamino, (hetero)aryl(alkyl), etc.; R6 = H, (un)substituted alkyl, (di)(alkyl)amino, etc.; X1 = bond, CH2, CO, SO2, etc.; X2 = CO, CS, So2; Y1 =bond, alkylene, CH:CH, etc.; Y2 = bond, CH2, O, NH, CH:CH, etc.; Z = CH2 or CH2CH2; dashed line = optional addnl. bond] were prepared Thus, 7-nitro-1-tetralone was converted in 4 steps to trans-1-amino-7-nitro-2-naphthol which was amidated by 4-EtC6H4SO2Cl and the reduced product N-alkylated by 4-(F3CO)C6H4CH2Br to give title compound
trans-II. Data for biol. activity of I were given.
IT 1025930-48-6 1027305-40-3 1051400-63-5
1099524-91-0 1099524-92-1 1099524-93-2
1099524-94-3 1099525-08-2 1099525-10-6
1099525-11-7 1099525-12-8 1099525-13-9
1099525-14-0 1099525-15-1 1099525-16-2
1099525-17-3 1099525-18-4 1099525-19-5
1099525-20-8 1099525-21-9 1099525-22-0
1099525-23-1 1099525-24-2 1099525-25-3
1099525-26-4 1099525-27-5 1099525-29-7
1099525-30-0 1099525-31-1 1099525-32-2
1099525-33-3 1099525-34-4 1099525-36-6

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1099525-37-7 1099525-38-8 1099525-39-9
1099525-40-2 1099525-41-3 1099525-42-4
1099525-43-5 1099525-45-7 1099525-46-8
1099525-47-9 1099525-48-0 1099525-49-1
1099525-50-4 1099525-51-5 1099525-52-6
1099525-53-7 1099525-54-8 1099525-55-9
1099525-56-0 1099525-57-1 1099525-58-2
1099525-59-3 1099525-60-6 1099525-61-7
1099525-62-8 1099525-63-9 1099525-64-0
1099525-65-1 1099525-66-2 1099525-67-3
1099525-68-4 1099525-69-5 1099525-70-8
1099525-71-9 1099525-72-0 1099525-74-2
1099525-75-3 1099525-76-4 1099525-77-5
1099525-78-6 1099525-79-7 1099525-80-0
1099525-81-1 1099525-82-2 1099525-83-3
1099525-84-4 1099525-85-5 1099525-86-6
1099525-87-7 1099525-88-8 1099525-89-9
1099525-94-6 1099525-95-7 1099525-96-8
1099525-97-9 1099525-98-0 1099525-99-1
1099526-00-7 1099526-01-8 1099526-02-9
1099526-03-0 1099526-04-1 1099526-05-2
1099526-06-3 1099526-07-4 1099526-08-5
1099526-09-6 1099526-10-9 1099526-11-0
1099526-12-1 1099526-13-2 1099526-14-3
1099526-15-4 1099526-16-5 1099526-17-6
1099526-18-7 1099526-19-8 1099526-20-1
1099526-21-2 1099526-22-3 1099526-23-4
1099526-24-5 1099526-25-6 1099526-26-7
1099526-27-8 1099526-28-9 1099526-29-0
1099526-30-3 1099526-31-4 1099526-32-5
1099526-33-6 1099526-34-7 1099526-36-9
1099526-37-0 1099526-38-1 1099526-39-2
1099526-40-5 1099526-41-6 1099526-42-7
1099526-43-8 1099526-44-9
RL: PRPH (Prophetic)
(Preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs
as potassium channel blockers)
RN 1025930-48-6 CAPLUS
CN Benzamide, N-[8-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1027305-40-3 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 1051400-63-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 1099524-91-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099524-92-1 CAPLUS
CN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-[(4-methoxyphenyl)methylamino]- (CA INDEX NAME)



RN 1099524-93-2 CAPLUS
CN Acetamide, 2-[(3,4-dimethoxyphenyl)methylamino]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099524-94-3 CAPLUS
CN 2(1H)-Isoquinolineacetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3,4-dihydro- (CA INDEX NAME)



RN 1099525-08-2 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(phenylmethyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-10-6 CAPLUS
CN Benzamide, 2-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-nitrophenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-11-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099525-12-8 CAPLUS
CN Acetamide, 2-phenoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1099525-13-9 CAPLUS
CN Benzamide,
4-(dimethylamino)-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-14-0 CAPLUS
CN 2-Butenamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-15-1 CAPLUS
CN Benzamide, 4-nitro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-16-2 CAPLUS
CN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-17-3 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-18-4 CAPLUS
CN Benzamide,
3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-19-5 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(2-phenylethyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-20-8 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[(1E)-2-phenylethenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

Double bond geometry as shown.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-21-9 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-22-0 CAPLUS
CN Benzamide, N-[8-[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 1099525-23-1 CAPLUS

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzeneacetamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-24-2 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-25-3 CAPLUS
CN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-26-4 CAPLUS
CN Benzamide, N-[8-[[(3-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 1099525-27-5 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(phenylmethyl)- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-29-7 CAPLUS
CN Cyclopropanecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 1099525-30-0 CAPLUS
CN Benzamide, N-butyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 1099525-31-1 CAPLUS
CN Benzenesulfonamide, 4-methoxy-2,3,6-trimethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[(3-pyridinylmethyl)amino]-1-naphthalenyl]- (CA INDEX NAME)



RN 1099525-32-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099525-33-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-34-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099525-36-6 CAPLUS
CN Benzamide, 3-methyl-N-(3-pyridinylmethyl)-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-37-7 CAPLUS
CN Cyclopropanecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 1099525-38-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-39-9 CAPLUS
CN Benzamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-40-2 CAPLUS
CN Benzamide, 3-acetyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-41-3 CAPLUS
CN Benzamide, N-[8-[[(4-acetylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methyl- (CA INDEX NAME)



RN 1099525-42-4 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-43-5 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-45-7 CAPLUS
CN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxyphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-46-8 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-47-9 CAPLUS

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-50-4 CAPLUS
CN Benzeneacetamide, N-[8-[[(4-butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-51-5 CAPLUS
CN Benzeneacetamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-pentylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-48-0 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(2-thienylsulfonyl)amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-49-1 CAPLUS
CN Benzeneacetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-52-6 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-53-7 CAPLUS
CN Benzamide, 3,4-dimethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-54-8 CAPLUS
CN Benzamide, 3,4-dimethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-55-9 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methyl- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-56-0 CAPLUS
CN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-57-1 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-fluoro- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-60-6 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-61-7 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-nitrophenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-58-2 CAPLUS
CN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-59-3 CAPLUS
CN Benzamide, 4-fluoro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-62-8 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-3-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099525-63-9 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[(1E)-2-phenylethenyl]sulfonyl]amino]-2-naphthalenyl]-3-(trifluoromethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099525-64-0 CAPLUS
CN Benzamide, N-[8-[[(4-bromophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-ethoxy- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-65-1 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-nitrophenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-66-2 CAPLUS
CN 2-Propynamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(4-methylphenyl)- (CA INDEX NAME)



RN 1099525-67-3 CAPLUS
CN 2-Propynamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-68-4 CAPLUS
CN 2-Propenamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(4-methylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099525-69-5 CAPLUS
CN 2-Propenamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099525-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-71-9 CAPLUS
CN 2-Propenamide, 3-(4-methylphenyl)-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099525-72-0 CAPLUS
CN 2-Propenamide, 3-(4-chlorophenyl)-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-74-2 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099525-75-3 CAPLUS
CN Benzamide, N-[8-[[[6-(diethylamino)-2-naphthalenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-ethyl- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-76-4 CAPLUS
CN Benzamide, N-[8-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methyl- (CA INDEX NAME)



RN 1099525-77-5 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-pentylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-81-1 CAPLUS
CN 1(2H)-Quinolineacetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3,4-dihydro- (CA INDEX NAME)



RN 1099525-82-2 CAPLUS
CN 3-Piperidinecarboxamide, 1-[(3-chlorophenyl)methyl]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-78-6 CAPLUS
CN Cyclopropanecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-phenyl- (CA INDEX NAME)



RN 1099525-79-7 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-80-0 CAPLUS
CN Benzamide, N-[8-[[(3-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-83-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1099525-84-4 CAPLUS
CN 4-Piperidinecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-1-(phenylmethyl)- (CA INDEX NAME)



RN 1099525-85-5 CAPLUS
CN Benzamide, N-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]methylamino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-86-6 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]methylamino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 1099525-87-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-88-8 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-methyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[(3-methoxyphenyl)methyl]methylamino]-1-naphthalenyl]- (CA INDEX NAME)



RN 1099525-89-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-94-6 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy- (CA INDEX NAME)



RN 1099525-95-7 CAPLUS
CN Benzamide, 4-chloro-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099525-96-8 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-(pentyloxy)- (CA INDEX NAME)



RN 1099525-97-9 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099525-98-0 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099525-99-1 CAPLUS
CN Benzamide, 3-ethoxy-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-00-7 CAPLUS
CN Benzamide, N-[8-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-ethoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-01-8 CAPLUS
CN Benzamide, N-[8-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-02-9 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-03-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 1099526-04-1 CAPLUS
CN Benzamide, N-[8-[[[2-(4-chlorophenyl)ethynyl]sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 1099526-05-2 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(2-phenylethynyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-06-3 CAPLUS
CN Benzenepropanamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-07-4 CAPLUS
CN Benzenepropanamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-08-5 CAPLUS
CN Benzenepropanamide, N-[8-[[(4-cyanophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-09-6 CAPLUS
CN Benzamide, 3-chloro-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-10-9 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[(phenylamino)carbonyl]amino]-1-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-11-0 CAPLUS
CN 2-Propenamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099526-12-1 CAPLUS
CN 2-Propynamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(4-methoxyphenyl)- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-13-2 CAPLUS
CN Benzamide, 2-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-14-3 CAPLUS
CN Benzamide, 4-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1099526-15-4 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-16-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099526-17-6 CAPLUS
CN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-18-7 CAPLUS
CN Benzamide, 3-ethoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-19-8 CAPLUS
CN Benzamide, 3-ethoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-20-1 CAPLUS
CN Benzamide, 4-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(2-naphthalenylsulfonyl)amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 1099526-21-2 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-22-3 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxyphenyl)sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099526-23-4 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-24-5 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[(phenylsulfonyl)amino]-2-naphthalenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1099526-25-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 1099526-26-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-27-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099526-28-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1099526-29-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-30-3 CAPLUS
CN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-(phenylamino)- (CA INDEX NAME)



RN 1099526-31-4 CAPLUS
CN Benzamide, N-[8-[[(5-chloro-2-naphthalenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-4-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-32-5 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-1-naphthalenyl]- (CA INDEX NAME)



RN 1099526-33-6 CAPLUS
CN Benzamide, N-[8-[[(3,4-dichlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-(trifluoromethoxy)- (CA INDEX NAME)



RN 1099526-34-7 CAPLUS

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1099526-36-9 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[(4-pyridinylmethyl)amino]-1-naphthalenyl]- (CA INDEX NAME)



RN 1099526-37-0 CAPLUS
CN Benzenesulfonamide, 4-methoxy-2,3,6-trimethyl-N-[1,2,3,4-tetrahydro-2-hydroxy-7-[(2-pyridinylmethyl)amino]-1-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-38-1 CAPLUS
CN Benzamide, N-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 1099526-39-2 CAPLUS
CN Propanamide, N-[8-[[(4-ethylphenyl)sulfonyl](3-pyridinylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2,2-dimethyl- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-40-5 CAPLUS
CN Benzamide, N-[8-[butyl[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 1099526-41-6 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl](phenylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-42-7 CAPLUS
CN Acetamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 1099526-43-8 CAPLUS
CN Acetamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1099526-44-9 CAPLUS
CN Acetamide, 2-[(3,4-dimethylphenyl)methylamino]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)



IT 232265-82-6P 232265-83-7P 232265-84-8P
232265-85-9P 232265-86-0P 232265-87-1P
232265-88-2P 232265-89-3P 232265-90-6P
232265-91-7P 232265-92-8P 232265-93-9P
232265-94-0P 232265-95-1P 232265-96-2P
232265-97-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as
potassium channel blockers)
RN 232265-82-6 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-1-naphthalenyl]-, rel- (CA INDEX

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
NAME)

Relative stereochemistry.



RN 232265-83-7 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[(7R,8R)-5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 232265-84-8 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-87-1 CAPLUS
CN 4-Isoquinolinecarboxamide, 2-ethyl-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 232265-88-2 CAPLUS
CN 2-Propynamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-phenyl- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-85-9 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-2-methoxy- (CA INDEX NAME)



RN 232265-86-0 CAPLUS
CN Benzamide, N-[8-[[(4-butylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-89-3 CAPLUS
CN Benzamide, 4-ethyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 232265-90-6 CAPLUS
CN Benzamide, 3-methoxy-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(phenylmethyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 232265-91-7 CAPLUS
CN Benzamide, 4-nitro-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-propylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-92-8 CAPLUS
CN Benzamide, 3-methyl-N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(3-methylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 232265-93-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-94-0 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-7-hydroxy-8-[[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-2-naphthalenyl]- (CA INDEX NAME)



RN 232265-95-1 CAPLUS
CN Cyclopropanecarboxamide, N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232265-96-2 CAPLUS
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl](3-pyridinylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (CA INDEX NAME)



RN 232265-97-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3-chlorophenyl)methyl]-N-[8-[[(4-ethylphenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]- (CA INDEX NAME)

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 232266-03-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as
potassium channel blockers)
RN 232266-03-4 CAPLUS
CN Benzenesulfonamide, N-[(1R,2R)-7-amino-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]-4-propyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 194028-97-2P 232266-00-1P 232266-01-2P
232266-02-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as
potassium channel blockers)
RN 194028-97-2 CAPLUS
CN 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-7-nitro-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 232266-00-1 CAPLUS
CN 2-Naphthalenol, 1,2,3,4-tetrahydro-7-nitro-1-[(phenylmethyl)amino]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 232266-01-2 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-nitro-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 232266-02-3 CAPLUS
CN Benzenesulfonamide, N-[(1R,2R)-7-amino-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]-4-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

1998:224078 Document No. 129:326 Original Reference No. 129:79a,82a

Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea pig hearts. D'alonzo, Albert J.; Zhu, Jia L.; Darbenzio, Raymond B.; Dorso, Charles R.; Grover, Gary J. (Department of Cardiovascular Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA). Journal of Molecular and Cellular Cardiology, 30(2), 415-423 (English) 1998. CODEN: JMCDAY. ISSN: 0022-2828. Publisher: Academic Press Ltd..

AB The contribution of adrenergic stimulation to the proarrhythmic effects of pinacidil (30 μM), an opener of ATP-sensitive potassium channels (K+ATP), was tested in an isolated guinea-pig heart model of global ischemia (10 min) and reperfusion (10 min). None (0%) of the control hearts (n= 10) elicited arrhythmias during ischemia or reperfusion. In the pinacidil-treated group, one heart (5%) experienced episodes of ventricular tachycardia (VT)/fibrillation (VF) during normoxia. During ischemia, 63% (12 out of 19) of pinacidil-treated hearts exhibited episodes of VT or VF. Hearts not in VT or VF (n=7) at the time of reperfusion, exhibited 71% VT and 43% VT/VF upon reperfusion. Proarrhythmic effects of pinacidil during ischemia or reperfusion were completely reversed by glyburide (n=9: 10 μM), a K+ATP antagonist, or nadolol (n = 9: 3 μM), a β-adrenergic antagonist. Isoproterenol (n = 10; 50 nM), a β-adrenergic agonist, induced a 20% incidence of ischemic VT and VF, and a 70% incidence of reperfusion VF, while methoxamine (n = 10; 10 μM), an α-adrenergic agonist, demonstrated little proarrhythmia (20% VT/VF at reperfusion only). Proarrhythmic effects of isoproterenol were reversed by nadolol, but not glyburide. Pinacidil caused a slight potentiation of tachycardia induced by a bolus injection of tyramine (30 μg), an indirectly acting sympathomimetic, but bolus injections of pinacidil (100 μg) had no effect on heart rate. Nisoxetine, a catecholamine uptake 1 inhibitor, had no proarrhythmic effects when given alone. Catecholamine levels were reduced in pinacidil-treated hearts relative to vehicle-treated. In conclusion, it is suggested that the proarrhythmic effects of pinacidil following global ischemia and reperfusion in the isolated perfused guinea-pig heart appears to involve stimulation of β-adrenoceptors. These proarrhythmic effects of pinacidil do not appear to be mediated solely through direct opening of K+ATP, but rather through an indirect enhancement of catecholamine release.

IT 42200-33-9, Nadolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea pig hearts)

RN 42200-33-9 CAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (CA INDEX NAME)

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



10575027.trn

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1997:468341 Document No. 127:117358 Original Reference No. 127:22501a,22504a
Screening for novel drug effects with a microphysiometer: a potent effect of clofilium unrelated to potassium channel blockade.
Rabinowitz, Joshua D.; Rigler, Per; Carswell-Crumpton, Cathy; Beeson, Craig; McConnel, Harden M. (Dep. Chemistry, Stanford Univ., Stanford, CA, 94305, USA). Life Sciences, 61(7), PL87-PL94 (English) 1997.
CODEN: LIFSAK. ISSN: 0024-3205. Publisher: Elsevier.
AB Changes in cellular metabolism in response to pharmacol. compds. can be detected by using a biosensor known as a microphysiometer, which measures the rate at which cells release acidic metabolites. This technique was used to screen for effects of cation channel blockers on the metabolism of a variety of human and murine cell lines. At concns. sufficient for cation channel blockade, most of these drugs had little or no effect on cellular metabolism, as measured by acid release. In contrast, the K+ channel blocker clofilium triggered sustained increases in acid release at low (≥3 μM) concns. Acid release persisted in media containing high (150 mM) extracellular K+. This release was not triggered by chemical similar K+ channel blockers. Thus, these metabolic effects reflect a potent and specific function of clofilium which is unrelated to K+ channel blockade. Attempts to identify physiol. correlates to this response revealed that low concns. of clofilium but not of other K+ channel blockers caused lymphoma apoptosis. Thus, the effects of clofilium found in other studies may not be due to changes in plasma membrane K+ conductance.
IT 42200-33-9, Nadolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(screening for novel effects of β-adrenergic blockers such as)
RN 42200-33-9 CAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (CA INDEX NAME)



L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1996:368450 Document No. 125:53246 Original Reference No. 125:10133a,10136a
Asymmetric bioreduction of a β-tetralone to its corresponding (S)-alcohol by the yeast Trichosporon capitatum MY 1890. Reddy, Jayanthi; Tschaen, David; Shi, Yao-Jun; Pecore, Victor; Katz, Lorraine; Greasham, Randolph; Chartrain, Michel (Merck Research Laboratory, Rahway, NJ, 07065, USA). Journal of Fermentation and Bioengineering, 81(4), 304-309 (English) 1996. CODEN: JFBIEX. ISSN: 0922-338X. Publisher: Society for Fermentation and Bioengineering, Japan.
AB The yeast Trichosporon capitatum MY 1890 was identified by microbial screening as a suitable biocatalyst for the asym. bioredn. of 6-bromo-β-tetralone to its corresponding (S)-alc. (β-tetralol). This β-tetralol is a precursor to the chiral drug candidate MK-0499, a potassium channel blocker targeted for the treatment of ventricular arrhythmias. Process development studies, employing statistical exploratory designs, yielded a 10-fold increase in the rate of bioredn. and improved the (S)-β-tetralol enantiomeric excess from 71% to 99%. The (S)-β-tetralol enantiomeric excess was highly dependent on glucose catabolism by T. capitatum. Elevated enantiomeric excesses were achieved when switching to a glycerol containing medium. Other process parameters such as pH, temperature and medium composition were found to mostly influence the rate of bioredn. The developed shake flask process was scaled up to laboratory reactors (23-L scale) and supported the production of gram quantities of highly optically pure (S)-β-tetralol.
IT 20107-40-8P 171965-24-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation)
(asym. bioredn. of β-tetralone to its corresponding (S)-alc. by yeast Trichosporon capitatum MY 1890)
RN 20107-40-8 CAPLUS
CN 2-Naphthalenol, 1,2,3,4-tetrahydro-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 171965-24-5 CAPLUS
CN 2-Naphthalenol, 6-bromo-1,2,3,4-tetrahydro-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1994:595469 Document No. 121:195469 Original Reference No. 121:35239a,35242a
Propranolol antagonizes coronary artery relaxation by a potassium channel opener. Kalsner, Stanley (Dep. Physiol., City Univ. New York Med. Sch., New York, NY, 10031, USA). Life Sciences, 55(14), 1109-21
(English) 1994. CODEN: LIFSAK. ISSN: 0024-3205.
AB Coronary artery prepns. from cattle hearts responded with stable contractions to the thromboxane A2 analog, U 46619. These contractions were progressively reduced by increasing concns. of the prototypical potassium channel opener pinacidil (3.8 + 10-8 to 1.1. + 10-4 M). Pinacidil-induced relaxations were antagonized significantly by d,l-propranolol (1.2 + 10-6 to 1.2 + 10-5 M). Forskolin-induced relaxations of coronary prepns. were also antagonized by d,l-propranolol, but those to nitroprusside were not. D-Propranolol also antagonized relaxations to pinacidil but only when used in higher concns. than the l-isomer. Nadolol and metoprolol, two other beta receptor antagonists with differing profiles of action, also antagonized to some extent the vasodilator action of pinacidil. arterial. The known potassium channel antagonist, glibenclamide, shifted the concentration-relaxation curve for pinacidil to the right, but d,l-propranolol produced an addnl. antagonistic effect in the presence of glibenclamide. Relaxations of contracted tracheal ring prepns. of guinea pig by pinacidil, however, were not antagonized by d,l-propranolol, suggesting specificity for vascular tissue. Isoproterenol increased significantly the cAMP levels in coronary tissue, but pinacidil had no such effect, ruling out an adrenergic component to pinacidil action. Pinacidil increased the efflux of 86Rb in isolated coronary prepns., and this effect was blunted by propranolol. It is concluded that beta receptor antagonists inhibit relaxations to a potassium channel opener by a mechanism independent of beta adrenergic receptors and that this effect may have therapeutic implications.
IT 42200-33-9, Nadolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(propranolol antagonizes coronary artery relaxation by potassium channel opener)
RN 42200-33-9 CAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (CA INDEX NAME)



L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1993:560066 Document No. 119:160066 Original Reference No.
119:28677a,28680a
2,2-Dialkylnaphthalen-1-ones as new potassium channel
activators. Almansa, Carmen; Gomez, Luis A.; Cavalcanti, Fernando L.;
Rodriguez, Ricardo; Carceller, Elena; Bartroli, Javier; Garcia-Rafanell,
Julian; Forn, Javier (Res. Cent., J. Uriach y Cia.S.A., Barcelona, 08026,
Spain). Journal of Medicinal Chemistry, 36(15), 2121-33 (English)
1993. CODEN: JMCMAR. ISSN: 0022-2623.
GI



I

AB A new series of 2,2-dialkylnaphthalen-1-one potassium
channel activators has been prepared, and their in vitro relaxant
activities in isolated rat portal vein and guinea pig tracheal spirals as
well as their oral antihypertensive effect in spontaneously hypertensive
rats have been evaluated. The group of
1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethylnaphthalen-1-ones
with an electron-withdrawing substituent at the 6-position contain the
most active compds. and 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-
dimethyl-1-oxonaphthalene-6-carbonitrile, (UR-8225) (I), has been
selected
for further pharmacol. development.
IT 149455-77-6P 149455-81-2P 149455-86-7P
149455-90-3P 149455-94-7P 149455-99-2P
149456-05-3P 149456-10-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclization of, with chlorobutyryl chloride)
RN 149455-77-6 CAPLUS
CN 1(2H)-Naphthalenone, 4-amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-,
(3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-81-2 CAPLUS
CN 1(2H)-Naphthalenone,
4-amino-3,4-dihydro-3-hydroxy-6-methoxy-2,2-dimethyl-
, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-86-7 CAPLUS
CN 1(2H)-Naphthalenone,
4-amino-6-chloro-3,4-dihydro-3-hydroxy-2,2-dimethyl-,
(3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-90-3 CAPLUS
CN 1(2H)-Naphthalenone, 4-amino-6-bromo-3,4-dihydro-3-hydroxy-2,2-dimethyl-,
(3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-94-7 CAPLUS
CN 2-Naphthalenecarbonitrile, 8-amino-5,6,7,8-tetrahydro-7-hydroxy-6,6-
dimethyl-5-oxo-, (7R,8R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-99-2 CAPLUS
CN 1(2H)-Naphthalenone,
4-amino-6-fluoro-3,4-dihydro-3-hydroxy-2,2-dimethyl-,
(3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149456-05-3 CAPLUS
CN Acetamide,
N-[(7R,8R)-8-amino-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-
oxo-2-naphthalenyl]-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149456-10-0 CAPLUS
CN 1(2H)-Naphthalenone, 4-amino-7-bromo-3,4-dihydro-3-hydroxy-2,2-dimethyl-,
(3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 149455-91-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and intramol. cyclization of)
RN 149455-91-4 CAPLUS
CN Butanamide,
N-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-
oxo-1-naphthalenyl]-4-chloro-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 148925-41-1P 148925-42-2P 148925-46-6P
148925-49-9P 148925-52-4P 148925-53-5P
148925-54-6P 148925-55-7P 148925-60-4P
148925-61-5P 148925-62-6P 148925-65-9P
149455-11-8P 149455-15-2P 149455-19-6P

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
149455-24-3P 149455-28-7P 149455-32-3P
149455-33-4P 149455-38-9P 149455-41-4P
149455-43-6P 149455-46-9P 149455-51-6P
149455-61-8P 149455-67-4P 149455-70-9P
149915-53-7P 149915-54-8P 149915-55-9P
149915-59-3P 149915-60-6P 149915-61-7P
149915-65-1P 149915-66-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and potassium channel activator activity of)
RN 148925-41-1 CAPLUS
CN 2-Naphthalenecarbonitrile, 8-[(1,6-dihydro-6-oxo-3-pyridazinyl)oxy]-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-42-2 CAPLUS
CN 2-Naphthalenecarbonitrile, 8-[(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)oxy]-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, (7R,8R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 148925-46-6 CAPLUS
CN 2-Naphthalenecarbonitrile, 8-[[1,6-dihydro-6-oxo-1-(2-propenyl)-3-pyridazinyl]oxy]-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-49-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 148925-52-4 CAPLUS
CN 1(2H)-Naphthalenone, 6-bromo-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-pyridinyloxy)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-53-5 CAPLUS
CN 2-Naphthalenecarbonitrile, 5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-8-(2-pyridinyloxy)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 148925-54-6 CAPLUS
CN 2-Naphthalenecarbonitrile, 5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-8-[(3-oxo-1-cyclopenten-1-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-55-7 CAPLUS
CN Acetamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-60-4 CAPLUS
CN 3-Furancarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 148925-61-5 CAPLUS
CN Benzamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-62-6 CAPLUS
CN Benzamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-4-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 149455-15-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-methoxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-19-6 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-7-chloro-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-24-3 CAPLUS

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 148925-65-9 CAPLUS
CN Ethanimidamide, N-cyano-N'-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 149455-11-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 2(1H)-Pyridinone, 1-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-28-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-32-3 CAPLUS
CN 1H-Isoindol-1-one, 2-[(1R,2R)-7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-2,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 149455-33-4 CAPLUS
CN 2-Naphthalenecarbonitrile,
5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-
8-(2-oxo-1(2H)-pyridinyl)-, (7R,8R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-38-9 CAPLUS
CN 2-Naphthalenecarbonitrile,
5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-
8-(2-oxo-1-pyrrolidinyl)-, (7R,8R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 149455-46-9 CAPLUS
CN Acetamide,
N-methyl-N-[(7R,8R)-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-5-
oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-51-6 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-
oxo-7-(trifluoromethyl)-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 149455-41-4 CAPLUS
CN 2-Naphthalenecarbonitrile,
8-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-5,6,7,8-
tetrahydro-7-hydroxy-6,6-dimethyl-5-oxo-, (7R,8R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-43-6 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-7-fluoro-1,2,3,4-tetrahydro-2-hydroxy-3,3-
dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 149455-61-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-6-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-
dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-67-4 CAPLUS
CN 2(1H)-Pyridinone,
1-[(1R,2R)-6,7-dichloro-1,2,3,4-tetrahydro-2-hydroxy-3,3-
dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149455-70-9 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-
oxo-7-(phenylsulfonyl)-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-53-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-54-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149915-55-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-59-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-60-6 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-61-7 CAPLUS
CN Benzamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl]-4-nitro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 149915-65-1 CAPLUS
CN Cyanamide, [1-(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-4,5-dihydro-1H-imidazol-2-yl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149915-66-2 CAPLUS
CN Cyanamide, [3-(7-bromo-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-2-thiazolidinylidene]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 149915-78-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 149915-78-6 CAPLUS
CN 1(2H)-Naphthalenone, 4-amino-6-bromo-3,4-dihydro-3-hydroxy-2,2-dimethyl-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1993:32764 Document No. 118:32764 Original Reference No. 118:5811a,5814a
Blockade by antiarrhythmic drugs of glibenclamide-sensitive K+ channels in
Xenopus oocytes. Sakuta, Hidenari; Okamoto, Koichi; Watanabe, Yasuhiro (Dep. Pharmacol., Natl. Def. Med. Coll., Tokorozawa, 359, Japan). British
Journal of Pharmacology, 107(4), 1061-7 (English) 1992. CODEN: BJPCBM. ISSN: 0007-1188.
AB The outward K+ current induced by KRN2391 (K+ channel opener) in Xenopus oocytes is blocked by glibenclamide. The effects of various classes (I-IV) of antiarrhythmic drugs on this KRN2391-induced response were studied. All class I antiarrhythmic drugs (Na+ channel blockers) concentration-dependently suppressed the KRN2391-induced responses with the rank
order of potency (IC50 in μM) of disopyramide (17.8) > aprindine (29.5) > propafenone (63.1) > ajmaline (145) > quinidine (151). Flecainide, SUN1165, lignocaine, mexiletine, and procainamide were much less potent (IC50 = 450 to >1000 μM) than quinidine. The class II antiarrhythmic drugs (β-blockers) timolol, (-)- and (±)- propranolol, and (+)-propranolol (a non-β-blocker) inhibited the KRN2391-induced K+ currents in a concentration-dependent manner with values for IC50 (μM) of 79,
131, 151, and 129, resp., while butoxamine, oxprenolol, alprenolol, pindolol, nadolol, metoprolol, and acebutolol were either weak (IC50 = 300
μM to 600 μM) or virtually inactive (IC50 >1000 μM). The class III antiarrhythmic drugs amiodarone and (+)-sotalol scarcely affected the KRN2391 responses. The class IV drugs (Ca2+ antagonists) suppressed the KRN2391-induced responses in a concentration-dependent manner, with IC50 values
of 6.3 μM for bepridil, 38 μM for prenylamine, 85 μM for verapamil, and 135 μM for diltiazem. Thus, antiarrhythmic drugs of classes I, II, and IV potently block the glibenclamide-sensitive K+ channels in Xenopus oocytes.
IT 42200-33-9, Nadolol
RL: BIOL (Biological study)
(potassium channel response to KRN-2391 and, in Xenopus oocytes)
RN 42200-33-9 CAPLUS
CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (CA INDEX NAME)



L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1993:11842 Document No. 118:11842 Original Reference No. 118:2213a,2216a
Separation of the enantiomers of some potassium channel activators using an α1-acid glycoprotein column. Evans, John M.; Smith, Richard J.; Stemp, Geoffrey (SmithKline Beecham Pharm., The Pinnacles, Coldharbour Road, Harlow Essex, CM19 5AD, UK). Journal of Chromatography, 623(1), 163-7 (English) 1992. CODEN: JOCRAM. ISSN: 0021-9673.
AB The sepns. of the enantiomers of some 3,4-dihydro-2,2'-dimethyl-2H-1-benzopyrans and a related tetrahydronaphthalene on α1-acid glycoprotein (Chiral-AGP) are presented, together with the results from an investigation of the effects of organic modifier and pH on the sepns. achieved. The general utility of
Chiral-AGP in separating the enantiomers of compds. from this class of antihypertensive agents was demonstrated in this study.
IT 137433-98-8
RL: PROC (Process)
(resolution of, by HPLC on α1-acid glycoprotein column)
RN 137433-98-8 CAPLUS
CN Acetamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 144940-09-0 144940-14-7
RL: PROC (Process)
(separation of, by HPLC on α1-acid glycoprotein column)
RN 144940-09-0 CAPLUS
CN Acetamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144940-14-7 CAPLUS
CN Acetamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
1992:6373 Document No. 116:63730 Original Reference No. 116:1259a,1262a
Synthesis and antihypertensive activity of pyran oxygen and amide nitrogen
replacement analogs of the potassium channel activator cromakalim. Ashwood, Valerie A.; Cassidy, Frederick; Evans, John M.; Gagliardi, Stefania; Stemp, Geoffrey (SmithKline Beecham Pharm., Harlow/Essex, CM19 5AD, UK). Journal of Medicinal Chemistry, 34(11), 3261-7 (English) 1991. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 116:6373.
GI



II

AB The synthesis and oral antihypertensive activity in conscious spontaneously hypertensive rats of 2 new series of compds. related to the prototype potassium channel activator cromakalim (I) are described. In the 1st series, replacement of the benzopyran oxygen atom by nitrogen or methylene led to the 1,2,3,4-tetrahydroquinoline II (R = 2-oxo-1-pyrrolidinyl, R1 = H, R2 = OH, X = NH) and 1,2,3,4-tetrahydronaphthalene II (R = 2-oxo-1-pyrrolidinyl, R1 = H, R2 = OH, X = CH2) (III) which were both less active than I. However, in contrast to the equivalent activity found previously for I and its dehydrated analog II (R = 2-oxo-1-pyrrolidinyl, R1R2 = bond, X = O), the dihydronaphthalene II (R = 2-oxo-1-pyrrolidinyl, R1R2 = bond, X = CH2) was found to be more active than III. In the second series, replacement of the C-4 amide N atom in acyclic amides related to cromakalim by methylene gave ketone II (R = CH2COMe, R1 = H, R2 = OH, X = O) (IV) that was less active than the corresponding amide II (R = NHCOMe, R1 = H, R2 = OH, X = O). However, replacement of the 4-acetonyl substituent in IV by N,N-dimethylacetamido as in compound II (R = CH2CONMe2, R1 = H, R2 = OH, X = O) resulted in a marked enhancement in activity.
IT 102568-27-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)
RN 102568-27-4 CAPLUS
CN 2-Naphthalenecarbonitrile, 8-amino-5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 102568-33-2 CAPLUS
CN Benzamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 137433-98-8 CAPLUS
CN Acetamide, N-[(1R,2R)-7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 102568-30-9P 102568-32-1P 102568-33-2P
137433-98-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihypertensive activity of)
RN 102568-30-9 CAPLUS
CN 2-Naphthalenecarbonitrile, 5,6,7,8-tetrahydro-7-hydroxy-6,6-dimethyl-8-(2-oxo-1-pyrrolidinyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 102568-32-1 CAPLUS
CN Urea, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-1-naphthalenyl)-N'-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10575027.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 15:09:33 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2          50 S L1
L3       32022 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009
L4       58115 S L3
L5           1 S L4 AND PD<=10152003
L6       42824 S L4 AND PD<=2003
L7          55 S L6 AND "POTASSIUM CHANNEL"

     FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009

     FILE 'CAPLUS' ENTERED AT 15:11:14 ON 12 MAR 2009
L8             TRA L7 1- RN :     2659 TERMS

     FILE 'REGISTRY' ENTERED AT 15:11:17 ON 12 MAR 2009
L9          2659 SEA L8
L10          237 S L9 AND L3
L11          210 S L10 AND C10/RF

     FILE 'CAPLUS' ENTERED AT 15:17:07 ON 12 MAR 2009
L12         1253 S L11
```

10575027.trn

```
=> d l14 cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y
```

10575027.trn

L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2005:672875 Document No. 143:146730 Codrugs for the treatment of genitourinary tract disorders. Ashton, Paul; Cynkowska, Grazyna; Cynkowski, Tadeusz; Smith, Thomas J. (Control Deliver Systems, Inc., USA).
U.S. Pat. Appl. Publ. US 20050164994 A1 20050728, 29 pp., Cont.-in-part of U.S. Ser. No. 316,137. (English). CODEN: USXXCO. APPLICATION: US 2004-859902 20040603. PRIORITY: US 2001-337126P 20011210; US 2002-316137 20021210; US 2003-477526P 20030611; US 2003-479023P 20030616.
AB Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments. The invention discloses drug delivery devices comprising codrugs. The codrug comprises at least 2 biol. active residues, linked by a cleavable linkage. Preparation of e.g. a codrug of flurbiprofen with 5-FU is described. The release rate of a 5-FU-fluocinolone acetonide codrug in prostate tissue and in liver tissue was evaluated.
IT 20830-81-3D, Daunorubicin, conjugates 23214-92-8D, Doxorubicin, conjugates 56124-62-0D, Valrubicin, conjugates 56420-45-2D, Epirubicin, conjugates 58957-92-9D, Idarubicin, conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs for treatment of genitourinary tract disorders)
RN 20830-81-3 CAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 23214-92-8 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 58957-92-9 CAPLUS
CN 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 56124-62-0 CAPLUS
CN Pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 56420-45-2 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2003:913140 Document No. 139:3812590 Preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists. Yura, Takeshi; Mogi, Muneto; Urbahns, Klaus; Fujishima, Hiroshi; Masuda, Tsutomu; Moriwaki, Toshiya; Yoshida, Nagahiro; Kokubo, Toshio; Shiroo, Masahiro; Tajimi, Masaomi; Tsukimi, Yasuhiro; Yamamoto, Noriyuki (Bayer Aktiengesellschaft, Germany; et al.). PCT Int. Appl. WO 2003095420 A1 20031120, 100 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP4395 20030428. PRIORITY: GB 2002-10512 20020508; GB 2002-27262 20021121.
GI



I

AB Title compds. I [R1, R2 = H, alkyl; X = alkyl, YR3; Y = bond, (un)substituted CH2, CH2CH2; R3 = (un)substituted Ph, naphthyl] were prepared for use as VR1 antagonists useful in treating urgent urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD. Thus, 7-ethoxy-5,8-dihydronaphthalen-1-ylamine, prepared from 8-amino-2-naphthol by N-protection, ethylation, deprotection, and reduction, was treated with 4,3-Cl(F3C)C6H3NCO to give I [R1, R2 = H, X = 4,3Cl(F3C)C6H3] which had IC50 for inhibition of capsaicin-induced Ca influx in the human VR1-transfected CHO cell line ≤ 0.1 μM.
IT 624728-45-6P 624728-48-9P 624728-49-0P
624728-50-3P 624728-51-4P 624728-52-5P
624728-53-6P 624728-54-7P 624728-55-8P
624728-56-9P 624728-57-0P 624728-58-1P
624728-59-2P 624728-60-5P 624728-61-6P
624728-62-7P 624728-63-8P 624728-64-9P
624728-65-0P 624728-66-1P 624728-67-2P
624728-68-3P 624728-69-4P 624728-70-7P
624728-71-8P 624728-72-9P 624728-73-0P
624728-74-1P 624728-75-2P 624728-76-3P
624728-77-4P 624728-78-5P 624728-79-6P
624728-80-9P 624728-81-0P 624728-82-1P
624728-83-2P 624728-84-3P 624728-85-4P

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
624728-86-5P 624728-87-6P 624728-88-7P
624728-89-8P 624728-90-1P 624728-91-2P
624728-92-3P 624728-93-4P 624728-94-5P
624728-95-6P 624728-96-7P 624728-97-8P
624728-98-9P 624728-99-0P 624729-00-6P
624729-01-7P 624729-02-8P 624729-03-9P
624729-04-0P 624729-05-1P 624729-06-2P
624729-07-3P 624729-08-4P 624729-09-5P
624729-10-8P 624729-11-9P 624729-12-0P
624729-13-1P 624729-14-2P 624729-15-3P
624729-16-4P 624729-17-5P 624729-18-6P
624729-19-7P 624729-20-0P 624729-21-1P
624729-22-2P 624729-23-3P 624729-24-4P
624729-25-5P 624729-26-6P 624729-27-7P
624729-28-8P 624729-29-9P 624729-30-2P
624729-31-3P 624729-32-4P 624729-33-5P
624729-34-6P 624729-35-7P 624729-36-8P
624729-37-9P 624729-40-4P 624729-41-5P
624729-42-6P 624729-43-7P 624729-44-8P
624729-45-9P 624729-46-0P 624729-47-1P
624729-48-2P 624729-49-3P 624729-50-6P
624729-51-7P 624729-52-8P 624729-53-9P
624729-54-0P 624729-55-1P 624729-56-2P
624729-57-3P 624729-58-4P 624729-59-5P
624729-60-8P 624729-61-9P 624729-62-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624728-45-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-48-9 CAPLUS
CN Urea, N-phenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-49-0 CAPLUS
CN Urea,
N-(2-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-50-3 CAPLUS
CN Urea,
N-(3-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-51-4 CAPLUS
CN Urea,
N-(4-chlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-52-5 CAPLUS
CN Urea,
N-(3-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-53-6 CAPLUS
CN Urea,
N-(4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-54-7 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-55-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 624728-56-9 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-57-0 CAPLUS
CN Benzoic acid, 2-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 624728-58-1 CAPLUS
CN Benzoic acid, 3-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-59-2 CAPLUS
CN Benzoic acid, 4-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 624728-60-5 CAPLUS
CN Urea, N-1-naphthalenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-61-6 CAPLUS
CN Urea, N-2-naphthalenyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-62-7 CAPLUS
CN Urea, N-(4-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-63-8 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-64-9 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-65-0 CAPLUS
CN Urea,
N-(3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-68-3 CAPLUS
CN Urea, N-[4-(dimethylamino)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-69-4 CAPLUS
CN Urea, N-(phenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624728-70-7 CAPLUS
CN Urea, N-[(2-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-66-1 CAPLUS
CN Urea, N-[4-(1-methylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-67-2 CAPLUS
CN Urea,
N-(4-phenoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
naphthalenyl)- (CA INDEX NAME)



RN 624728-71-8 CAPLUS
CN Urea, N-[(3-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-72-9 CAPLUS
CN Urea, N-[(4-methylphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-73-0 CAPLUS
CN Urea, N-[(2-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-74-1 CAPLUS
CN Urea, N-[(3-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-77-4 CAPLUS
CN Urea, N-[(4-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-78-5 CAPLUS
CN Urea,
N-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-75-2 CAPLUS
CN Urea, N-[(4-fluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-76-3 CAPLUS
CN Urea, N-[(2-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 624728-79-6 CAPLUS
CN Urea, N-ethyl-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX
NAME)



RN 624728-80-9 CAPLUS
CN Urea, N-(4-chloro-3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-81-0 CAPLUS
CN Urea, N-(3,5-dimethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-82-1 CAPLUS
CN Urea,
N-(4-bromo-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 624728-83-2 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-4-methyl-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-84-3 CAPLUS
CN Urea, N'-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-85-4 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-7-methyl-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-86-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 624728-87-6 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-88-7 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-89-8 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-90-1 CAPLUS
CN Urea, N-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-91-2 CAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-92-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-93-4 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-94-5 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-95-6 CAPLUS
CN Urea, N-[(2-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-96-7 CAPLUS
CN Urea, N-[(3,4-difluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-97-8 CAPLUS
CN Urea, N-[(3-methoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624728-98-9 CAPLUS
CN Urea, N-[(3-chlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624728-99-0 CAPLUS
CN Urea, N-[(2,4-dichlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-00-6 CAPLUS
CN Urea, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-01-7 CAPLUS
CN Urea, N-[(3,4-dichlorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-02-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-03-9 CAPLUS
CN Urea, N-[(2,4-dimethoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-04-0 CAPLUS
CN Urea, N-[(2-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-05-1 CAPLUS
CN Benzoic acid, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 624729-06-2 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[(2,4,6-trimethoxyphenyl)methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-07-3 CAPLUS
CN Urea, N-[(3-bromophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-08-4 CAPLUS
CN Urea, N-[(4-nitrophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-09-5 CAPLUS
CN Urea, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-10-8 CAPLUS
CN Urea, N-[(3,4-dimethoxyphenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-11-9 CAPLUS
CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-12-0 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-13-1 CAPLUS
CN Benzoic acid, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 624729-14-2 CAPLUS
CN Urea, N-[(4-aminophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-15-3 CAPLUS
CN Urea, N-[(2-aminophenyl)methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-16-4 CAPLUS
CN Benzeneacetic acid, 4-[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-17-5 CAPLUS
CN Urea, N-[[4-(dimethylamino)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-18-6 CAPLUS
CN Urea, N-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-19-7 CAPLUS
CN Urea, N-[2-(4-chlorophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-20-0 CAPLUS
CN Urea, N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-21-1 CAPLUS
CN Urea, N-[4-(4-methylphenoxy)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A



RN 624729-22-2 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 624729-23-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-26-6 CAPLUS
CN Urea,
N-(diphenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-27-7 CAPLUS
CN Urea, N-[1-(4-chlorophenyl)-1-methylethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-24-4 CAPLUS
CN Urea, N-[1-(4-fluorophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-25-5 CAPLUS
CN Urea, N-[1-(4-bromophenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-28-8 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[[4-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)



RN 624729-29-9 CAPLUS
CN Urea, N-(1-naphthalenylmethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-30-2 CAPLUS
CN Urea, N-[4-(cyanomethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-31-3 CAPLUS
CN Urea,
N-(1-phenylethyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-32-4 CAPLUS
CN Urea, N-[1-(1-naphthalenyl)ethyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-35-7 CAPLUS
CN Urea, N-[[3-(cyclopentylamino)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 624729-36-8 CAPLUS
CN Urea,
N-[2-(4-chlorophenyl)ethyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
naphthalenyl)- (CA INDEX NAME)



RN 624729-33-5 CAPLUS
CN Benzenesulfonamide, 4-[[[[(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)amino]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 624729-34-6 CAPLUS
CN Urea, N-[[3-(cyclopentylamino)-4-(trifluoromethyl)phenyl]methyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-37-9 CAPLUS
CN Urea,
N-[2-(4-chlorophenyl)ethyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-40-4 CAPLUS
CN Urea,
N-(2-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-41-5 CAPLUS
CN Urea,
N-(3-fluorophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624729-42-6 CAPLUS
CN Urea,
N-(2-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-43-7 CAPLUS
CN Urea,
N-(3-bromophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624729-44-8 CAPLUS
CN Urea,
N-(2-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-45-9 CAPLUS
CN Urea,
N-(4-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)



RN 624729-46-0 CAPLUS
CN Urea, N-[3-(1-methylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-
naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-47-1 CAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-
naphthalenyl)- (CA INDEX NAME)



RN 624729-48-2 CAPLUS
CN Urea,
N-(3-phenoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-
(CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-49-3 CAPLUS
CN Urea, N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-N'-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 624729-50-6 CAPLUS
CN Urea, N-[3-methoxy-5-(trifluoromethyl)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-51-7 CAPLUS
CN Urea, N-(3-iodophenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-52-8 CAPLUS
CN Urea, N-(4-ethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-53-9 CAPLUS
CN Urea, N-(3-hydroxy-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-54-0 CAPLUS
CN Urea, N-[4-(methylthio)phenyl]-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-55-1 CAPLUS
CN Urea, N-(3-fluoro-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-56-2 CAPLUS
CN Urea, N-(3,4-dimethoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-57-3 CAPLUS
CN Urea, N-(3-chloro-4-methoxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-58-4 CAPLUS
CN Urea,
N-(4-hydroxyphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-61-9 CAPLUS
CN Urea,
N-(3-ethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-62-0 CAPLUS
CN Urea, N-(4-fluoro-3-methylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-59-5 CAPLUS
CN Urea, N-(3,5-dimethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 624729-60-8 CAPLUS
CN Urea, N-(3,4-dimethylphenyl)-N'-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 624728-46-7P 624728-47-8P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)

RN 624728-46-7 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624728-47-8 CAPLUS
CN Urea,
N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 624729-66-4P 624729-67-5P 624729-68-6P
624729-69-7P 624729-72-2P 624729-73-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624729-66-4 CAPLUS
CN 2-Naphthalenol, 8-amino-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 624729-67-5 CAPLUS
CN 2-Naphthalenol, 8-amino-1,2,3,4-tetrahydro-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-68-6 CAPLUS
CN 2-Naphthalenol, 8-amino-1,2,3,4-tetrahydro-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 624729-69-7 CAPLUS
CN Carbamic acid, [(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-72-2 CAPLUS
CN Carbamic acid, (5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 624729-73-3 CAPLUS
CN Carbamic acid, [(7S)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 624729-38-0P 624729-39-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydronaphthalenylureas as vanilloid receptor VR1 antagonists)
RN 624729-38-0 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[2-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 624729-39-1 CAPLUS
CN Urea, N-[(7R)-5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl]-N'-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2003:892603 Document No. 139:375032 Compositions and methods for preventing abuse of orally administered medications. Woolf, Clifford J. (The General Hospital Corporation, USA). PCT Int. Appl. WO 2003092676 A1 20031113, 23 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US12496 20030423. PRIORITY: US 2002-376147P 20020429.

AB Disclosed herein is the use of chemical irritants, such as vanilloid receptor-1 agonists, in sustained/controlled release pharmaceutical prepns. which also contain a drug typically having high abuse potential. Inclusion of the VR1 agonist in the pharmaceutical preparation interferes with illicit or inappropriate dosing without significantly interfering with the action of the therapeutic. Also disclosed are exemplary co-formulations of capsaicin (a VR1 agonist) and oxycodone (an opioid therapeutic having high abuse potential) in controlled release prepns.

IT 76-42-6, Oxycodone 42408-82-2, Butorphanol
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for preventing abuse of orally administered medications)

RN 76-42-6 CAPLUS
CN Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 42408-82-2 CAPLUS
CN Morphinan-3,14-diol, 17-(cyclobutylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2003:454837 Document No. 139:41797 Lipid vehicles for drug delivery. Chancellor, Michael B.; Fraser, Matthew O.; Chuang, Yao-Chi; De Groat, William C.; Huang, Leaf; Yoshimura, Naoki (University of Pittsburgh, USA).
U.S. Pat. Appl. Publ. US 20030108597 A1 20030612, 31 pp., Cont.-in-part of U.S. Provisional Ser. No. 311,868. (English). CODEN: USXXCO. APPLICATION: US 2002-218797 20020813. PRIORITY: US 2001-311868P 20010813.

AB The present invention relates to compns. and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compns. and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compds., such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction. Liposomes are capable of highly effective delivery of at least one hydrophobic drug, CAP, as evidenced by a dramatic increase in bladder contraction frequency and subsequent desensitization. Moreover, liposomes alone had no effect on the micturition reflex in the unirritated state. In combination with other expts. that have demonstrated a protective effect of liposomes, this suggested that the liposome vehicle may partially protect against the compromise of urothelial barrier function due to the neuro-inflammatory response caused by irritants.

IT 20830-81-3, Daunomycin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 56420-45-2, Epirubicin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid vehicles for drug delivery)

RN 20830-81-3 CAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 23214-92-8 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 25316-40-9 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 56420-45-2 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2003:154186 Document No. 138:193291 Application of lipid vehicles and use for drug delivery for bladder disorders. Chancellor, Michael B.; Fraser, Matthew O.; Chuang, Yao-Chi; de Groat, William C.; Huang, Leaf; Yoshimura, Naoki (University of Pittsburgh, USA). PCT Int. Appl. WO 2003015698 A2 20030227, 88 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US25860 20020813. PRIORITY: US 2001-311868P 20010813.

AB The present invention relates to compns. and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. The compns. are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compds., such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

IT 20830-81-3, Daunomycin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 56420-45-2, Epirubicin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid vehicles for drug delivery for bladder disorders)

RN 20830-81-3 CAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 23214-92-8 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 25316-40-9 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 56420-45-2 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
2002:675858 Document No. 137:222036 Compositions based on vanilloid -catechin synergies for prevention and treatment of cancer. Morre, Dorothy M.; Morre, James D. (Purdue Research Foundation, USA). PCT Int. Appl. WO 2002067966 A1 20020906, 51 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US5295 20020222. PRIORITY: US 2001-270557P 20010222.

AB The invention described herein encompasses methods and compns. of preventing or treating cancer comprising the administration of a combination of catechins and vanilloids. Compns. of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). In a preferred embodiment the catechins have been treated with tannase. Compns. of vanilloids include, but are not limited to vanillylamine, the head group of capsaicin. The unique compns. of the invention contain various combinations of the catechins and vanilloids, in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses various modes of administration of the therapeutic compds., including formulations which may be used as a dietary or nutritional supplement or as a therapeutic compound The effect of combinations of tea catechins (including tannase-treated Tegreen with and without gallic acid and EGCg) and the vanilloid vanillylamine, alone and in combination, was demonstrated on (i) cancer cell growth and (ii) NADH oxidase (tNOX) activity. The ratios of tea catechins and vanillyamine was varied to determine optimum ratios for the inhibition of cancer cell growth and the inhibition of tNOX activity. A synergy between tannase-treated Tegreen with gallic acid and vanillylamine in inhibiting the cell surface NADH oxidase was observed

IT 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 25316-40-9D, Adriamycin, conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. based on vanilloid-catechin synergies for prevention and treatment of cancer)

RN 20830-81-3 CAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 23214-92-8 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 25316-40-9 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 25316-40-9 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
1997:578793 Document No. 127:242907 Original Reference No. 127:47239a,47242a

Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?. Morre, D. James; Kim, Chinpal; Paulik, Mark; Morre, Dorothy M.; Faulk, W. Page (Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA). Journal of Bioenergetics and Biomembranes, 29(3), 269-280 (English) 1997. CODEN: JBBID4. ISSN: 0145-479X. Publisher: Plenum.

AB Enhanced growth inhibition and antitumor responses to adriamycin have been observed repeatedly from several labs. using impermeant forms of adriamycin where entry into the cell was greatly reduced or prevented. Our laboratory has described an NADH oxidase activity at the external surface of plasma membrane vesicles from tumor cells where inhibition by an antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984), and by the vanilloid, capsaicin (8-methyl-N-vanillyl-6-noneamide) correlated with inhibition of growth. Here we report that the oxidation of NADH by isolated plasma membrane vesicles was inhibited, as well, by adriamycin. An external site of inhibition was indicated from studies where impermeant adriamycin conjugates were used. The EC50 for inhibition of the oxidase of rat hepatoma plasma membranes by adriamycin was several orders of magnitude less than that for rat liver. Adriamycin cross-linked to diferric transferrin and other impermeant supports also was effective in inhibition of NADH oxidation by isolated plasma membrane vesicles and in inhibition of growth of cultured cells. The findings suggest the NADH oxidase of the plasma membrane as a growth-related adriamycin target at the surface of cancer cells responsive to adriamycin. Whereas DNA intercalation remains clearly one of the principal bases for the cytotoxic action of free adriamycin, this second site, possibly related to a more specific antitumor action, may be helpful in understanding the enhanced efficacy reported previously for immobilized adriamycin forms compared to free adriamycin.

IT 25316-40-9, Adriamycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NADH oxidase of the cancer cell plasma membrane a mol. target for adriamycin)

RN 25316-40-9 CAPLUS
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

10575027.trn

```
=> d his

     (FILE 'HOME' ENTERED AT 15:08:26 ON 12 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 15:09:33 ON 12 MAR 2009
L1             STRUCTURE UPLOADED
L2              50 S L1
L3           32022 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 15:09:56 ON 12 MAR 2009
L4           58115 S L3
L5               1 S L4 AND PD<=10152003
L6           42824 S L4 AND PD<=2003
L7              55 S L6 AND "POTASSIUM CHANNEL"

     FILE 'REGISTRY' ENTERED AT 15:11:10 ON 12 MAR 2009

     FILE 'CAPLUS' ENTERED AT 15:11:14 ON 12 MAR 2009
L8             TRA L7 1- RN :     2659 TERMS

     FILE 'REGISTRY' ENTERED AT 15:11:17 ON 12 MAR 2009
L9            2659 SEA L8
L10            237 S L9 AND L3
L11            210 S L10 AND C10/RF

     FILE 'CAPLUS' ENTERED AT 15:17:07 ON 12 MAR 2009
L12           1253 S L11
L13             10 S L12 AND L7
L14              7 S L6 AND VANILLOID
L15              3 S L6 AND VR1
L16           6146 S L4 AND PRD<=2003
L17             16 S L16 AND VANILLOID
L18             11 S L16 AND VR1

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 15:21:26 ON 12 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar  6, 2009 (20090306/UP).

=>
```